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Abstract 
Daptomycin (Dap) is a calcium-dependent cyclic lipodepsipeptide antibiotic used clinically to 
treat infections with pathogenic Gram-positive bacteria, including methicillin-resistant 
Staphylococcus aureus (MRSA). It targets the cell membrane, which must contain 
phosphatidylglycerol (PG) for activity.  Although Dap was discovered over 30 years ago, its 
mechanism of action is still debated among researchers. Many action mechanisms have been 
proposed for Dap.  The mechanism that has garnered the most attention involves Dap oligomerization 
in the cell membrane resulting in the formation of cation-selective pores, which lead to membrane 
depolarization and cell death.  To further investigate this proposed mechanism of action, I here 
studied the interaction of Dap with calcium, the activity and pore-forming abilities of a Dap dimer, 
and the effects of membrane lipid composition on Dap-membrane interactions and pore formation. 
The stoichiometry of calcium to Dap in the presence of liposomes and how calcium 
concentration affects Dap oligomerization and membrane insertion was investigated using 
fluorescence spectroscopy and isothermal titration calorimetry.  It was shown that Dap interacts with 
liposomes in two sequential calcium-binding events. The binding of the first calcium ion is suggested 
to cause oligomer formation of Dap in the membrane. The binding of a second calcium ion is 
suggested to cause a deeper insertion of this oligomer, followed, potentially, by translocation into the 
inner leaflet, ultimately forming a functional pore.  
The effect of Dap pre-oligomerization on antibacterial activity was studied via the synthesis 
and characterization of a Dap dimer. The dimer was prepared by connecting the N-termini of two Dap 
monomers via an octadecanedioate linker. It was anticipated that the dimer would decrease the 
entropic cost associated with oligomer formation. This would promote oligomer formation, thereby 
enhancing its activity. In contrast to expectation, the activity of the dimer was greatly reduced on 
vegetative cells yet was able to form cation-selective pores in liposomes. On bacterial L-forms, which 
lack a cell wall, dimer activity was close to that of the monomer. This suggests that the dimer was 
unable to cross the cell wall of vegetative cells, thus highlighting the role of the cell wall in Dap 
resistance. 
The effect of lipid acyl chain composition on Dap’s ability to interact with, oligomerize, and 
form pores in membranes was examined.  Dap was found to insert into and form oligomers on 
phosphatidylcholine (PC)/PG liposomes containing either dimyristoyl (DMPC/DMPG), dioleyl 
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(DOPC/DOPG) or dipalmitoleoyl (POPC/POPG) acyl chains.  DMPC/DMPG lipids were found to 
support pore formation, while DOPC/DOPG and POPC/POPG lipids did not support pore formation.  
Only 1-5% of an added oleoyl chained lipid, regardless of head group, was necessary to prevent pore 
formation in liposomes containing dimyristoyl acyl chains. Permeabilization was regained when the 
molar concentration of Dap surpassed the molar concentration of the dioleoyl chained lipid present. 
This indicates a near-stoichiometric dose-response interaction of a dioleoyl chained lipid, DOPC, to 
Dap.   
The reason for the reduced permeabilization of Dap on DOPC/DOPG lipids was further 
investigated. Experiments indicated that the acyl chain unsaturation of dioleoyl chained lipids alone is 
not sufficient for the inhibitory effect of DOPC/DOPG lipids on Dap; thus, the greater length of 
oleoyl relative to myristoyl acyl groups appears to be important. Moreover, the inhibitory effect 
cannot be overcome by extending the N-terminal acyl residue of Dap itself. Overall, the findings in 
this thesis provide substantial new detail on the mode of action of Dap. They also shed light on 
mechanisms of bacterial resistance to Dap, and they help to reconcile some of the conflicting findings 
on Dap activity that were obtained with model membranes differing in lipid composition.  
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Chapter 1 
 
Introduction 
 
 
 
 
The use of antibacterial agents to treat life-threatening conditions can be dated back to the 
time of the Egyptians who used clay and mold to treat anything from pain to disease1. Over the next 
several thousand years the use of antibacterial agents improved but their identity and mode of action 
was unknown. It was not until the early 1670’s that the world was introduced to microbes. Two 
centuries later, the connection between microbes and disease was made and antibacterial discovery 
became a pursuit based, at least to some degree, on science. The discovery of penicillin in the 1920’s, 
and its used in the 1940’s, revolutionized medicine, and from that point forward, antibiotics have 
continued to have a dramatic impact on human health and well-being2.  
In the late 1940’s the United Nations created the World Health Organization (WHO), a 
specialized agency that is concerned with international public health3. In the late 1970’s the first list 
of essential medicines was produced by WHO, which contains the medications considered to be the 
most effective and safe to meet the most important needs in a health care system4. Many medicines on 
this list are antibiotics. Unfortunately, due in part to the overuse of antibiotics, some bacteria have 
developed resistance5,6. This has brought about the rise of “super bugs,” i.e. bacteria that are resistant 
to just about every antibiotic available7. One such super bug is termed methicillin resistant 
Staphylococcus aureus (MRSA)7, classified by WHO as a serious infectious pathogen.  
To combat these super bugs, the WHO created a list of several so-called last resort 
antibiotics. The idea was that these antibiotics would only be used when other more commonly used 
antibiotics were ineffective. An important and widely used last resort antibiotic, particularly in the 
treatment of MRSA, is Daptomycin8–10. Daptomycin (Dap) was first approved by the FDA in the 
USA, in 2003, for treating complicated skin and skin structure infections, particularly caused by 
MRSA and vancomycin-resistant enterococci (VRE)11,12. Although resistance is still rare for this 
potent antibiotic, it has been observed in several clinical isolates13. Although determining Dap’s 
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mechanism of action has been a focus for many researchers for several decades, its mechanism of 
action is still incompletely understood. Knowing Dap’s mode of action could facilitate the 
development of Dap analogs that are active against Dap-resistant bacteria. The work presented in this 
thesis is directed to obtaining a better understanding of Dap’s action mechanism.  
 
1.1 Antibiotics 
Antibiotics have been the forefront of medicine for almost a century. In the early 1900’s, Paul 
Ehrlich believed that antibiotics could become a “magic bullet” that directly targeted an infection, 
killing the cell14. He then led an exhaustive chemical screening program to discover compounds with 
antibacterial properties. This work culminated in the discovery of the antibacterial, salvarsan 
(arsphenamine)15. In the 1920’s, Alexander Fleming discovered the well-known antibiotic 
penicillin2,16. Penicillin was the first antibiotic to be widely adopted around the world in a very short 
period of time. Since the 1930’s, many antibiotics have been created synthetically, like salvarsan, or 
discovered, like penicillin17. A timeline of these discoveries is highlighted in Figure 1.1.   
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Figure 1.1 The history of discovered antibacterials from the initial discovery of salvarsan to 
Daptomcyin17. Each box represents a new antibiotic class. The green boxes indicate natural 
compounds isolated from soil microorganisms (fungi or bacteria), whereas the yellow boxes indicate 
synthetic compounds. The figure was used with permission. 
 
As seen in Figure 1.1, antibacterial discovery was extremely fruitful from the early 1940’s to 
the 1960’s. These years have been termed the “Golden Era” of antibiotic development. The discovery 
and synthesis of antibacterials slowed down considerably after the discovery of Dap, in the late 
1980’s. This period of time is called the “Discovery Void,” as very few new or improved antibiotics 
have been created or discovered since the 1980s. This is mainly due to the high cost of drug 
development, which has deterred pharmaceutical companies from developing new antibiotics, since 
these are not as profitable as other classes of drugs17. DiMasi, et al. pointed out that average cost of 
getting a drug approved to market from 1979 to 1991, effectively doubled, to a value of 
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approximately 230 million dollars18. By 2010, the total cost has risen to over one billion dollars, with 
the time required to pass all clinical trials increasing to almost 15 years19. 
Interestingly, many of the antibiotics discovered over the past hundred years have been 
obtained from the same host organism, Streptomyces spp.20 The reason for this has been suggested to 
be due to the sheer number of species and versatility that this organism has, combined with their high 
metabolite production rate20. A shortened list to give an idea of this is shown in Table 1.1. Bacteria 
are constantly in competition for resources. Due to the large number of Streptomyces species, and the 
fact that most of these species require similar growth conditions, these bacteria have developed an 
array of defence mechanisms (antibiotics)21. 
Host Microorganism Antibiotic 
Bacteria 
Streptomyces spp. Chloroamphenicol 
 Erythromycin 
 Neomycin 
 Nystatin 
 Rifampicin 
 Streptomycin 
 Tetracyclines 
 Vancomycin 
 Daptomycin 
Bacillus spp. Bacitracin 
 Polymyxins 
Micromonospora spp. Gentamicin 
 
Fungi  
Penicillium spp. Griseofulvin 
 Penicillin 
Cephalosporium spp. Cephalosporins 
 
Table 1.1 Several important antibiotics are outlined in regards to the host microorganism that 
produces them. As can be seen, Streptomyces spp. is a powerhouse of antibiotic discovery.  
 
Although many antibiotic classes exist, the last decade has seen the largest drop in antibiotic 
discovery. This reduced rate of antibiotic discovery has become a very growing concern. Antibiotics 
are used widely across the world without caution. This selects for the mutations in bacteria that results 
in resistance to even the most potent last resort antibiotics. This highlights the need for the synthesis 
of new and improved antibiotics to counter this ever-growing threat to human health.  
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1.2 Mechanisms of Action and Resistance of Antibiotics 
Understanding the molecular mechanisms of action of antibiotics, as well as of bacterial 
resistance to them, will facilitate a rational approach to the design of antibiotics with improved 
activity. The major targets include the cell wall, protein synthesis, DNA/RNA, and the cell 
membrane. This section will outline these targets and how bacteria become resistant to the antibiotics 
used. 
 
1.2.1 Cell Wall 
The cell wall is the structural barrier in bacteria that protects the cytosol from the external 
environment. The cell wall structures of Gram-negative and Gram-positive bacteria, as well as 
mycobacteria are illustrated in Figure 1.2 below.  
 
Figure 1.2 The cell wall and membrane of Gram-negative, Gram-positive and Mycobacteria16. Each 
cell type contains an inner membrane, but otherwise is entirely varied. Gram-negative bacteria 
contain a thin peptidoglycan layer, with a second outer membrane. This outer membrane contains 
lipopolysaccharides (LPS). Gram-positive bacteria contain only an inner membrane, thick 
peptidoglycan layer and lipoteichoic acid (LTA) groups stemming from the membrane. This figure was 
used with permission. 
 
Antibiotics that disrupt the cell wall usually do so by inhibiting peptidoglycan synthesis, at 
several different steps22. Peptidoglycan synthesis is a complex process as outline in Figure 1.3.  
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11.4 Antibiotics and the bacterial cell wall
In contrast to human cells, which are simply delimited by their cytoplasmic membranes,
most bacteria have cell walls that consist of one or more protective layers stacked on
top of their cytoplasmic membranes. While these cell walls may protect the bacteria
from antibiotics, they also provide targets for chemotherapy. Note that some bacteria—
mycoplasmas, and the vegetative forms of ricket sias and chlamydias—h v no cell wa l
at all and therefore are not susceptible to the agents discussed in this section.
11.4.1 Bacterial cell wall structure
Inner
membrane
Murein
Outer
membrane
LPS LTA
Outer
membrane
Mycolic
acids
Arabino-
galactan
Gram-negative Gram-positive Mycobacteria
PorinPorin MDR system
Notes: The innermost layer of a bacterial cell wall consists of murein or peptidoglycan,
a meshwork of polysaccharide strands crosslinked by oligopeptides. Gram-negative
bacteria have a comparatively thin peptidoglycan layer (blue) that is surrounded and
protected by an outer membrane. The outer leaflet of this lipid embrane consists
mostly of lipopolysaccharide (LPS, green), which is also known as endotoxin.4 Porins
in the outer membrane facilitate diﬀusion of small polar solutes. Multidrug resistance
(MDR) proteins that extrude antibiotics from the cell may be located in the cytoplasmic
membrane alone or span both membranes.5
Gram-posi ive bacteria lack an outer membrane but have a much th cker murein
layer, which is decorated with lipoteichoic acids (LTA). The lack of an outer membrane
makes them more amenable to penicillin (see slide 1.3.10) and many other antibiotics.6
In mycobacteria, the murein layer is surrounded by arabinogalactan polysaccharide,
to which branched, long-chain fatty acids (mycolic acids, red) are attached. The mycolic
acids act as anchors for a particularly thick, wax-like and impenetrable outer membrane.
Because of their sturdy cell wall,7 mycobacteria have always been among the most diﬃ-
cult microbes to treat—although decades of selection have bred some real champions
of resistance among the Gram-positives and Gram-negatives also.
4The “toxic” eﬀect of endotoxin results not from any intrinsic biochemical activity of the LPS molecule
but instead from a violent response of the non-specific immune system to it.
5The two types of pumps cooperate synergistically in extruding drugs from the cell—see [80] and
references therein.
6The outer membrane in Gram-negatives excludes crystal violet, and therefore prevents the bacteria
from staining dark blue in the Gram stain procedure. In contrast, Gram-positives absorb and retain the
dark-blue dye.
7The thick cell wall enables the mycobacteria to persist inside host phagocytes, which further impedes
access of drugs to bacterial targets.
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Figure 1.3 Synthesis of peptidoglycan from N-acetylglucosamine to crosslinking of lipid II containing 
chains16. 1: An enolpyruvyltransferase, MurA, catalyzes the reaction between phosphoenolpyruvate 
(PEP) to a UDP attached N-acetylglucosamine. This reaction supplies the substrate with a lactate 
(Lac) moiety. 2: Alanine racemase converts a L-alanine to the D configuration. 3: A pentapeptide 
consisting of L and D – alanine residues is attached to the Lac group on N-acetylglucosamine. 4: This 
building block is then transferred to undecaprenol phosphate within the membrane with the 
dislodgment of UDP. This process creates a membrane bound building block that is named, Lipid I. 
Lipid I is then extended, with a glycosyltranserase (MurG), with a second N-acetylglucosamine moiety 
producing Lipid II. 5: Lipid II is then flipped from the inner membrane to the outer membrane. 6: Lipid 
II building blocks are then connected in unison through reaction with a transglycosylase. 7: A 
transpeptidase enzyme finally crosslinks the Lipid II linked building blocks by displacing a D-alanine. 
This figure was used with permission. 
 
 Several antibiotics that disrupt this process include: β-lactams (penicillin, methicillin, 
ampicillin, etc.), vancomycin, bacitracin, laspartomycin, fosfomycin and cycloserine22. β-lactams and 
vancomycin interact directly with the transpeptidase reaction. Vancomycin specifically binds to the 
D-alanine dipeptide of lipid II16, a key intermediate that is formed during the synthesis of the bacterial 
cell wall. Disrupting the transpeptidase reaction prevents the cross-linking of lipid II, resulting in the 
disruption of the structural integrity of the cell wall23,24. Fosfomycin has been found to inhibit step 1 
of Figure 1.3 and cycloserine inhibits steps 2-3, with bacitracin interacting directly with undecaprenol 
phosphate, preventing the flipping of lipid II to outer leaflet25–27. The inhibition of most other steps in 
this process leads to the interruption of lipid II production; therefore the cell wall components are 
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The transglycosylase and transpeptidase ctivities are bo h loca ed on the same enzyme
protein, variously referred to as muramyl-transpeptidase or penicillin-binding protein
(PBP). Most bacterial contain several PBP subtypes that may diﬀer in susceptibility to
penicillins and related antibiotics.
11.4.4 Fosfomycin mimics both ph sphoe olpyruvate and glycerophosphate
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Fosfomycin PEP Glycerophosphate
Notes: Fosfomycin is an antimetabolite of phosphoenolpyruvate (PEP) in the first step
of mure n precursor synthesis. Considering its structure, it may not surprise you to
hear that the reaction with the target enzyme is covalent and involves the thiol group
of a cysteine residue [81].
For uptake across the cytoplasmic membrane, fosfomycin piggybacks on a transport
protein that mediat s u take of glycer phosph te. This transpor er is not essential for
the bacterial cell; therefore, mutations that inactivate the transporter tend to cause
rapid development of resistance under therapy. Fosfomycin can therefore only be used
in combination with other antibiotics that are less prone to rapid evolution of resistance.
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never formed25,26,28,29. A common resistance mechanism is the chemical modification of the target or 
the inhibitor. This includes ring opening for fosfomycin and β-lactams5, mutations in the enzymes 
that these antibiotics bind to and in the case of bacitracin, over-expression of undecaprenol phosphate, 
a lipid involved in the flipping of lipid II from the inner to outer leaflet of bacterial memrbanes27.  
 
1.2.2 Protein Synthesis 
The protein synthesis machinery is a common target shared by many antibiotics. Bacterial 
ribosomes (Figure 1.4) have a 50S subunit and a smaller 30S subunit30.  
 
Figure 1.4 Transcription of a messenger RNA strand into a polypeptide chain. An amino acid bound 
to its specific tRNA binds to the RNA strand, at the aminoacyl (A) site. At this site an elongation factor 
protein binds, and the tRNA is transitioned into the peptidyl (P) site. A peptidyl transferase then links 
the incoming amino acid to the growing chain. This reaction then forces the tRNA to enter the exit (E) 
site, leaving the RNA strand.  
 
There are many structural differences between bacterial and eukaryotic ribosomes, with many 
antibiotics specifically targeting the smaller, simpler bacterial form16. Examples of antibiotics that 
target this process include: streptomycin, gentamycin, chloramphenicol, erythromycin, 
chlortetracycline and linezolid. Most of these antibiotics target the 23S ribosomal RNA elongation 
factor, which is part of the larger 50S subunit, preventing amino acid elongation31–33. This factor 
contains a peptidyl transferase site needed for elongating the incoming peptide with amino acids. 
Streptomycin and gentamycin more specifically prevent the reading of the incoming RNA strand, 
binding the 30S subunit31. The most common resistance mechanism involves the bacterial mutation of 
the 23S elongation factor, thereby preventing the antibiotic from binding33.  
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1.2.3 DNA/RNA 
Another target of antibiotics is the inhibition of the synthesis of DNA or RNA. DNA and 
RNA are normally replicated with a DNA-polymerase or a DNA-dependent RNA-polymerase34.  A 
DNA gyrase is important in DNA repair and assisting polymerases to open up the double stranded 
helix, facilitating polymerase binding35,36. Common antibiotics that interfere with this process include: 
rifampicin, metronidazole, nalidixic acid, novobiocin and ciprofloxacin. Rifampicin specifically 
interacts with the DNA-dependent RNA-polymerase, preventing this polymerase from binding37. 
Nalidixic acid, novobiocin and ciprofloxacin interact directly with DNA gyrase, preventing DNA 
repair and transcription35,36. A common resistance mechanism to these antibiotics is the mutation of 
the enzymes they target, mainly either the polymerase or DNA gyrase.   
 
1.2.4 Cell Membranes 
The cell membrane is made of mainly proteins and lipids, but the specifics and percentages of 
these components are dependent on the bacterial species16,38. The majority of lipids found in bacterial 
membranes are phospholipids. Antibiotics that target the cell membrane function by either affecting 
the membrane potential or by dislodging and/ore inactivating proteins (or macromolecules) attached 
to the membrane39. Dislodging or binding to proteins/macromolecules bound to the cytoplasmic 
membrane can disrupt cell wall synthesis and proper efflux of compounds. Antibiotics that disrupt 
membrane potential do so by forming a pore or lesion in the membrane, which results in loss of ions 
across the membrane. The enzyme ATPase drives ATP production, which is dependent on the cell 
membrane potential. A loss of ions will destroy the cell membrane potential, therefore stopping the 
production of ATP, and therefore most other functions of the cell40. Several antibiotics that target the 
cytosolic membrane include polymyxin, nisin and Dap41,42. Polymyxin’s mechanism of action 
involves the binding and dislodging of lipopolysaccharides (LPS), found on the outer membrane of 
Gram-negative bacteria43. Nisin has been observed to cause a loss of membrane potential but also an 
inhibition of cell wall synthesis44. In the case of Dap, many mechanisms have been proposed. One 
such proposal is the loss of membrane potential40,45,46. Resistance to these types of antibiotics includes 
modification of the cell membrane, mainly the lipoteichoic (LTA) groups of Gram-positive or LPS 
groups of Gram-negative bacteria39. LTA groups, as shown in Figure 1.2, are anchored to the cell 
membrane but likely span the entirety of the cell wall. Modifications to LTA could be affecting the 
ability of antibiotics, for example Dap, to traverse the cell wall, preventing its interaction with the 
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cytoplasmic membrane47. Another common mechanism of resistance involves the alteration of the 
membrane lipid composition, preventing certain antibiotics from properly inserting into the 
membrane48. 
 
1.3 Daptomycin 
Daptomycin (Dap) is a cyclic lipodepsipeptide used to treat serious skin infections caused by 
Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin-resistant enterococci (VRE)9,11,12,40,48–58. Dap is a last resort antibiotic, meaning it should 
be used only when necessary. Widespread resistance has not yet been observed59. Dap is part of the 
A21978C class of antibiotics. This class, consisting of Dap, A54145 and the so-called calcium-
dependent antibiotic (CDA) are shown in Figure 1.5. They have other certain conserved features, 
which will be discussed in Section 1.3.1. This class of antibiotics contains a cyclic macrolactone ring 
enclosed by an ester bond. These lipopeptides also contain exocyclic portions connected to different 
fatty acyl chains. Dap is currently the only clinically used antibiotic of this class12. 
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Figure 1.5 The structures of Daptomycin, A54145-Factor D and CDA. Each lipopeptide has a ten 
amino acid membered cyclic portion. The cyclic region is closed by a depsi bond between the 
conserved threonine residue and the thirteenth amino acid. The other conserved amino acids are 
shown in blue. Each amino acid has a glutamate residue in position 12 and a conserved DXDG, 
calcium-binding sequence.  
 
Dap was first discovered by researchers at Eli Lily© in the early 1980’s in cultures of the 
bacterium Streptomyces roseosporus9,60. In 1985, Eli Lily© began studies on Dap, attempting to 
determine the proper dose regimen for clinical use. They later abandoned this work due to mycopathy 
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in phase II clinical trials. In 1997, Cubist Inc.© (recently purchased by Merck & Co.©) acquired the 
rights and continued clinical trials, adjusting the dose61. They determined that the mycopathic effects 
observed by Eli Lily© could be diminished if the dose was lowered61. Dap was approved by the FDA 
in 2003, in USA and Europe, for the treatment of complicated skin and skin-structure conditions, 
particularly methicillin-susceptible S. aureus (MSSA) and MRSA11,40. In 2006, Dap was approved for 
use in the treatment of bacteremia causing right-sided endocartitis, due to MSSA or MRSA12. The 
dose regimen for Dap involves a 4 mg/kg injection daily for MRSA and 6 mg/kg daily for 
bacteremia61. The increased dosage used for bacteremia has been shown to decrease the emergence of 
resistance, in S. aureus strains62. Dap, having a lipophilic tail, binds to proteins63 (mainly albumin in 
the blood) decreasing its overall free concentration, when exposed to the pathogenic bacteria. This 
proten binding is dependent on the concentration of Dap used, ranging from 4-8 mg/kg63. Carpenter, 
et al. showed that the half-life of Dap is ~8-9 hours with a maximal plasma concentration of 57.8 
µg/mL (4 mg/kg dose) and 98.6 µg/mL (6 mg/kg dose)63. Dvorchik, et al. further stated that the 
plasma concentration decreases quickly over time, with only ~20 µg/mL Dap, 12 hours after 
administration64.   
Interestingly, Dap has been found to be inactive against community-acquired pneumoniae 
caused by Streptococcus pneumoniae. This is thought to be due to a sequestering of Dap by 
pulmonary surfactant65. Dap has also been shown recently in increase the compressibility of lung 
surfactant, which may facilitate further sequestration of the antibiotic66. Pulmonary surfactant 
contains a higher percentage, compared to all other mammalian lipid membranes, of 
phosphatidylglycerol (PG), a required lipid for Dap action. Dap interacts with the high PG content of 
the lung surfactant, thus preventing its interaction with S. pneumoniae65. Efforts have been made to 
improve Dap’s activity within lung surfactant67–69. One approach is through the study of A54145, 
which is active in pulmonary surfactant, but is too toxic to be used clinically10,70,71. Investigating the 
similarities and differences between Dap and A54145 might lead to compounds that combine the 
favourable traits of both. An example of this was shown by Nguyen, et al. with the creation of hybrid 
analogs, discussed in Section 1.5.172. 
 
1.3.1 Structure of A21978C Antibiotics 
As stated previously, Dap, A54145 and CDA are cyclic lipodepsipeptides. The “depsi” in this 
name refers to the ester bond linkage found within the macrocyclic core. They all have a conserved 
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aspartate-X-aspartate-glycine (DXDG) sequence9,11,50,52,57. This sequence is also found in the EF hand 
motif of many proteins that bind calcium11,68,72,73. This conserved feature could explain the 
dependence of these antibiotics to calcium, suggesting each lipopeptide has a conserved mechanism 
of action.  
Dap contains a 10 amino acid-membered macrolactone ring that is closed by an ester bond 
between threonine4 and kynurenine1357,74. It also has a 3 amino acid exocyclic portion, where the 
terminal amino acid, tryptophan1, is attached to a decanoyl tail. Dap contains six non-proteinogenic 
amino acids, including three D-amino acids: ornithine, kynurenine, (2S,3R)-3-methylglutamate, D-
serine, D-alanine and D-asparagine are highlighted in red in Figure 1.6.  
 
Figure 1.6 The non-proteinogenic amino acids found in Daptomycin. These non-proteinogenic amino 
acids are highlighted in red.  
 
The A54145 family of antibiotics all have the same general core structure9,10,71. Boeck, et al. 
isolated eight different factors of A54145 that differ, mainly in the fatty acyl tail moiety70. From this 
work, it was determined that A54145-Factor D (A5, Figure 1.5) had comparable activity to Dap 
against S. aureus strains. A5 contains an 8-methyldecanoyl tail, varying slightly from Dap’s decanoyl 
moiety. A5 was used in this thesis, since it has been determined that this factor of A54145 has the 
lowest toxicity to activity ratio, of this class. That being said, A5 is still too toxic to be used clinically 
and has lower activity in vivo compared to the clinically used vancomycin57,67,72. 
When comparing the physiochemical properties of Dap and A5, both are found to have 
several amino acids with ionizable side chains, shown in red (cationic) and blue (anionic) in Figure 
1.7.  
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Figure 1.7 Conserved amino acids found with Daptomycin and A54145-Factor D. The anionic amino 
acids are highlighted in blue within each lipopeptide. The cationic amino acids are highlighted in red. 
As can be seen, the ionic amino acids are highly conserved between the two calcium dependent 
antibiotics. 
 
In the case of Dap, the pKa’s of each of the ionizable amino acids have been determined 
through several methods, including NMR spectroscopy, ultraviolet spectrophotometry and 
potentiometric titration75. The pKa’s of these groups are shown in Table 1.2.  
 Amino acid pKa 
Cationic residues kynurenine13 0.8-1.3 
 ornithine6 10.7 
Anionic residues aspartate3 4.3 
 aspartate7 1.0 
 aspartate9 3.8 
 3-methylglutamate12 4.6 
Table 1.2 The pKa’s for the ionic residues found within Daptomycin, determined through varying 
methods mentioned previously. 
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All of the ionizable amino acids, except kynurenine13, will be bear a single positive or 
negative charge at physiological pH. Therefore, Dap will have an overall charge of -3 at pH 7.4, with 
no calcium bound. As seen in Table 1.2, the pKa of aspartate7 is unexpectedly lower than the other 
aspartates within Dap, though the reason for this is not clear75. The same set of experiments has not 
been done on A5; however; it is likely that A5 also has an overall charge of -3 at pH 7.4, since the 
DXDG motif is conserved between Dap and A5, which suggests that both lipopeptides would interact 
with calcium similarly.  
Dap and A5 also contain one or more fluorophore(s). Dap contains both kynurenine and 
tryptophan, whereas A5 only contains the latter. The fluorescence emission spectrum of tryptophan 
overlaps the absorption spectrum of kynurenine76. Therefore, when studying Dap using fluorescence 
spectroscopy, exciting the tryptophan residue will result in fluorescence resonance energy transfer 
(FRET) to kynurenine76, and only the fluorescence of the kynurenine residue will be observed. The 
fluorescence properties of Dap and A5 are explained in more detail in Section 1.6. 
 
1.3.2 Biosynthesis 
The A21978C class of calcium-dependent antibiotics are produced by their host organisms 
through several non-ribosomal peptide synthetases (NRPSs)11,57,77,78. In the case of Dap the host 
organism is Staphylococcus roseosporus11, for A5 it is Staphylococcus fradiae72. Each organism uses 
separate NRPS modules, as outlined in Figure 1.8.  
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Figure 1.8 The NRPS enzymes found in the biosynthetic pathways of Dap and A5. Three 
multifunctional enzymes, DptA, DptBC and DptD control the biosynthesis of Dap. Dpt D contains the 
thioesterase domain necessary for cyclization and release of the peptide. Four enzymes, LptA, LptB, 
LptC and LptD that work in the same manner as Dap’s enzymes, carry out the biosynthesis of A5. 
Figure was adapted from Miao, et al.71 
 
 
The syntheses of Dap and A5 are similar, whereby modules, each of which has a 
condensation-adenylation-thiolation (CAT) domain, incorporate an amino acid. There is also an 
optional epimerization (E) domain. In the case of Dap (Figure 1.9), three large, multifunctional 
enzymes, DptA, DptBC and DptD, govern the assembly11,40,72,77,79. A module called DptE initiates the 
synthesis by activating decanoic acid in an ATP-dependent manner. The activated decanoic acid is 
then transferred to a module called DptF. The N-terminus of the C-domain of the DptA initiation 
module then catalyzes the condensation between the enzyme-bound decanoyl tail and tryptophan. 
After this initial condensation, the peptide chain is elongated by linearly operating NRPSs: DptA, 
DptBC, and DptD. Once the peptide chain has been completed, it encounters the thioesterase (TE) 
domain, which is located in DptD. This TE domain directs the intramolecular attack of the hydroxyl 
group of threonine on the enzyme-O-TE oxoester intermediate, which leads to the release of the 
cyclic lipopeptide.  
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Figure 1.9 The biosynthesis of Dap, that occurs through three separate NRPSs77. Each amino acid is 
added to the growing peptide chain through a conserved C-A-T/PCP domain. This domain mediates 
condensation, adenylation and thiolation. There can also be an epimerization (E) domain present. 
The amino acids are first adenylated by the A domain and then attached to the T domain on the same 
module. The C domain bridges the first amino acid with the second through formation of a peptide 
bond. Three large enzymes carry out the synthesis of Dap (DptA, DptBC and DptD). Each enzyme 
FIGURE2.SchematicoverviewofdaptomycinbiosynthesisbyS. roseosporus.Theassemblyof thepeptidecore isgovernedby the threeNRPSsDptA,DptBC,and
DptD, comprising 43 catalytic domains. Initiationof daptomycinbiosynthesis ismediatedbyDptE andDptF, both responsible for the activation and incorporationof
theFAmoiety. In thismodel, theN-terminalCIII-domainofDptAcatalyzes the transferof theDptF-boundFAonto the!-aminogroupofTrp1. ThesynthesisofMeGlu12
is carried ut by the S-adenosylmethionine (SAM)-dependent methyltransferase DptI and a currently unknown aminotransferase. Cyclorelease is mediated by the
C-terminalTEdomainofDptD.Thecyclizationposition isshowningray.A, adenylation;AL,acyl-CoAligase;AT, aminotransferase;C, condensation;E, epimerization;MT,
methyltransferase; PCP, peptidyl carrier protein.
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contains multiple C-A-T modules, with additional domains as necessary. The DptF module is attached 
to the proper acyl tails, which is added initially to DptA. The thioesterase domain (TE), cyclizes and 
released the lipopeptide. The figure was used with permission.  
 
1.4 Three-Dimensional Structure of Daptomycin 
One property that has not been addressed so far is the three-dimensional (3-D) structure of 
Dap. Knowing the 3-D structure both in solution and within the membrane would assist in 
determining Dap’s mechanism of action. Dap occurs mainly in three forms: free in solution with and 
without calcium bound and in a membrane with calcium bound.  
Several researchers have studied the structure of apo-Dap (no calcium bound). Unfortunately, 
all of these researchers differ on their conclusions. Dap, at physiological pH 7.4 has a -3 charge40. The 
anionic residues repel one another, preventing Dap aggregation even at millimolar concentrations75. 
When the pH is lowered, Dap losses some of these negative charges, which results in aggregation, 
even at sub-millimolar concentrations80,81. Hancock and coworkers determined the structure of apo-
Dap by NMR, in solution at a concentration of 2 mM at pH 6.682. At this pH, the charge of Dap is still 
-3, and so aggregation was not occurring. What they concluded was a lack of a preferential structure 
for Dap, although an averaged model of the structure exhibited two bends at aspartate7 and 
aspartate9, and a highly variable region around glycine582. Rotondi, et al. also utilized NMR to 
determine the structure of Dap at 1.9 mM, pH 5.381.  Under these conditions, aggregation is unlikely 
to occur. These researchers concluded that Dap did have a preferential structure. The macrocycle 
adopted a hairpin-loop like structure81. A type II beta-turn83 was found near D-alanine8 and 
aspartate9. There was a second hairpin loop with a beta turn at threonine4 and kynurenine13. The 
hydrophobic portions of Dap (tryptophan, kynurenine, and the decanoyl tail) were clustered at one 
end of the hairpin loop, with the polar amino acids at the other. In another study, Ball, et al. 
determined the NMR structure using a 0.8 mM solution of Dap at pH 5.080. At this acidic pH, 
aggregation will be more likely to occur75. Ball, et al. also observed a low energy structure. They 
stated that Dap was mostly fully extended, but with sharper turns in the structure near D-alanine8 and 
glycine10/D-serine1180. The R-groups of the amino acids were solvent exposed, showing a 
preferential side chain orientation. They stated that, overall, the amino acids were orientated 
randomly and that the anionic amino acids would not be close enough to bind a calcium ion.  
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Hancock and coworkers also attempted to determine the structure of calcium-bound Dap 
(holo-Dap), by NMR82. They used 2 mM Dap, in the presence of 5 mM Ca2+ at pH 6.6. They noted 
only a small degree of line broadening, suggesting minimal aggregation. Their structure of holo-Dap 
was more defined than their structure of apo-Dap. Several medium and long range Nuclear 
Overhauser Effects (NOEs), such as between aspartate3 and alanine8, were observed. Only sequential 
NOEs were found for apo-Dap82. On the basis of these medium and long range NOEs, they concluded 
that the cyclic ring of Dap was less circular and that the side chain of aspartate3 was underneath the 
ring. They also concluded that a calcium-binding site might be found between aspartate3 and 
aspartate7. The data also suggested that a significant change in the re-alignment of the hydrophobic 
portions of Dap, to external solvent, had occurred upon calcium binding. They, therefore, further 
concluded that Dap must undergo a large conformational change upon the binding of calcium82. 
However, later work by Rotondi, et al. showed that the concentration of Dap used by Hancock was 
high enough, with the added calcium ions, to induce aggregation81. They suggested that some or all of 
Hancock’s measured medium and long range NOEs, which were key pieces of information leading to 
Hancock’s determined structure, might have arisen from intermolecular interactions rather than 
intermolecular ones.   
The Hancock laboratory therefore reexamined their finding84. From molecular dynamic (MD) 
simulations, it was concluded that the previously reported NOE restraints were intermolecular and 
should not have been included during structure refinement. Overall, they concluded that the structure 
of holo-Dap did not differ from their calcium-free strcuture84. No calcium-binding site was evident in 
the refined structure. They then utilized circular dichroism (CD) to show that Dap only exhibited 
minor changes in solution, upon the addition of calcium. Ball, et al. further showed, using NMR, that 
the structure of holo-Dap (0.8 mM at pH 5.0 with one molar equivalent of calcium) was very similar 
to apo-Dap80.  
Straus, et al. reported the NMR structure of Dap bound to diheptanoylphosphatidylcholine 
(DHPC) micelles in the presence of calcium85. They used a 2 mM Dap solution at pH 6.7, to which 
they added 5 mM Ca2+ and titrated in ~ 100 mM DHPC (1:50 ratio). The found that it resembled the 
structure that they reported for apo-Dap. They then speculated that Dap experiences only minor 
conformational rearrangements when binding to these model membranes. Although this finding is 
interesting, it must be taken lightly as these lipid membranes, are not an accurate model to mimic 
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susceptible lipid membranes, due mainly to the lack of phosphatidylglycerol (PG), which is necessary 
for Dap activity (See Section 1.7.1)86,87.  
Although the structure of Dap is still elusive, it would be helpful to examine the structure of 
another calcium-dependent antibiotic. So far only one class of calcium-dependent antibiotics, the 
A21978C class, has been discussed. A second class of these antibiotics includes, but is not limited to, 
tsushimycin, amphomycin and laspartomycin. This group differs from the A2198C class in several 
ways, one of which is the replacement of the depsi bond with an amide linkage. Nevertheless, as 
shown in Figure 1.10, there are conserved portions within each class of the calcium-dependent 
antibiotics, including the DXDG motif. Studying this other class could shed light onto the structure of 
Dap in solution.  
 
Figure 1.10 The conserved residues between calcium-dependent antibiotics. Daptomycin, A54145-
Factor D and tsushimycin are shown from left to right. As seen, there is considerable similarity 
between the lipopeptides. The conserved amino acids are shown in blue, which correspond to the 
anionic residues. The amino acids highlight in red show the cationic residues found in Dap and A5. 
For tsushimycin there are three unnatural amino acids, pipecolinic acid (Pip), β-methylaspartate 
(Map) and 2,3-diaminobutyric acid (Dab).  
 
The X-ray crystal structure of tsushimycin has been reported at 1.0 Å resolution (Figure 
1.11)88. The antibiotic has a saddle like structure where a calcium ion is bound in the middle, 
interacting with two acidic residues (aspartate1 and aspartate5), four carbonyl atoms (diaminobutyric 
acid (Dab)2, glycine6, glycine8 and valine10) and a water molecule. The antibiotic forms a dimer 
whose subunits are linked by hydrogen bonds between aspartate7 of one monomer and Dab9 of 
another. The carboxyl groups of aspartate7 and aspartate1 interact with additional calcium. There is a 
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tunnel found in the center of the dimer, large enough to fit a phospholipid molecule. The antibiotic’s 
charged groups point outwards while the hydrophobic regions point internally.  
 
Figure 1.11 The crystal structure of tsushimycin and the H-NMR generated structure of Dap40. A: The 
structure of tsushimycin shows a Ca2+ ion coordinated by an asparate5 residue88. Additional calcium 
ions that bridge dimers of tsushimycin are not shown in image. B: Ball, et al. reported the structure of 
Dap in a calcium free environment80. This structure is more loosely fitted than tsushimycin, with the 
anionic residues on opposing sides of the ring. No calcium-binding site was observed. For both 
structures, the acyl tail has been removed from the presented image. Figure was taken from Taylor, 
et al.40 with permission.  
 
As discussed above, the amino acid sequence of Dap is different from tsushimycin, however; 
there are several conserved features40. The aspartate1 and aspartate5 of tsushimycin, which bind 
calcium, are conserved in Dap as aspartate3 and aspartate7. This suggests that these residues are also 
crucial for Dap-Ca2+ interaction. That being said, aspartate3 of Dap has been replaced with D-
asparagine, the amino acid found natively in tsushimycin, at this position. This replacement causes 
only a fourfold reduction on Dap’s activity (Section 1.5)67, suggesting aspartate3 is not essential to 
activity. The Dab9 residue of tsushimycin has been shown to be the determining factor of dimer 
formation88. 
In summary, this section showed that the 3-D structure of Dap has yet to be determined with 
certainty. Apo-Dap appears to be highly flexible in solution. Dap does not appear to undergo major 
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conformational changes when bound to calcium in solution or within DHPC membranes. Although 
the crystal structure of tsushimycin implicates certain residues important in the calcium binding of 
Dap, there is still no certainty regarding the structure when bound to susceptible membranes. 
1.5 Structure-Activity Relationships  
Daptomycin is currently used clinically as a last resort antibiotic against serious skin infections. 
Unfortunately, resistance to Dap has been already been observed in some clinical studies9,11,12,59,89. To 
combat this growing resistance new and improved analogs of Dap must be created. The synthesis of 
new analogs of Dap has been reported in the literature. The methods that have been used to create 
these analogs and the activity of these analogs are outlined in this section. 
1.5.1 The Biosynthetic Approach to Preparing Dap and A5 Analogs 
As mentioned in Section 1.3, Dap is naturally produced by Streptomyces roseosporus via 
non-ribosomally, site-directed mutagenesis52. Since Dap is made non-ribosomaly, mutagenesis/over-
expression is not a suitable approach to produce new Dap analogs. This feature forced scientists to 
investigate other options. One option is to utilize combinatorial biosynthesis10,52,67,90,91. In this 
approach, entire modules responsible for the incorporation of individual amino acids are swapped 
with NRPS systems encoding other lipopeptides, in particular A5 or CDA.  
Cubist Inc.© has investigated this combinatorial approach to prepare analogs of Dap and A5. 
Using this approach they reported the preparation of 40 Dap and A5 analogs shown in Table 1.3. 
Cubist Inc.©’s objective was to prepare non-toxic hybrids of Dap and A5 that were active in the 
presence of lung surfactant.  
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Table 1.3 Dap and A5 analogs created through combinatorial biosynthesis67. The analogs above 
A54145D are more similar to Dap, the one below are more similar to A54145. The MICs are reported 
both in the presence and absence of lung surfactant. aDap contains a decanoyl residue, all other 
lipopeptides contain an anteiso-undecanoyl chain. bAmino acid changes are shown in bold italics. 
cMICs against S. aureus were determined in the presence of 1% lung surfactant. Reprinted with 
permission from Baltz, R. H. Am. Chem. Soc. – Synth. Biol. 2014, 3, 748-758. Copywright 2014, 
American Chemical Society. 
 
 
As shown in Table 1.3, it is clear that the combinatorial biosynthetic approach has been 
fruitful in synthesizing new Dap derivatives. Some interesting trends were observed with these 
analogs. When kynurenine 13 was replaced with more hydrophobic residues (tryptophan, isoleucine 
and may have evolved from an ancestral module that processed
a D-amino acid. Docking sequences are ommonly associated
with carboxy terminal E domains that interact with do king
domains at the amino terminal of CII domains. It is noteworthy
that all other cyclic lipodepsipeptides and lipopeptides distantly
related to daptomycin (e.g., CDA, friulimicins, amphomycins,
and laspartamycins) have D-amino acids at positions com-
parable to those of Gly5 and Sar5.
10 Other subtle diﬀerences in
biosynthetic logic are discussed below.
The enzymatic functions required for the individual
couplings (coupling devices) are shown in Table 2. It is
noteworthy that A21978C and A54145 use very similar
coupling devices. All told, 17 diﬀerent types of coupling device
are used. If we remove three subtle diﬀerences between the two
pathw ys, the umber of devi es is reduced to 12, 11 of w ich
are used once and the other twice in each pathway. The three
diﬀerences are (i) dptE and dptF have a fused counterpart lptEF
encoding AL and ACP or AL-ACP, respectively; (ii) the dptBC
gene has split gene counterparts lptB and lptC that have been
successfully fused in genetic engineering experiments;23 and
(iii) lptA module 5 has an M domain to incorporate Sar that
can be deleted to incorporate Gly.42 Table 2 shows which parts
of the coupling devices have been successfully engineered, and
Table 3 shows some of the speciﬁc changes and product yields
from strains generated by combinatorial biosynthe-
sis.22,23,26,35,42−49 Ten of the 17 devices have been engineered
Table 4. Lipopeptide Antibiotics Generated by Combinatorial Biosynthesis
amino acid at position listedb S. aureus MIC (μg/mL)c
compounda 2 3 5 6 8 9 11 12 13 − surf + surf ratio (+/−)
daptomycin D-Asn Asp Gly Orn D-Ala Asp D-Ser 3mGlu Kyn 0.5 64 128
CB-181,220 D-Asn Asp Gly Orn D-Ala Asp D-Ser 3mGlu Kyn 0.5 64 128
CB-182,098 D-Asn Asp Gly Orn D-Ala Asp D-Ser 3mGlu Trp 1 32 32
CB-182,107 D-Asn Asp Gly Orn D-Ala Asp D-Ser 3mGlu Ile 2 8 4
CB-182,106 D-Asn Asp Gly Orn D-Ala Asp D-Ser 3mGlu Val 4 8 2
A21978C1(Asn13) D-Asn Asp Gly Orn D-Ala Asp D-Ser 3mGlu Asn 128 ND ND
CB-182,130 D-Asn Asp Gly Orn D-Ala Asp D-Ser Glu Kyn 8 16 2
CB-182,166 D-Asn Asp Gly Orn D-Ala Asp D-Ala 3mGlu Kyn 1 16 16
CB-182,290 D-Asn Asp Gly Orn D-Ala Asp D-Asn 3mGlu Kyn 1 16 16
CB-182,123 D-Asn Asp Gly Orn D-Ser Asp D-Ser 3mGlu Kyn 1 32 32
CB-182,257 D-Asn Asp Gly Orn D-Asn Asp D-Ser 3mGlu Kyn 8 ND ND
CB-182,286 D-Asn Asp Gly Orn D-Ala Asp D-Asn 3mGlu Ile 4 ND ND
CB-182,251 D-Asn Asp Gly Orn D-Ala Asp D-Asn Glu Kyn 32 ND ND
CB-182,263 D-Asn Asp Gly Orn D-Asn Asp D-Ser 3mGlu Ile 16 ND ND
CB-182,269 D-Asn Asp Gly Orn D-Asn Asp D-Ser Glu Kyn 128 ND ND
CB-182,296 D-Asn Asp Gly Orn D-Lys Asp D-Asn 3mGlu Kyn 1 32 32
A54145E D-Glu hAsn Sar Ala D-Lys moAsp D-Asn 3mGlu Ile 1 32 32
A54145D D-Glu hAsn Sar Ala D-Lys moAsp D-Asn Glu Ile 2 4 2
CB-182,548 D-Glu hAsn Sar Ala D-Lys moAsp D-Ala 3mGlu Ile 1 16 16
CB-182,332 D-Glu hAsn Sar Ala D-Lys moAsp D-Ser 3mGlu Ile 2 16 8
CB-182,443 D-Glu hAsn Sar Ala D-Lys Asp D-Asn 3mGlu Ile 2 4 2
CB-182,571 D-Glu hAsn Sar Ala D-Ala moAsp D-Asn 3mGlu Ile 1 32 32
CB-182,549 D-Glu hAsn Sar Ala D-Ser moAsp D-Asn 3mGlu Ile 1 16 16
CB-182,510 D-Glu hAsn Sar Ala D-Asn moAsp D-Asn 3mGlu Ile 8 64 8
CB-182,363 D-Glu Asn Sar Ala D-Lys moAsp D-Asn 3mGlu Ile 2 16 8
CB-182,575 D-Asn hAsn Sar Ala D-Lys moAsp D-Asn 3mGlu Ile 2 4 2
CB-183,296 D-Glu hAsn Sar Ala D-Lys moAsp D-Asn Glu Kyn 1 2 2
CB-182,509 D-Glu hAsn Sar Ala D-Lys moAsp D-Ala Glu Ile 8 16 2
CB-182,336 D-Glu hAsn Sar Ala D-Lys moAsp D-Ser Glu Ile 64 128 2
CB-182,350 D-Glu hAsn Sar Ala D-Lys hAsp D-Asn Glu Ile 8 16 2
CB-182,333 D-Glu hAsn Sar Ala D-Lys Asp D-Asn Glu Ile 32 64 2
CB-182,567 D-Glu hAsn Sar Ala D-Ala moAsp D-Asn Glu Ile 4 8 2
CB-182,532 D-Glu hAsn Sar Ala D-Ser moAsp D-Asn Glu Ile 8 8 1
CB-182,531 D-Glu hAsn Sar Ala D-Asn moAsp D-Asn Glu Ile 16 16 1
CB-182,391 D-Glu hAsn Gly Ala D-Lys moAsp D-Asn Glu Ile 16 32 2
CB-182,325 D-Glu Asn Sar Ala D-Lys moAsp D-Asn Glu Ile 32 32 1
CB-182,444 D-Asn hAsn Sar Ala D-Lys moAsp D-Asn Glu Ile 8 8 1
CB-182,597 D-Glu Asn Sar Ala D-Lys hAsp D-Asn 3mGlu Ile 1 16 16
CB-182,390 D-Glu Asn Sar Ala D-Lys Asp D-Asn 3mGlu Ile 2 2 1
CB-182,561 D-Asn Asp Sar Ala D-Lys moAsp D-Asn 3mGlu Ile 1 2 2
CB-182,349 D-Glu Asn Sar Ala D-Lys hAsp D-Asn Glu Ile 32 64 2
CB-182,348 D-Glu Asn Sar Ala D-Lys Asp D-Asn Glu Ile 16 32 2
CB-182,560 D-Asn Asp Sar Ala D-Lys moAsp D-Asn Glu Ile 8 16 2
aDaptomycin has an N-decanoyl side chain. All others compounds have anteiso-undecanoyl side chains. bAmino acid changes are shown in bold
italics. cMICs against S. aureus 42 were determined in the presence and absence of 1% bovine surfactant (surf). Table reproduced from Baltz et al.42
ACS Synthetic Biology Review
dx.doi.org/10.1021/sb3000673 | ACS Synth. Biol. 2014, 3, 748−758753
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or valine) the activity in lung surfactant increased but the activity without surfactant decreased. This 
suggests that the kynurenine is likely interacting more with PG in the membrane than the other amino 
acids tested. An interchange of kynurenine13 for asparagine eliminated activity, suggesting that a 
non-polar residue is necessary at this position. Replacing 3-methylglutamate with glutamate 
significantly reduced the activity, but the relative effect of surfactant was lowered. Positions 12 and 
13 when substituted together increase activity in surfactant but have an increased MIC value without 
surfactant. Substituting D-serine with D-alanine or D-asparagine slightly increased activity in 
surfactant with minimal change the MICs without surfactant, suggesting that the D-serine residue is 
likely not vital for Dap action.  
Although the use of combinatorial biosynthesis is a powerful tool for the discovery of new 
analogs of Dap, there are several shortcomings that make this approach less useful92. The S. 
roseosporus gene cluster has been sequenced, cloned and heterogeneously expressed, but utilizing 
this technique still requires the use of the host organism52,79. Therefore, although some changes can be 
made to the amino acid structure, no dramatic changes can be done. For example, Cubist Inc.© was 
able to delete the methyltransferase module responsible for converting glutamate to 3-
methylglutamate, but they were unable to change this residue for anything other than glutamate67. 
This highlights that combinatorial biosynthesis is ultimately reliant on the specificity of the host 
organism for certain modules, with no guarantee that added modules will be accepted by this 
bacterium. This issue is also apparent in the inability to alter the stereochemistry of certain amino 
acids at positions 2, 8 and 11. Overall, combinatorial biosynthesis is a helpful tool in discovering 
more lipopeptide antibiotics; unfortunately, this method is restricted to the limitations of what each 
bacterial NRPS can handle. 
 
1.5.2 The Chemo-enzymatic Approach to Dap and A5 Analogs 
The chemo-enzymatic approach to Dap analog synthesis involves the use of solid phase 
peptide synthesis (SPPS) to prepare a linear Dap analog which, after removal from the solid support, 
is then cyclized using a thioesterase/cyclase10,40,73,78. This approach is appealing as a larger variety of 
amino acids can be used, compared to the biosynthetic approach, as the NRPS machinery is mostly 
avoided. Grunewald, et al. synthesized nine Dap analogs with this approach utilizing a CDA cyclase 
enzyme73. The analogs tested are shown in Table 1.4.  
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Entry Compound MIC (µg/mL) at 
73.6 mg/L Ca2+ 
1 Dap-L-N2E12 20 
2 Authentic Dap 3 
3 Dap-L-N2E12 linear >960 
4 Dap- L-N2N3E12 80 
5 Dap- L-N2N7E12 >960 
6 Dap- L-N2N9E12 >960 
7 Dap- L-N2Q12 30 
8 Dap- L-N2D11E12 >320 
9 Dap- L- N2AlocE12 80 
10 Dap- L-N2E12W13 100 
11 Dap- L-N2K6E12W13 100 
Table 1.4 MIC’s of the analogs created by the chemo-enzymatic approach using a CDA cyclase73. 
The analogs were tested against B. subtilis PY79 at 73.6 mg/L calcium.  
 
At the time of this work, the stereochemistry of asparagine2 in Dap was believed to be of the 
L form and so an L-asparagine was used. It was later determined that Dap contains a D-asparagine at 
this position57. Moreover, in all of their analogs, 3-methylglutamate was replaced with glutamate, 
since 3-methylglutamate is very challenging to synthesize68. Consequently, most of their Dap analogs 
were triple mutants containing glutamate in place of 3-methylglutamte12, the unintended L-
asparagine2 substitution, and the additional substitution of interest at a third position within the 
peptide. Nevertheless, this study still provided some useful information regarding the importance of 
certain amino acids to Dap activity.  
Aspartate at positions 7 and 9, have been suggested to be important for calcium binding, as 
they are part of the DXDG sequence found in the EF hand motif of many calcium binding 
proteins73,78. This appears accurate, as the replacement of these amino acids with asparagine (entries 5 
and 6, in Table 1.4), abolished activity. Another interesting finding was the relatively minor decrease 
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in activity found when aspartate3 and 3-methylglutamate12 were replaced with asparagine and 
glutamine, respectively (entries 4 and 7, in Table 1.4). This suggests that these particular residues are 
not directly involved in calcium binding.  
Two years after this work was published, Kopp, et al. reported an improved chemo-
enzymatic approach to Dap and A5 analogs78, by replacing the CDA cyclase with one native to Dap 
and A5’s own NRPSs, which resulted in higher peptide yields78. In this work, the Dap analogs 
contained D-asparagine at position 2 and glutamate instead of 3-methylglutamte at position 12.  They 
synthesized nine new analogs of Dap and A5 (Table 1.5). 
Entry Compound MIC (µg/mL) at 73.6 
mg/L Ca2+ 
1 Authentic Dap 3 
2 Dap-E12 11 
3 A54145(Val) 200 
4 A54145(Ile) 25 
5 Dap(A541-3) 20 
6 Dap(A541-6) 20 
7 A54145(Dap) 25 
8 A54145(NXDG) >900 
9 A54145(DXNG) >900 
10 A54145(NXNG) >900 
Table 1.5 MIC’s of the analogs created by the chemo-enzymatic approach using a Dap or A5 
cyclase. The analogs were tested against B. subtilis PY79 at 73.6 mg/L calcium. Dap-E12 varied from 
authentic Dap, by glutamate in position 12, instead of 3-methylglutamate. All other analogs were 
based off Dap-E12. Kopp, et al.’s A54145 varied from native A54145 by asparagine instead of 
hydroxyl-asparagine in position 3, aspartate instead of methoxy-aspartate in position 9 and glutamate 
instead of 3-methylglutamate in psotion12. A54145(Val) and A54145(Ile) had these amino acids in 
position 13. Dap(A541-3) and Dap(A541-6) had Dap-E12’s structure with the amino acids native to 
A54145 replaced for either the first three or six residues. A54145(Dap) had a diaminopropionic acid 
residue instead of threonine4, thus creating an amide linkage. A54145-(NXDG), -(DXNG), and –
(NXNG) had asparagine’s in replace of aspartate residues, in positions 7 and 9 alone and together.  
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The glutamate13 analog of Dap (entry 2, in Table 1.5) only saw a ~5 fold decrease in activity. 
They determined that position 13 of A5 is largely sensitive to changes in amino acids (entries 3 and 4 
in Table 1.5), compared to what has been observed previously with Dap. They also made two A5 and 
Dap hybrids. The first analog had residues 1-3 of Dap (tryptophan, D-asparagine and aspartate) 
replaced with tryptophan, D-glutamate and asparagine, native to A5 (entry 5 of Table 1.5). The 
second hybrid had the initial 6 amino acids changed, having tryptophan-D-asparagine-aspartate-
threonine-glycine-ornithine replaced with tryptophan-D-glutamate-asparagine-threonine-sarcosine-
alanine (entry 6 of Table 1.5). These both exhibited significantly reduced activity.  
Overall, the chemo-enzymatic approach shows another unique way to synthesize Dap 
analogs. There are, unfortunately, several downsides to this approach. Although this allows for a 
more diverse number of amino acids to be incorporated, there are still limits due to the specificity of 
each cyclase. The overall yields for this reaction were also quite low73,78, which makes this method 
non-ideal for the creation of a library of analogs. The peptides have to be purified by HPLC both 
before and after cyclization, which does not make it very amenable to high throughput analog 
synthesis. Nevertheless, the analogs synthesized by this method highlighted the importance of several 
amino acids in Dap. 
 
1.5.3 Chemical Synthesis of Dap Analogs 
Dap analogs have been prepared via semi- or total synthesis68,93,94. Although many analogs 
can and have been made by other methods, the synthetic approach allows for any and all Dap analogs 
to be made, without having to rely on the limitations of Streptomyces roseosporus selective enzymes, 
mainly the NRPS domains and cyclases.  
Semi-synthesis involves making structural alterations to native Dap. This can include 
removing the acyl tail60 and replacing the exocyclic amino acids69 or altering the structure of certain 
amino acids within the macrolactone ring95,96. Another option is altering the fatty acyl tail moiety 
attached to the N-terminal tryptophan residue of Dap.  
Eli Lily© researchers first investigated this semi-synthesis, following the initial discovery of 
Dap10,60. Debono, et al. studied the effects of different fatty acyl tails on the activity of A21978C60. 
They utilized an Actinoplanes utahensis strain of bacteria for de-acylation, and then re-acylated the 
terminal tryptophan through addition of varying acyl tail lengths coupled with activated esters. They 
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determined that the fatty acyl tail composition is highly important to the antibiotics activity, with an 
optimal balance of activity and toxicity for the decanoyl moiety, which they termed Daptomycin. Dap 
was promising as it was also found to have the highest therapeutic index in mice. When the tail length 
was increased above a decanoyl residue the MIC became slightly lower, but the LD50 decreased 
drastically. When the tail length was lowered below a decanoyl group the activity was dramatically 
reduced.  
Knight-Connoni, et al. utilized semi-synthesis to create several Dap analogs in which the 
decanoyl tail was replaced with cyclic or aromatic hydrocarbons97. From their studies, a novel 
antibiotic was discovered. This antibiotic, surotomycin, contains an (E)-3-(4-pentylphenyl)but-2-
enoyl tail instead of Dap’s intrinsic decanoyl group. Surotomycin was determined to have high 
activity against Clostridium difficile, with a high therapeutic index. It entered Phase III clinical trials 
in 2014 but these studies were discontinued in February of 2016 as it failed to exhibit non-inferiority 
to current therapies.  
Cubist Inc.© has made many Dap analogs by attaching a wide variety of chemical entities to 
the ornithine residue via an array of different chemical procedures95,96. Many of these analogs retained 
activity though none made it to human clinical trials. These results suggested that the ornithine 
residue is not overly important for antibacterial activity. The role of this amino acid for Dap’s mode 
of action is still unclear. 
He, et al. replaced the tryptophan residue in Dap with a wide range of unnatural aromatic 
amino acids69. In this procedure, Dap was first protected on the ornithine with an allyl group. The 
decanoyl tail was then removed enzymatically, and tryptophan1 by Edman degradation. A 
surprisingly large number of these analogs exhibited activity close to that of Dap. Some of these 
analogs also had increased activity in the presence of lung surfactant compared to Dap. This work 
highlights that the tryptophan residue is not essential for activity and it can be changed to further 
improve Dap’s antibacterial properties. 
Only recently was the total synthesis of Dap completed. In 2013, Lam, et al. reported the first 
total synthesis of Dap94. Unfortunately, they were unable to form the ester bond between threonine 
and kynurenine either in solution or on a solid support. They had to resort to a 12-step solution phase 
synthesis of a tetrapeptide, which contained the crucial ester linkage between kynurenine13 and 
threonine4. They then used this tetrapeptide as a building block in their solid phase synthesis. The 
cyclization was achieved via a solution phase serine ligation reaction; unfortunately, the antibacterial 
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activity was never determined. This combination of solid and solution phase chemistry made for a 
very laborious synthesis and is therefore not well suited to the preparation of large numbers of 
analogs.  
In 2014, Martin, et al. also reported the total chemical synthesis of several Dap analogs93. 
They synthesized a branched, acyclic version of their Dap analogs in the solid phase, which, after 
cleavage from the solid support, was cyclized in solution to give the Dap analogs. They did not have 
the same issues as Lam, et al. with regard to depsi bond formation because they utilized a 
diaminopropionic acid (DAPA) derivative instead of threonine at position 4, which resulted in the 
Dap analogs having an amide linkage between residue 4 and 13 instead of an ester linkage. Four 
analogs were prepared (Table 1.6). One analog contained DAPA at position 4 and glutamate in place 
of 3-methylglutamate at position 12 (entry 2, Table 1.6). Another contained DAPA at position 4, 
glutamate in place of 3-methylglutamate at position 12 and tryptophan at position 13 (entry 3, Table 
1.6). The other two analogs were the enantiomers of these analogs (entries 4 and 5, Table 1.6). The 
analogs containing the correct stereochemistry were 100-200 times less active than Dap, indicating 
that the ester bond and/or the methyl group of the threonine side chain is crucial for activity. The 
enantiomers of these analogs were inactive, which suggests that the overall stereochemistry of Dap is 
vital to activity.  
Entry Compound MIC (µM) at 
50 mg/L Ca2+ 
1 Daptomycin 3 
2 Dap-DAPA4E12 201 
3 Dap-DAPA4E12W13 101 
4 Dap-DAPA4E12 (ent) Not active 
5 Dap-DAPA4E12W13 (ent) Not active 
Table 1.6 MIC’s of the analogs created by the combinatorial synthetic approach by Martin, et al. The 
analogs were tested against S. aureus ATCC 29123 at 50 mg/L calcium. Dap-DAPA4E12 varied from 
authentic Dap by having a diaminopropionic acid instead of threonine at position 4, thus creating an 
amide linkage for cyclization. This analog also had a glutamate instead of 3-methylglutamte in 
position 12. Dap-DAPA4E12W13 was based of the previous analog but with kynurenine replaced with 
tryptophan at position 13. The last two analogs in the table are the enantiomers of the previously 
described derivatives.   
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In 2015, Lohani, et al. published the total synthesis of Dap performed entirely on the solid 
phase68 using a combination of Fmoc amino acids and azido acids. Several Dap analogs were initially 
synthesized using this approach (Table 1.7).  
  MIC (µg/mL) 
Entry Compound B. subtilis 
ATCC 1046 
B. subtilis 
PY79 
1 Daptomycin 0.75a, 0.5b,c 0.75a 
2 Dap-(2S,3S)-MeGlu 40a, 5.0b, 5.0c >40a 
3 Dap-E12W13 1.5a 3.0a 
4 Dap-E12Y13 35a, 3.0b, 1.3c ND 
Table 1.7 MIC’s of the analogs created by total synthesis by Lohani, et al. The analogs were tested 
against two B. subtilis strains at 5 mMa, 25 mMb and 100 mMc CaCl2. Dap-(2S,3S)-MeGlu replaced 
the 3-methylglutamate in position 13 with the opposite stereochemistry. Dap-E12W13 had glutamate 
instead of 3-methylglutamate in position 12 and tryptophan instead of kynurenine in position 13. Dap-
E12Y13 had glutamate instead of 3-methylglutamate in position12 and tyrosine instead of kynurenine 
in position 13.  
 
 
When the stereochemistry of the side chain of 3-methylglutamate was reversed (entry 2, 
Table 1.7), the activity was greatly reduced. It has been observed previously that the substitution of 3-
methylglutamate with glutamate, and kynurenine with tryptophan, separately, decrease activity67,78,98. 
Unexpectedly, when both were simultaneously replaced (entry 3, Table 1.7), the activity was 
comparative to Dap at 5 mM calcium.  
Another analog of Dap was synthesized that had 3-methylglutamate replaced with glutamate 
and kynurenine replaced with tyrosine (entry 4, Table 1.7)68. This analog was found to be 
approximately 50-fold less active than Dap at 5 mM calcium, but only 6- and 3-fold less active at 25 
and 100 mM calcium, respectively. This trend was also observed with the Dap-(2S,3S)-MeGlu 
analog. This suggests that these substitutions reduce Dap activity, at least in part, by reducing calcium 
affinity.  
The approach developed by Lohani, et al. was recently improved upon,99 and the new method 
used to create several new Dap analogs based upon Dap-E12W13 (Table 1.8). When a glutamine is 
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replaced with 3-methylglutamate (entry 2, Table 1.8), the resulting analog is 10-fold less active than 
Dap at 5 mM calcium but as active as Dap at 100 mM calcium. This suggests that the glutamate 
residue is involved in calcium binding, though probably not directly. When aspartate7 was replaced 
with alanine (entry 4, Table 1.8), activity was completely lost, even at high calcium concentrations. 
This indicates that this amino acid is likely directly involved in binding calcium, which is plausible as 
it is contained within the DXDG motif. 
Entry Compound MIC (µg/mL) 
 CaCl2 (mM) 1.8 5.0 100.0 
1 Daptomycin 1.0 0.75 0.5 
2 Dap-Q12W13 ND 7 0.75 
3 Dap-E12W13 5.0 1.5 1.5 
4 Dap-A7E12W13 >100 >100 >100 
5 Dap-S4E12W13 >100 65 3 
6 Dap-E3E12W13a N/A 40 1.5 
7 Dap-K6E12W13a 1.0 1.0 0.5 
Table 1.8 MIC’s of other analogs utilizing Lohani, et al.’s methodology. The analogs were tested 
against B. subtilis ATCC 1046 at 1.8 mM, 5.0 mM and 100 mM CaCl2. Dap-Q12W13 had glutamine 
instead of 3-methylglutamate in position 12 and tryptophan instead of kynurenine in position 13. Dap-
E12W13 had glutamate instead of 3-methylglutamate in position 12 and tryptophan instead of 
kynurenine in position 13. All other analogs listed were based of Dap-E12W13, with the 
corresponding amino acid changes shown. aDap-E3E12W13 and Dap-K6E12W13 are unpublished 
data, synthesized by Dr. Chuda Lohani and characterized by Robert Taylor. 
 
Surprisingly, when aspartate3 was replaced with glutamate (entry 6, Table 1.8), the activity 
was greatly reduced. Similarly, when threonine4 was replaced with serine (entry 5, Table 1.8), the 
activity was also significantly reduced. In both of these analogs the only difference is a methylene or 
methyl group. These two analogs highlight that even the smallest of changes to the structure of Dap 
can have large implications on global activity.  
One very interesting analog that was synthesized is the triple mutant Dap-K6E12W13. This 
analog has three of the non-proteinogenic amino acids (ornithine, 3-methylglutamate and kynurenine) 
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native to Dap, replaced with structurally similar proteinogenic ones (lysine, glutamate and 
tryptophan). The activity of this analog was almost identical to native Dap against Bacillus subtilis 
strains at physiological (1.25 mM) or greater than physiological concentrations of calcium (5 and 100 
mM). This analog was therefore investigated further against several Staphylococcus aureus strains 
(Table 1.9). 
 MSSA  MRSA 
 ATCC 
6538 
ATCC 
25293 
 Isolate 
1-3 
Isolates 
4, 5 
(1.25 mM Ca2+)      
Dap 0.75 1.0  1.0 1.5 
Dap-K6E12W13 3.0 3.0  3.0 >3.0 
(5.0 mM Ca2+)      
Dap 0.75 0.5  0.5 0.5 
Dap-K6E12W13 0.3 0.5  0.5 0.5 
Table 1.9 MIC’s of Dap and Dap-K6E12W13 on various strains of either methicillin-susceptible 
(MSSA), or methicillin-resistant (MRSA), Staphylococcus aureus. Two calcium concentrations were 
used, either 1.25 mM or 5.0 mM CaCl2. The MRSA strains were distinct clinical isolates, not 
contained in type culture collections. Data shown in table is unpublished work by Robert Taylor.  
 
Dap-K6E12W13 is an important discovery in the synthesis of new Dap analogs. This analog 
proves that it is possible to obtain an analog that has activity that is at least equal to that of Dap. 
Moreover, it also shows that several of the non-proteinogenic amino acids, which can be time-
consuming and challenging to prepare, are not required for high activity. This analog is currently 
being used in Dr. Taylor’s laboratory as a lead for the synthesis of new and improved Dap analogs 
and for studying Dap’s mechanism of action. Overall, from this section, it is clear that SPPS is a 
powerful approach to the synthesis and preparation of a large scale of new Dap analogs.  
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1.6 Methodologies Utilized to Study Daptomycin’s Action Mechanism 
Although structure-activity relationship studies have determined the importance of a few of 
Dap’s residues, it is not possible to predict which amino acids should be varied in order to obtain 
analogs with improved activity. It would be easier to determine which amino acids should be varied 
with certainty and in greater molecular detail, if the mechanism of action of Dap was known. Many 
action mechanisms have been proposed for Dap and a variety of methodologies/techniques have been 
employed to investigate Dap’s action mechanism. A few of these methodologies/techniques are 
outline in this section, with a focus on the ones that were used throughout this thesis. In Section 1.7, 
the various mechanisms that have been proposed for Dap are outlined. 
 
1.6.1 Membrane Systems 
Ideally, when studying Dap viable pathogenic bacterial strains, which are treated clinically 
with Dap, should be used. Dap action has indeed been investigated on several pathogenic bacteria, 
including S. aureus, E. faecalis, E. faecilium and S. pneumoniae. Unfortunately, pathogenic bacteria 
can be somewhat dangerous to use and require a level II biosafety facility. Therefore, non-pathogenic 
bacteria, mainly Bacillus subtilis, have been used frequently to study Dap. The limitations of the use 
of B. subtilis as a stand-in for pathogens, such as S. aureus are discussed in more detail within 
Chapter 4.  
A convenient approach for studying how Dap interacts with bacterial membranes is to use 
simplistic model membranes. There are different types of model membranes including monolayers, 
planar lipid membranes and unilamellar liposomes, which are small (SUV), large (LUV) or giant 
(GUV). Since bacterial membranes consist of a bilayer in aqueous solvent, unilamellar liposomes are 
the best-suited model membranes to investigate Dap. Liposomes are prepared by mixing varying 
phospholipids, followed by hydration/agitation of these lipids with aqueous solvent. The liposomes 
will vary in size and bilayer thickness initially, and are considered multiple lamellar vesicles (MLVs). 
MLVs are further subjected to varying methods, including sonication (for preparing SUVs) or 
extrusion (for preparing LUVs). LUVs (≥100 nm) have less curvature strain than SUVs (10-50 nm) 
and are used primarily in this thesis.  
It is desirable when studying Dap that the model membrane used mimics the lipid 
composition of a clinically susceptible pathogen, such as S. aureus. Several studies have shown that 
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the lipid composition of the S. aureus contains a large percentage of PG (~80%), with lower 
percentages of lysyl-PG and cardiolipin (CL), at ~15% and 10%100,101–103,104. It should be noted that 
the lipid composition of bacteria varies strain to strain (See Chapter 4 for more detail). The model 
membrane most commonly used to study Dap in the literature, consists of a one-to-one mixture of 
phosphatidylcholine (PC) and phosphatidylglycerol (PG). Although this composition varies compared 
to a S. aureus cytoplasmic membrane, Muraih, et al. showed that Dap requires the same concentration 
of calcium to observe membrane interaction on either these model membranes or bacterial 
membranes. This was accomplished by utilizing fluorescence with a perylene labeled Dap analog105. 
S. aureus contains >50% PG, but higher percentages of PG have been shown to cause LUVs (used 
primarily in this thesis) to be less stable. Although PC is not found in Gram-positive bacteria106, it is a 
neutral phospholipid and Dap has only been found to interact with this lipid at very high calcium 
concentrations105. Therefore, PC can be regarded as an inert “filler lipid” that allows investigations of 
the interaction of Dap with the other, “specific” lipids such as PG. The Leonenko group has also 
shown recently that model membranes (both monolayers and LUVs) can be made that more closely 
mimic the membrane composition of S. pneumoniae66. These lipid mixtures have been utilized to 
investigate the sequestering of Dap by lung surfactant. The role of the lipid head group when 
comparing varying bacteria and the effect of the acyl tail composition of these membranes, are 
discussed in more detail within Chapter 4.   
 
1.6.2 Characterizing the Interaction of Daptomycin with Membranes  
The interaction of Dap with model and bacterial membranes has been examined using an 
extensive array of techniques, such as: circular dichroism (CD)82,107, nuclear magnetic resonance 
(NMR)82,85,108,109, isothermal titration calorimetry (ITC)110,111, fluorescence spectroscopy45,84,112–120 and 
atomic force microscopy (AFM)55. Each of these techniques has their own unique advantages and 
disadvantages. ITC and fluorescence spectroscopy are discussed below, as these were the two 
dominant techniques that were utilized in this thesis to study the interaction of Dap with model 
membranes.  
ITC has been used in the literature to study the interaction of Dap with PG containing 
membranes110,111. ITC provides information on the binding energies (enthalpy, Gibbs free energy, 
entropy) of Dap within membranes and its interaction/stoichiometry with calcium.  
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ITC is a sensitive calorimetric technique used to determine the full thermodynamic profile of 
a system, by directly measuring the release (exothermic) or absorption (endothermic) of the heat in a 
reaction121–124. ITC works by dispensing one reactant into a reaction cell, and then injecting the other 
reactant in small increments. The heat released or consumed with each injection is observed by 
measuring the electric energy required to restore the reaction cell to the preset temperature, which is 
maintained in a reference cell (an example of this type of isotherm is shown in Figure 1.12).  This 
creates an isotherm of peaks that eventually reach a saturation point (Figure 1.12B). The calorimeter 
then converts this raw data into an integrated curve shown in Figure 1.12C, with the molar ratio 
representing the x-axis and the enthalpy representing the y-axis. From this isotherm, the 
thermodynamic parameters can be calculated and the data can be modeled through external software 
(namely Origin software). To model this data, one must assume one or multiple equilibria; varying 
the stoichiometry and equilibrium constants until the best fit to the data, with the smallest number of 
variable parameters, is determined.  
 
Figure 1.12 Isothermal titration calorimetry (ITC). A: The calorimeter is composed of two cells, a 
reference cell and a sample cell. The reference cell is maintained at a constant temperature. The 
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syringe both injects reactant into the sample cell and stirs the mixture. B: The isotherm that is 
generated from the changes in electric energy after, in this case, an exothermic reaction has occurred 
within the sample cell. The peaks will lose intensity over time due to a saturation effect. C: The 
integrated isotherm shows the molar ratio of ligand to reactant, versus the enthalpy. Each point 
represents the area under one peak of the curve in B.  
 
 Fluorescence spectroscopy has proven to be a powerful technique for probing how specific 
parts of Dap interact with membranes. When Dap interacts with membranes in the presence of 
calcium, it goes from the polar environment of the aqueous solvent to the apolar environment of the 
membrane. If any intrinsic or extrinsic fluorophores attached to Dap experience this change in 
environment, a blue shift and/or a significant increase in the intensity of the fluorescence spectrum 
occurs. Depending on the fluorophore used, a blue shift will be more prominent (tryptophan) versus 
an intensity increase (pyrene, perylene, NBD, etc.). 
 Dap, as discussed briefly in Section 1.3 contains the fluorophores, kynurenine and 
tryptophan. Since kynurenine’s quantum yield is higher than tryptophan76, and its excitation spectrum 
(λex,max = 360 nm) overlaps with the emission spectrum of tryptophan (λem,max = 340 nm) a photon 
originating from the excitation of tryptophan will transfer to the kynurenine and so only kynurenine 
fluorescence is observed. This phenomenon is known as fluorescence resonance energy transfer 
(FRET). 
Semi-synthesis has been used in the literature to incorporate external fluorophores, usually 
ones that has a much higher quantum yield than a standard amino acid, into Dap105,116,125–127. This has 
been done with a variety of fluorophores including pyrene45,125, perylene105, nitrobenzoxadiazole126 
and acrylodan116,127.  
Another indirect method of studying Dap is through using a fluorescent dye in solution or in 
the membrane, including 3,3’-Dipropylthiadicarbocyanine iodide (DiSC3)49,128, 4,4′-[1,4,10,13-
tetraoxa-7,16 diazacyclooctadecane-7,16-diylbis(5-methoxy-6,2-benzofurandiyl)]bis-1,3 
benzenedicarboxylic acid (PBFI)112,118, calcein82,114 and laurdan119, that can be detected when Dap is 
in proximity to a membrane or eliciting an effect. The use of dyes to study Dap is explored in Section 
1.7, when the mechanism of action of Dap is discussed. Overall, fluorescence is a very versatile and 
important technique in studying Dap, mainly due to its high sensitivity. 
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1.7 Proposed Mechanisms of Action for Daptomycin 
Dap has been studied for over 30 years and yet its mechanism of action has not been 
determined with certainty. Many research groups have investigated the action mechanism of Dap on 
bacterial cells. Determining the mechanism of action should allow for a more rational approach to the 
creation of new analogs of Dap that will, hopefully, combat growing multi-drug resistance bacteria. 
This section outlines the many different proposed mechanisms of Dap action, including confirmed 
and suspected targets for Dap activity.  
 
1.7.1 Target of Daptomycin Action 
Daptomycin, as discussed in Section 1.3, is a calcium-dependent antibiotic. Eliopoulos, et al. 
first reported this dependence on calcium, when they observed that it was required in the growth 
medium when analyzing the antibacterial activity of Dap129. When calcium was replaced with other 
divalent ions (Mg2+, Zn2+, or Ba2+) activity was not observed129. Barry, et al. observed maximal Dap 
activity when the concentration of calcium in the medium was 50 mg/L (1.25 mM)130, corresponding 
to the concentration found within human blood plasma. Calcium-dependent antibiotics, including 
Dap, contain a highly conserved sequence of amino acids, related to their affinity for calcium. This 
sequence motif (DXDG) has been found in many proteins that bind calcium selectively, including 
calmodulin11,40,72,73. 
In Section 1.5, it was observed that when either aspartate (D) residue within this motif was 
replaced with asparagine or alanine, activity was completely lost even at high calcium ion 
concentrations99. This suggests that this conserved sequence is likely selectively binding to calcium. 
The ‘X’ position contains a D-amino acid in both Dap and A5, suggesting the stereochemistry of this 
amino acid is important to calcium affinity. Very recently, Barnawi, et al. synthesized an alanine scan 
of a Dap analog that has 3-methylglutamate12 replaced with glutamate and kynurenine13 replaced 
with tryptophan. This Dap-E12W13 analog showed only a 3-4-fold decrease in activity comparative 
to Dap at physiological calcium concentrations (1.25 mM). Barnawi, et al. showed that the further 
replacement of D-alanine8 with L-alanine8 had a ~80 fold increase in MIC. This suggests that the 
stereochemistry of this position is important but not vital to activity.  
Canepari, et al. have demonstrated, using radiolabelled Dap, that Dap interacts with the cell 
wall and membrane but not to the cytosolic components131. Initial studies on Dap utilized model 
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membranes consisting of both phosphatidylcholine (PC) and PC-cholesterol76,132. Although Dap was 
shown to insert within76 and permeabilize these membranes, detected using planar bilayer 
conductivity132, they are, unfortunately, not a good model to mimic bacterial cells as they contain no 
PG87,106.  
PG is a required lipid for Dap activity9,11,12,40,48,52,104. CD spectroscopy has shown that Dap 
when bound to calcium and membranes that contain PC and PG, undergoes a significant 
conformational change82. It was also observed that the inclusion of PG into model membranes 
significantly increased the fluorescent quantum yield of the kynurenine residue in comparison to 
liposomes that did not contain PG76,82. This suggests that kynurenine is inserting more deeply into PG 
than the PC.  
Several research groups have determined the stoichiometry of Dap to PG in model 
membranes. Muraih, et al. showed, using a Dap analog that had perylene attached to the terminal 
tryptophan residue, that the stoichiometry was 1:1115. However, work by Zhang, et al. suggested, 
utilizing isothermal titration calorimetry (ITC), that Dap actually has a 1:2 stoichiometry with PG110. 
The model membranes each group utilized could explain the reason for these discrepancies. The work 
with perylene-Dap used a bicelle, whereas ITC analysis used a liposome. Bicelles would allow for 
Dap to insert into both the inner and outer leaflets, whereas liposomes might only detect insertion on 
the outer leaflet. Another reason for these different stoichiometries could be the nature of the 
experimental technique, whereby fluorescence detects only one binding interaction with PG wherase 
ITC detects two. In either case, these data support the findings mentioned above that Dap inserts into 
PG within the membrane, selectively and directly.  
Streptomyces roseosporus is the organism that naturally produces Dap10. Since it is also a 
Gram-positive bacterium, one would expect Dap to kill its host. Ingeniously, S. roseosporus contains 
very little if any PG within its membrane9,11,12,57. It has also been shown that lower percentages of PG 
within S. aureus strains diminish the bactericidal activity of Dap133. Dap has also been shown to  
interact with PG rich regions (cell division septa) within the model organism B. subtilis134,135. PG is 
also absent from mammalian cells, which may explain Dap’s low toxicity in humans 38. All of these 
findings further support that PG is absolutely required for Dap activity, but not strictly for membrane 
interaction.  
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1.7.2 Membrane Depolarization, Membrane Integrity and Oligomer Formation 
In 1987, Allen, et al. using a potassium selective electrode, reported that Dap, promoted the 
loss of intracellular potassium ions from S. aureus136. In 1991, they reported that Dap, in a Ca2+-
dependent manner, promoted the release of the membrane permeant anion teteraphenylphosphonium 
bromide (TPP)137. On the basis of these results, the authors suggested that dissipation of membrane 
potential might be the primary mechanism of action of Dap.  Previous studies demonstrating Dap’s 
inhibition of protein, RNA, DNA, peptidoglycan, lipid and LTA biosynthesis with equal facility was 
proposed to be a downstream effect of the loss of membrane potential74.  
To further elucidate the role of membrane potential loss in the mechanism of action of Dap, 
Silverman, et al. examined the effect of Dap on the membrane potential under conditions typically 
used for determining the time-kill kinetics of Dap46.  Using both fluorometric and flow cytometric 
assays they found that at 8 times the MIC, a concentration required due to the high cell density, that 
the cell viability of S. aureus decreased in parallel with changes in membrane potential, in a dose-
dependent manner.  No loss of membrane potential or loss of cell viability occurred at a concentration 
of Dap equal to the MIC, over 60 minutes. They observed that bactericidal activity and membrane 
depolarization occurred on the same time scale, suggesting that depolarization is the primary 
mechanism of action of Dap.  Employing a K+-sensitive fluorescent probe, they demonstrated that 
Dap triggered K+ release from S. aureus in a Ca2+-dependent manner and that K+ release was 
correlated with bactericidal activity46.  The much slower loss of membrane potential that was 
promoted by Dap compared to the pore-forming peptide nisin and the proton ionophore CCCP (which 
disrupted membrane potential within 5 min) suggested to them that Dap’s action mechanism was 
different from these and other antibacterials that are capable of rapid depolarization of bacterial 
membranes. The trans-membrane pH gradient of cell membranes remained intact, suggesting that 
Dap is forming a membrane lesion that is selective for only small cations to pass across the bilayer. 
Free protons might also diffuse across the membrane, but this proton concentration will be quite low 
and undetected. The authors proposed a model for the mechanism of action of Dap (Figure 1.13) 
where Dap inserts into the bacterial cytoplasmic membrane in a Ca2+-dependent fashion presumably 
by interaction with PG.  This is followed by oligomerization to give either ion channels, larger non-
specific pores or irregular aggregate structures.  Formation of any of these structures would disrupt 
the functional integrity of the membrane and trigger release of K+ ions and cell death46. 
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Figure 1.13 The mechanism of action of Dap proposed by Silverman, et al.46 The authors proposed 
that Dap inserts into bacterial membranes (that contain PG) in a calcium dependent manner. Once 
bound to the membrane Dap oligomerizes, forming ion channels or non-specific pores that allow for 
the relapse of potassium ions from the cell, resulting in cell death. The figure was used with 
permission. 
 
Rubinchik, et al. using the same fluorometric assay employed by Silverman, et al. also 
reported that Dap, at 8 times its MIC, induced depolarization of S. epidermidus within 15 minutes and 
cell viability decreased in parallel with the reduction in membrane potential138. 
Several groups have reported that, in contrast to Silverman, et al.46 and Rubinchik, et al.138, 
loss of membrane potential is not temporal with cell death82,128.  Jung, et al. examined Dap-induced 
membrane depolarization of S. aureus using a fluorometric assay similar to that employed by 
Silverman, et al.82 In contrast to Silverman, et al. results, where membrane potential was reduced by 
>90% within 30 min of adding Dap; Jung, et al. reported that at 10-fold above the MIC, 99% of 
bacterial killing also occurred but only 36% membrane depolarization was reported, after 90 minutes. 
Jung, et al. proposed that depolarization might be a consequence rather than the cause of cell death82.  
Using a fluorometric assay similar to that employed by Silverman, et al., Hobbs, et al. also 
reported that loss of viability preceded membrane depolarization of S. aureus upon exposure to 4 
times the MIC of Dap128. The capacity of the cells to synthesize macromolecules was used as an 
indicator of the viability of the bacteria.  These workers suggested that membrane depolarization may 
not be solely responsible for loss of viability and may also involve more general damage to the 
membrane.  
A report that clinical isolates of S. aureus that have developed reduced susceptibility to Dap 
did not display membrane depolarization at a dose 2 fold higher than MIC also suggests that 
proper maintenance of the K! gradient is important to bacte-
rial viability, we measured K! release during exposure to dap-
tomycin in S. aureus. Adding daptomycin resulted in a calcium-
dependent release of K! in S. aureus. This calcium-dependent
activity supports previous observations indicating that physio-
logic concentrations of calcium are required for daptomycin
activity (3, 13). In addition, potassium release and viability loss
were correlated. In these experiments, bactericidal activity was
more rapid compared than in membrane depolarization stud-
ies. This increased activity resulted from the use of HEPES-
glucose assay media in these experiments as opposed to the
rich media (MHBc) used in the membrane potential assays.
The analysis of the K! gradient during daptomycin exposure
suggests that K! release may be responsible for membrane
depolarization or that K! may be one of several ions released
during membrane depolarization by daptomycin.
We have demonstrated a clear correlation between dapto-
mycin bactericidal activity and membrane potential dissipation
and the calcium-dependent release of potassium from dapto-
mycin-exposed cells. We have proposed a multistep model for
the mechanism of action of daptomycin based on the results of
these and previously published experiments (Fig. 7). During
step 1 of the process, daptomycin inserts into the cytoplasmic
membrane of bacteria, as indicated by whole-cell and artificial
membrane studies (8, 13). Artificial bilayer studies suggest that
insertion can occur in the absence of a bacterium-specific com-
ponent; however, the possible existence of a gram-positive
specific receptor for daptomycin has not been ruled out. Step
2 postulates an as-yet-unproven oligomerization event: dapto-
mycin oligomers could form ion channels, larger nonspecific
pores, or irregular aggregate structures (25). The latter have
been implicated in the mechanism of action of iturin A, an
antifungal membrane-active lipopeptide (15). Alternatively, a
cellular component could contribute to this process (5, 6).
Formation of any of these structures disrupts the functional
integrity of the membrane and triggers a release of intracellu-
lar ions (e.g., K!) leading to rapid cell death (step 3). Addi-
tional whole-cell and in vitro studies are being conducted to
understand the behavior of other ions (e.g., Na! and H!) and
larger molecules (e.g., ATP and proteins) in the presence of
FIG. 6. Bactericidal activity and potassium release. Potassium release was triggered by the addition of 1 mM CaCl2. Data were normalized to
the pre-calcium addition baseline values. The cell viability determined 15 min after calcium addition is indicated for each daptomycin dose level.
FIG. 7. Proposed model for the bactericidal mechanism of action of daptomycin. Daptomycin (Dap) inserts into the bacterial cytoplasmic
membrane in a calcium-dependent fashion and is followed by oligomerization and disruption of the functional integrity of the cytoplasmic
membrane (as described in the text), triggering a release of intracellular ions and rapid cell death.
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membrane depolarization may not be the only cause of cell death by Dap139. Although interesting, this 
study must be taken with caution, as the assay was dependent on the release of calcein from S. aureus 
cells. As will be discussed below, Dap does not allow for the transport of calcein, therefore the 
argument that this indicates a lack of permeabilization is erroneous.  
Scanning electron microscopy (SEM) studies have shown that Dap does not cause lysis of S. 
aureus and E. faecalis, at concentrations of Dap that far surpass the MIC (8 mg/mL)140. Transmission 
electron microscopy (TEM) experiments have also shown that Dap does not cause lysis of S. aureus, 
at Dap concentrations only slightly above its MIC (4 µg/mL)114. Cotroneo, et al. showed that Dap, at 
concentrations above its MIC (4 µg/mL), caused a thousand-fold decrease in cell viability but that the 
optical density remained the same114. This indicates that the cells were dying but that lysis was not 
occurring. As noted above, Silverman, et al. has proposed that depolarization is the controlling factor 
for bactericidal action46. In direct contrast, Müller, et al. stated, through optical density 
measurements, that lysis of B. subtilis at a concentration of Dap above its MIC (4 µg/mL) does 
occur119. The reason for this discrepancy is not clear, but the type of bacteria studied might have 
influenced the results. 
The effect of Dap on membrane integrity has been examined by monitoring the loss or uptake 
of fluorescent organic molecules into or out of model liposomes and bacteria upon exposure to Dap. 
One of these dyes is calcein (Figure 1.14).  Cotroneo, et al. reported that treatment of calcein-loaded 
S. aureus cells with 2 µg/mL of Dap produced rapid bactericidal activity without significant calcein 
release114. In contrast, both the pore-forming antibiotic nisin and lysostaphin, which is bactericidal 
through the destruction of the S. aureus cell wall, exhibited 100% calcein release after just 20 
minutes114.  This suggests that Dap transports ions smaller than calcein across the membrane. 
Another fluorescent dye, To-Pro3, which interacts with and strains DNA, was unable to enter 
cells when treated with Dap114.  Several researchers have also attempted to utilize the live-dead dye, 
propidium iodide46,119,141. This dye has been used widely to determine if cells are alive or not. 
Rubinchik, et al. stated that this dye was able to cross bacterial membranes in the presence of Dap, as 
witnessed by a change in this dye’s fluorescence138. Unfortunately, propidium iodide is very similar in 
structure to ethidium bromide, which is used to study the efficiency of bacterial efflux systems142. Ion 
gradients or ATP, both of which disappear upon Dap activity, drive many efflux systems. Therefore, 
propidium iodide, when observed to be entering cells, is measuring more than one process. This 
makes the results obtained from studying propidium iodide harder to interpret.   
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Figure 1.14 The relative size comparison of several dyes used in the study of Dap’s pore. Dap has 
been shown to transport small cations, mainly sodium and potassium. In the To-Pro-3 structure, 
several amino acids are shown. These include: tryptophan (W), D-valine (DV), Proline (P), Sarcosine 
(Sa) and methyl-valine (VM).  
 
The effect of Dap on the integrity of model membranes using calcein has provided similar 
results to the work on bacterial cells mentioned above. The Hancock group loaded model membranes 
with calcein.138 Calcein was retained inside membranes after exposure to Dap indicating that it was 
being prevented from leaving the liposome.  
Using a coupled fluorescence assay, Zhang, et al. found that Dap forms ion selective pores in 
model membranes45. This assay (Figure 1.15), similar to one developed by Clement, et al.143 utilized a 
pH sensitive fluorophore, pyranine.  Pyranine was encapsulated within the model membranes, and a 
pH gradient was created across the membrane. The use of two buffers containing either low salt 
(inside liposome) or high salt (outside liposome) concentrations produced a dual salt/pH gradient 
across a model membrane, stabilizing the charged ion ratio across the bilayer. When a proton 
ionophore, cyanide m-chlorophenyl hydrazone (CCCP, 5 nM) was added alone to these membranes 
minimal pyranine fluorescence is observed. The high concentration of salt ions outside the liposome 
will prevent the flow of protons against the liposomes diffusional potential. Dap (1-2 µM) when 
added alone (with calcium) also produced minimal fluorescence. It is not until both compounds are 
added collectively that proper efflux of protons concomitantly with influx of salt ions can occur. This 
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release of protons increases the pH of the internal buffer, deprotonating the pyranine reside found 
within, increasing its fluorescent signal143.  
 
Figure 1.15 Schematic for the permeabilization assay explored by Zhang, et al.45 A: Liposomes are 
encapsulated with the pH sensitive fluorophore, pyranine, in a low salt concentration and low pH 
buffer. The external buffer contains a high concentration of salt (in this case K+) and a more alkaline 
pH. This creates a salt-pH gradient across the membrane, equalizing the charge ratio across the 
liposome. B: When a proton ionophore, cyanide m-chlorophenyl hydrazone (CCCP) is added alone, 
no proton efflux is observed as the charge ratio of the ions present is not kept constant. C: When both 
Dap and CCCP are added in unison an influx of K+ (Dap) occurs concomitantly with an efflux of 
proton (CCCP). This removal of protons from the liposome creates a more alkaline buffer inside the 
liposome, deprotonating the hydroxyl group of the pyranine, increasing its fluorescent signal. This 
figure was used with permission.  
 
The authors demonstrated that Dap form pores in DMPC/DMPG liposomes45.  The pores are 
selective for cations, with permeabilities being highest for Na+, K+, and other alkali metal ions. The 
permeability was approximately two-times less for Mg++, and even lower for the organic cations 
choline and hexamethonium.  Anions were excluded. Dap-promoted leakage of K+ was slow 
compared with that of valinomycin, a K+-specific ionophore, at comparable concentrations. 
As stated above, Silverman, et al. first theorized that Dap forms oligomeric structures within 
the membrane that lead to pore formation46. This is plausible, as many pore forming compounds form 
oligomers in cell membranes144,145.  Studies on model liposomes support this hypothesis. 
Using a polarity-sensitive fluorophore nitrobenzodiaxole (NBD), attached to the ornithine6 
residue of Dap, Muraih, et al. were able to detect Ca2+-dependent FRET between the kynurenine 
residue of unlabelled Dap and the NBD group of NBD-Dap on liposomes126. These liposomes 
contained DMPC, combined with or without DMPG, as well as membrane vesicles prepared from B. 
subtilis cells. The presence of PG was necessary for FRET to occur as no FRET was observed with 
the pyranine-loaded liposomes into the ﬁnal reaction buffer containing
100 mM KCl at pH 8 creates two opposite ion concentration gradients
across the liposomemembrane: the K+ concentration is higher outside,
whereas the H+ concentrati n is higher inside (Fig. 2A). Additi n of t
proton ionophore CC P alone to this system will cause little change to
the pH within the liposomes, since the efﬂux of protons will very soon
be restricted by the ensuing diffusion potential (Fig. 2B). The internal
pH will change signiﬁcantly only after addition of daptomycin, if, and
only if, daptomycin allows the inﬂux of potassium ions. Both ion gradi-
ents will then dissipate, the interior pH will rise, and pyranine will dis-
sociate and ﬂuoresce (Fig. 2C).
The ﬁndings obtained using this assay with different cations are il-
lustrated in Fig. 3. Panel A shows that the experimentworks as expected
with valinomycin, a potassium-speciﬁc ionophore.With potassium, but
not with sodium, the combination of valinomycin and CCCP induces
a rapid change that indicates swift dissipation of the proton gradient,
facilitated by exchange of protons and potassium ions across the mem-
brane. CCCP alone does not induce an appreciable change in ﬂuores-
cence, while valinomycin al ne shows a minor one; it may be that
valinomycin has a limited ability to translocate protons bound to it, as
has been suggested earlier [22].
Fig. 3B shows the same experiment with daptomycin instead of
valinomycin. Again, only the combination of daptomycin and CCCP in-
duces a majo change f ﬂuorescence, while either agent alone induces
negligible changes in ﬂuoresce ce. This indicates that daptomycin al-
lows the inﬂux of potassium ions. Also note that the rate of ﬂuorescence
change induced with daptomycin/CCCP was signiﬁcantly smaller than
with valinomycin/CCCP, which indicates that under the given experi-
mental conditions the rate of ﬂuorescence change was constrained by
daptomycin and not by CCCP. This latter conclusion is further supported
by the experiments shown in Figs. S2 and S3.
Furthermore,when CCCPwas added severalminutes after daptomy-
cin in order to allow lead time for daptomycin pore assembly before
triggering ion gradient dissipation, the ensuing ﬂuorescence traces
were very similar to those obtained with simultaneous application
(data not shown). This indicates that the rate of ion ﬂuxwas not limited
by the process of pore assembly, but rather by the permeability of the
al ady assembled pores.
A B C
Fig. 2. Schematic representation of the pyranine-based liposome permeabilization assay, using K+ ions as an example. Liposomes loadedwith pyraninewere diluted into theﬁnal reaction
buffer to create two opposite ion concentration gradients across themembrane (A). Application of the protonophor CCCP alonewill create a diffusion potential, whichwill prevent amajor
efﬂux of protons (B). If daptomycin is added also and allows K+ ions to enter, both ion gradients can dissipate, the pH in the liposomewill rise, and pyranineﬂuorescencewill increase (C).
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Fig. 3. Time-based ﬂuorescence traces of pyranine-loaded liposomes after exposure to different test solutes and permeabilizing agents, which were added at t = 0. The interior pHwas 6
and the exterior pHwas 8. Test solutes added to the exterior buffer at 100mMwereKCl in B, andotherwise as indicated; “hexa” in C andD is hexamethonium. After 300 s, the sampleswere
solubilizedwith Triton-X100, and the ﬂuorescencemonitored for anotherminute. The ﬂuorescence intensity observed after Triton solubilization was used to normalize each ﬂuorescence
trace. A: Valinomycin (val., 0.5 μM) with CCCP (5 nM) permeabilizes liposomes for potassium but not sodium. B: Daptomycin (1 μM) plus CCCP (5 nM) also causes permeabilization for
potassium of membranes containing PG, but not cardiolipin. C: Permeabilization traces obtained with both daptomycin and CCCP present, after subtraction of the traces obtained with
CCCP only. D: Averages and standard deviations of ﬂuorescence intensities after 300 s of incubation, for 3 or 4 independent experiments performed as in C (“chol.” is choline).
2427T. Zhang et al. / Biochimica et Biophysica Acta 1838 (2014) 2425–2430
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liposomes containing just DMPC.  Self-quenching of NBD fluorescence was observed using just 
NBD-Dap at concentrations similar to those required for biological activity, on both DMPC/DMPG 
liposomes and B. subtilis cell membranes but not on DMPC liposomes.  Self-quenching could be 
reversed upon the addition of an excess of unlabeled Dap126.  These results strongly indicate that Dap 
oligomerizes on model and bacterial membranes.  The proposed oligomers were found to be stable for 
several hours. The number of subunits contained in one Dap oligomer was determined to be 
approximately 7 in DMPC/DMPG liposomes. 
Zhang, et al. have provided evidence that oligomerization is necessary but not sufficient for 
activity110. In a mixture of CB-182,462 (a semi-synthetic derivative of A5, Figure 1.16) and Dap on 
DMPC/DMPG liposomes (5 mM Ca2+), the fluorescence of the tryptophan residue in CB-182,462 
was largely suppressed by FRET to the kynurenine residue of Dap, indicating the formation of hybrid 
oligomers110.  
 
 
Figure 1.16 Structures of A5, CB-182,462 and NBD-labeled CB-182,462 (NBD-CB). 
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The authors also concluded that self-quenching of NBD fluorescence in NBD-labeled CB-
182,462 (NBD-CB, Figure 1.16) on B. subtilis cell membranes was inhibited by unlabelled Dap, 
indicating that hybrid oligomers can also form on bacteria cell membranes. ITC studies using 
DOPC/DOPG liposomes indicated that the thermodynamic stability of the hybrid, pure Dap, and pure 
CB oligomers is approximately the same110.  However, Dap and CB displayed less than additive 
antibacterial activity suggesting that the hybrid oligomers were functionally impaired and that 
oligomerization alone is not sufficient for antibacterial activity. This result also provides evidence 
that oligomerization contributes to the bactericidal effect of Dap (or CB-182,462) on bacterial 
membranes; if each individual monomer contributed independently and proportionally to the 
antibacterial action, combinations of the two antibiotics should have displayed strictly additive 
activity. 
Muraih, et al. have used excimer fluorescence to look at Dap oligomerization on 
membranes105.  As excimer fluorescence requires very close interaction between two fluorophores, 
the detection of excimer fluorescence imposes a more stringent constraint on the distance of the 
interaction than that implied by the observation of FRET in their previous studies.  The N-terminal 
decanoyl group of Dap was replaced with perylene butanoic acid (perylene-Dap, Figure 1.17).   
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Figure 1.17 Structures of perylene-labeled Dap (perylene-Dap) and pyrene-labeled A54145 Factor D 
(Py-A54145). 
 
While perylene-Dap exhibited little or no excimer formation in solution or in the presence of 
DMPC liposomes and Ca2+, strong Ca2+-dependent excimer fluorescence was observed upon 
incubation of perylene-Dap with DMPC/DMPG liposomes and with bacterial cells105. The formation 
of perylene excimers on model membranes was inhibited by unlabeled Dap.  The formation of 
perylene excimers in the presence of B. subtilis cells was inhibited by NBD-CB providing further 
support that hybrid oligomers can form on bacterial membranes. The extent of oligomerization of 
perylene-Dap was determined to be greater than 90% on DMPC/DMPG liposomes and slightly lower 
on bacterial membranes.  
Zhang, et al. have studied the oligomerization of A5 using pyrene-labeled A5 (Py-A54145), 
Figure 1.17)125. In their study, different states of membrane-bound A5 could be distinguished, and 
their molar fractions determined as a function of calcium concentrations. Their results indicate that 
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A5 undergoes two Ca2+-dependent transitions upon insertion within the membrane and 
oligomerization125.  A mutual interaction of the Py-A54145 molecules was observed as the Ca2+ 
concentration was increased to up to 1 mM.  Although membrane insertion was 90% complete at 1 
mM Ca2+, the excimer fluorescence increased further as the concentration of Ca2+ was increased 
above 1 mM indicating that the interaction between the pyrene moieties became tighter and/or 
involved a larger number of subunits.  It should be noted that this work was carried out 
simultaneously with the work presented in Chapter 2, therefore this knowledge was not known 
beforehand. 
Zhang, et al. also showed that Dap can translocate between the inner and outer leaflets of a 
model membrane111. They determined this using a dithionite quenching experiment and NBD-Dap. 
This experiment is described in Figure 1.18.  If the NBD group is accessible to dithionite, the 
dithionite will quench NBD fluorescence.  However, if the NBD group is buried within a membrane, 
it is not accessible to dithionite and so its fluorescence cannot be quenched.  It was found that 
dithionite could quench only 50% of the fluorescence of NBD-Dap bound to DMPC/DMPG 
liposomes, suggesting that one half of the NBD-Dap was in the outer leaflet and the other half was in 
the inner leaflet of the membrane111. The presence of cardiolipin (whose presence in bacterial 
membranes may impart resistance to Dap, see Section 1.8) prevented translocation from the outer to 
the inner leaflet111.  
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Figure 1.18 Schematic for a dithionite quenching experiment, utilizing nitrobenzoxadiazole (NBD). 
The NBD is attached to the ornithine residue of Dap. When bound to a membrane, Dap will partition 
across both membrane leaflets. Dithionite is known to quench NBD’s fluorescence, and its addition 
will initially quench the NBD found only on the outer leaflet. Therefore, the percentage of Dap’s 
translocation into the inner membrane leaflet can be determined.  
  
On the basis of the above-mentioned oligomerization and translocation studies, Zhang, et al. 
suggested that Dap initially forms a tetramer in the outer membrane leaflet.  This tetramer 
translocates to the inner leaflet and then combines with a second tetramer in the outer leaflet, which 
gives an octameric pore (Figure 1.19).  Cardiolipin prevents the translocation to the inner leaflet 
(Figure 1.19C).  
 
Figure 1.19 A hypothetical model of the membrane inserted oligomer of Dap. A and B: Top and side 
views of the octamer that spans both leaflets, leading to pore formation. C: When cardiolipin is 
included within the membrane, Dap is prevented from translocating to the inner leaflet, forming a 
tetramer that is retained in the outer leaflet. This model was constructed based on the fluorescence 
data described above, by Dr. Michael Palmer40. The Figure was used with permission. 
A B C
Figure 6: Hypothetical model of the membrane-associated daptomycin oligomer. A and B:
Top and side view of the octamer that spans both leaflets and forms a functional pore. C: A
tetrameric form that is confined to the outer leaflet has been observed on membranes con-
taining cardiolipin64 and may also occur at sub-saturating calcium concentrations.81
Emission blue-shifts and increased quantum yields are also observed with
the extrinsic labels NBD and acrylodan attached to Orn(6) in daptomycin and
to Lys(6) in A54145, indicating that these residues, too, assumemembrane-in-
serted positions.43,61,82
When the fluorescence of all four residues—1, 6, 8, and 13—are moni-
tored at different calciumconcentrations, it turns out that the spectral changes
that signal membrane insertion occur at lower calcium concentrations with
residues 6 and 8 thanwith residues 1 and 13,82 suggesting that residues 6 and 8
insert in a partially Ca2+-saturated state of daptomycin, whereas residues 1 an
13 insert only at full Ca2+ saturation. This agrees with the observation by ITC
that, in the presence of PC/PG liposomes in molar excess, each daptomycin
molecule binds two Ca2+ ions.82 Concomitantly with insertion of residues 1
and 13, the fluorescence of acrylodan-labelled residues 6 and 8 decreases due
to self-quenching, indicating that these residues are involved in the interaction
between adjacent subunits in the oligomer.82
Proximity also exists between the fatty acyl tails of adjacent oligomer sub-
units. This is evident from the excimer fluorescence of perylene or pyrene
incorporated into the acyl residues of daptomycin49 and A54145,81 respec-
tively (see Figure 7). In spite of their direct attachment to Trp(1), excimer
fluorescence—and thus, aggregation of fatty acyl residues—arises already
in the partially Ca2+-saturated state,81 while Trp(1) responds only at full Ca2+
saturation. Intriguingly, global analysis of time-resolved excimer fluorescence
indicates that, even at partial Ca2+ saturation, membrane-bound A54145 al-
ready exists as an oligomer, which however has a lower number of subunits
that the one observed at full saturation.81 This observation may be related to
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Recently, Müller, et al. provided evidence that Dap does not form discrete pores in B. 
subtilis119. They utilized inductively coupled plasma – optical emission spectroscopy (ICP-EOS) on 
B. subtilis cells that were treated with either valinomycin or Dap. When valinomycin was added, they 
observed a dramatic decrease in the concentration of potassium in the cell, indicating that 
valinomycin was causing a selective efflux of this cation. When these cells were treated with Dap at 
concentrations that caused cell death but did not induce cell lysis (3.5 µg/mL), they did not see loss of 
potassium or any other common mono or divalent cations.  However, the authors were not clear in 
their experimental if calcium was present during the experiment (after the cells were initially washed 
with ethylenediaminetetraacetic acid (EDTA)). Since this detail was omitted, it is difficult to conclude 
if the experiment was conducted properly. If calcium was not added, it is logical that Dap would not 
form a pore. 
 
1.7.3 Disruption of Cell Wall Synthesis Enzymes and Macromolecules  
Daptomycin has been compared directly to another cyclic peptide, nisin. Nisin has also been 
observed to form a pore within bacterial membranes, and to function by inhibiting peptidoglycan 
synthesis146.  As discussed in the previous section, when permeabilization occurs, a loss of ions leads 
to the depolarization of the membrane. This loss of membrane potential will immediately reduce the 
production of ATP128. ATP is necessary in the function of many enzymes involved in cell wall 
synthesis147,148. Therefore, to truly understand if Dap selectively inhibits this synthesis, researchers 
must report more detailed analyses more than just whole cell death. 
It has been suggested that the biosynthesis of lipoteichoic acid (LTA), is one of the primary 
targets of Dap136.  Although the exact role of LTA in Gram-positive bacteria is still uncertain, it is 
crucial to the viability of Gram-positive bacteria as mutants display significant growth and 
physiological defects.  
In E. faecium and S. aureus, Canepari, et al. showed that Dap, at its MIC concentration, 
inhibited the incorporation of glycerol into lipoteichoic acid (LTA) by greater than 90% and the 
incorporation of phosphate into teichoic acid by greater than 50%, in 20 min131.  Partial blockage of 
RNA, DNA, protein and PepG biosynthesis was also found to occur in E. faecium.  Dap was shown to 
interact with the cell wall and cell membrane irreversibly and not enter the cytoplasm.  Later, they 
demonstrated, using E. faecium protoplasts, that Dap caused 82% inhibition of LTA biosynthesis, 
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40% inhibition of lipid biosynthesis as well as 14-23% inhibition of RNA, DNA and protein 
biosynthesis149.   
 Laganas, et al. have provided evidence that suggests that inhibition of LTA biosynthesis is 
not the target of Dap150.  They demonstrated that Dap, at two times its MIC and in the presence of 
Ca2+, inhibited all macromolecular synthesis in S. aureus, E. faecalis and E. hirae without kinetic or 
dose specificity for LTA.  The possibility that the bactericidal activity of Dap might require ongoing 
LTA biosynthesis, even if it was not the primary target, was also investigated.  As it was known that 
treatment of S. aureus and E. faecalis for 1 hour with rifampin results in a complete cessation of 
macromolecular synthesis, including that of LTA, with no significant loss in bacterial viability, they 
reasoned that if active or concurrent LTA biosynthesis is required for the action of Dap, then pre-
treatment with rifampin should protect bacteria from the activity of Dap150.  Exposure to Dap at eight 
times the MIC for 1 hour effectively killed both exponentially growing and rifampin-growth-arrested 
S. aureus. In contrast, the growth-arrested S. aureus was protected against the bactericidal activity of 
ciprofloxacin, an antibiotic that requires active cell division, as well as RNA and protein synthesis150. 
This suggests that LTA biosynthesis is not required for Dap activity.  It is unlikely that LTA itself is a 
target for Dap as it was shown that addition of purified LTA, at concentrations up to 500 µg/mL, did 
not inhibit the activity of Dap against S. aureus and E. faecalis150. 
Hachmann, et al. has observed, through use of BOPIDY-labeled Dap, that when Bacillus 
subtilis134 is exposed to Dap it locates to the cell division septum, probably because of the higher 
percentage of PG found there. Dap was also found to locate to regions where vancomycin and 
penicillin are usually located. This led some researchers to initially believe that Dap had a similar 
mode of action to these cell wall synthesis inhibitors. Pogliano, et al. suggested that membrane 
curvature was crucial to Dap’s activity135. They stated that Dap prefers negative curvature, but failed 
to determine whether Dap was distributed between membrane leaflets. This theory also does not 
account for the curvature difference between the outer and inner leaflets, as Dap is likely to interact 
with both. In a recent study, Müller, et al. further disproved this curvature theory by analyzing the 
effects of Dap addition to a membrane bound ATPase complex119. This complex has been used as a 
reporter for abnormal membrane shapes151. From this work they determined that Dap had no effect on 
this reporter, suggesting that Dap is not selectively choosing a membrane of negative curvature, as 
previously thought.  Nevertheless, when Dap localizes to the cell division septa of B. subtilis, likely 
due to the higher percentage of PG found here, elongated cells are observed134. This would suggest 
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that cell division is affected, especially since DiviVA, a protein that controls cell division, is localized 
here also. When cells of S. aureus were examined for similar morphological changes, elongated cells 
were not seen, however; cells displayed aberrant division septa114. The lack of elongation of the 
clinically susceptible S. aureus cells suggests that Dap could be deregulating cell division, but not 
actually inhibiting it.  
Müller, et al. recently proposed a new mechanism of action for Dap119.  Proteomic studies 
suggested that Dap inhibits cell wall synthesis in B. subtilis. They provide evidence that interaction of 
Dap to B. subtilis membranes leads with a rearrangement of fluid lipid domains, affecting overall 
membrane fluidity. This resulted in the rapid detachment of the membrane-associated lipid II 
synthase MurG and the phospholipid synthase PlsX from the interior of the cell membrane.  Both 
proteins preferentially co-localize with fluid membrane microdomains.  Although their data, obtained 
using a range of fluorescence and proteomic techniques, support their claim, they did not 
acknowledge some of the previous research into this area. This includes the work by Laganas, et al. 
that suggested that Dap is not involved in cell wall synthesis inhibition since it was effective on 
bacteriostatic cells150. Bacteriostatic cells would not require active MurG. Similarly, Wolf, et al. 
showed that Dap is still active against bacterial L-forms which do not contain a cell wall152. This 
supports the notion that the dislodgment of MurG is not required for Dap activity. That being said, 
PlsX is likely to be active even in bacteriostatic cells. It is therefore possible that Dap works through a 
dual mechanism of action, dislodging this enzyme and also forming a pore.  
 
1.7.4 Lipid Flip-Flop, Membrane Fusion and Lipid Extraction 
Several researchers have shown, through studies on model membranes, that the interactions of 
Dap with the membrane can induce more dramatic disruptions of the membrane itself82,109,120. The 
studies described below were done utilizing model membranes only, and therefore must be taken 
tentatively since these mechanisms have not been shown to occur with Dap-susceptible bacteria.  
The Hancock group showed several unique interactions of Dap within model membranes. 
Jung, et al. observed, using differential scanning calorimetry (DSC) and NMR spectroscopy, that Dap 
(at concentrations above its MIC, 8 µg/mL), when added to PC/PG containing membranes, caused 
membrane fusion109. They stated that this likely occurred due to Dap reducing the charge of the acidic 
lipids on the outer membrane, making two or more vesicles more likely to interact. The authors 
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pointed out that it is unlikely that this mechanism would occur in vivo. This is due to the presence of 
the cell wall surrounding Gram-positive bacteria. This cell wall is thick (~80 nm38) and therefore it is 
highly unlikely that two or more cells would fuse together based on Dap interacting with their 
cytoplasmic membranes. Jung, et al. also observed a rapid flip flop in their model membranes with 
addition of Dap, when they incorporated a fluorophore (NBD) labeled synthetic lipid82. The increased 
polarity imparted by NBD on the acyl chain may have affected the vertical mobility of this lipid in the 
fluid bilayer. 
Recently, Chen, et al. suggested a novel mechanism of action for Dap120. They stated that Dap 
was selectively causing an extraction of lipids from their model membranes. They concluded this by 
visualizing the treatment of giant unilamellar vesicles with Dap, while keeping the vesicles under 
slightly negative pressure, with a pipette. When Dap was added they saw the vesicles retract from the 
pipette, which they stated was due to an increase in surface tension, solely through specific lipid 
molecule extraction. However, the author’s did not comment on the fact that Dap could be increasing 
the surface tension in other ways, including adding a strain to the membrane curvature.  
Overall, from this section it is clear that there are numerous proposed mechanisms of action 
for Dap. Among these are pore formation, inhibition of cell wall synthesis, lipid extraction, and cell 
division disruption. The most experimentally supported mechanism, substantiated on both model 
membranes and bacterial cells involves Dap oligomerization in the membrane resulting in the 
formation of a cation-selective pore which leads to membrane depolarization and cell 
death40,45,46,48,59,110,126,153–156.   
 
1.8 Proposed Mechanisms of Resistance for Daptomycin 
Although Dap has been used clinically for almost 15 years,12 clinical isolates of Dap-resistant 
bacteria are still relatively rare.9,10,12 Nevertheless, resistance to Dap is a growing concern as clinical 
isolates of Dap-resistant bacteria are appearing with increasing frequency59.  Determining how 
bacteria become resistant to Dap may allow for the rational development of Dap analogs that are 
active against Dap-resistant bacteria and can provide vital clues to elucidating Dap’s mechanism of 
action.  
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1.8.1 Reduction in PG Levels 
Most Gram-positive bacteria contain three main phospholipids, phosphatidylglycerol (PG), 
lysyl-PG and cardiolipin (CL) (Figure 1.18)38. PG, as discussed previously, is necessary for Dap 
activity. Therefore a decrease in the percentage of PG within the bacterial membrane would, 
logically, decrease Dap’s antibacterial effect. This likely explains the resistance of Streptomyces 
roseosporus, the natural producer of Dap, as this bacterium contains very little PG in its cell 
membrane9,10. This inherent feature also explains the lowered toxicity of Dap in humans, since 
mammalian cells contain less PG than most Gram-positive bacteria. Bacteria have recognized Dap’s 
dependence on PG, and therefore the main mechanism of Dap resistance is through cell membrane 
alternation, including PG depletion48.   
The pgsA gene encodes a phosphatidyltransferase, that is directly involved in the production 
of PG134,157,158. Mutations in this gene that reduce this enzymes activity have been found to lower the 
precentage of PG in the cell membrane.  Such mutations have been shown to occur in Dap-resistant B. 
subtillis and S. aureus.   
 
1.8.2 Mutations of mprF and Role of Lysyl-PG 
Lysyl-PG is a common phospholipid found in Gram-positive bacteria87. The biosynthesis of 
lysyl-PG occurs through a transesterification reaction that utilizes a PG lipid and lysyl-tRNA159,160. 
MprF, a multiple peptide resistance factor enzyme, mediates this process. MprF has a dual function 
(Figure 1.20) whereby it converts a PG lipid to lysyl-PG and then flips the lysyl-PG to the outer 
leaflet161,162. 
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Figure 1.20 The function of MprF. The MprF protein first converts PG into lysyl-PG through a 
transesterification process. The second step involves the flipping of lysyl-PG from the inner to outer 
membrane leaflet. The increase in positive charge on the outer leaflet prevents cationic antimicrobial 
peptides (CAMPs) from undergoing membrane insertion. Image is adapted from Ernst, et al161. 
 
Unlike PG, which bears a negative charge, lysyl-PG bears a positive charge. Lysylation of PG 
results in an increase in the positive charge on the surface of the cell membrane. It has been proposed 
that this affects the ability of Dap to interact with the membrane, by preventing or interfering with a 
proposed Ca2+-bridged interaction between the phosphate group of PG and an aspartate residue on 
Dap.   
Isolates of S. aureus that are resistant to Dap show an increase in the percentages of lysyl-PG 
within the membrane, through an up-regulation of MprF48,104. Expectedly, depletion of MprF causes a 
hypersensitivity to Dap.   Kilelee, et al. suggested that lysyl-PG’s resistance only occurs after Dap has 
become membrane bound163. This is supported with work by Mishra, et al. who found that not all 
mutations in MprF alter the membrane charge ratio164. Therefore it is possible that up regulation of 
MprF simply results in a reduction of the percentage of PG in the membrane. In summary, the 
increase in the amount of lysyl-PG in the membrane could affect Dap’s ability to function by three 
different mechanisms: by reducing the percentage of PG within the membrane, by repelling Dap and, 
when Dap is finally bound, by exerting another, currently unknown, effect.  
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not preclude other factors which may cause dap to have ineffective activity on Gram− bacteria, such 
as efflux transporters and a much lower PG content.95 
MprF, or multiple peptide resistance factor, has been characterized as an LPG synthetase. LPG is 
synthesized through the transfer of L-lysine from lysyl-tRNA to PG; this reverses the −1 charge of PG 
to +1.96 MprF gain-of-function mutants have been associated with increased resistance to many 
cationic antimicrobial peptides (CAMPs), such as host defense antimicrobial peptides (HDPs).97 As 
with dap, many HDPs initially interact with the bacterial cell membrane, but their subsequent 
mechanisms of action can be different.98 MprF was first characterized in S. aureus through gene 
deletion, complementation and recombinant trans-expression in E. coli.99 Two separate functions have 
been assigned to the C- and N-terminus.96 The hydrophilic C-terminal domain contains the synthetic 
machinery, while the hydrophobic N-terminal domain contains a lipid flippase. Incorporation of the 
MprF N-terminus alone did not confer CAMP resistance; in addition, incorporation of the MprF C-
terminal alone did not lead to effective CAMP resistance.96 Only when overexpressed together as one 
protein, or two, did the MprF C- and N-terminals successfully mediate full-level CAMP resistance. 
This indicates that CAMP resistance is dependent upon both increased LPG synthesis and its 
concomitant exposure to the outer surface of the membrane.96 
 
Figure 1.19: Model for the mode of MprF-mediated bacterial CAMP resistance.96 
The proposed mechanism through which MprF gain-of-function mutants decrease susceptibility to 
CAMP is decreased membrane association. The educed interaction is presumed o occur through 
electrostatic repulsion between the increased relative positive charge of the bacterial membrane and 
the cationic antibiotics (Figu e 1.19).96 In relation to dap resistance, the mechanism has yet to be 
characterized, but can potentially a t in a similar mann r; dap, in conjunction with calcium, w ul  
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Figure 1.21 Chemical structures of the three major phospholipids found in Gram-positive bacteria. 
Phosphatidylglycerol (PG), lysyl-PG and cardiolipin (CL) all have myristoyl acyl tails for 
representation. The anionic groups are shown in blue, the cationic groups in red. The net charge of 
CL has been controversial in recent years. Kates, et al. showed, through a potentiometric approach 
that the phosphate pKa’s are 2.8 and ~7.5-9.5165. Recent evidence by Sathappa, et al. suggests that 
each phosphate could instead act as independent strong acids, resulting in a net charge of -2166. The 
true net charge of CL, therefore, still remains unclear.  
 
1.8.3 YycFG (WalKR) Mutations 
The yycFG operon is a group of genes involved in Dap-resistant phenotypes.  Among the 
proteins that the yycFG operon encodes are YycG and YycF11. These two proteins are part of a two-
component regulatory system required for viability in Gram-positive bacteria. The yycFG system 
functions as a master regulatory system for cell wall metabolism and biofilm formation167.  In B. 
subtilis, YycG is the histidine kinase of the yycFG system, and is localized to the cell division septum 
where it regulates cell division and cell wall restructuring168. 
Several mutations in different locations of the yycFG operon in Dap resistant S. aureus were 
reported by Howden, et al., but the exact contribution of these mutations is unclear169. Nevertheless, a 
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single amino acid change in YycG was sufficient to increase Dap’s MIC from 0.5 to 2 µg/L, a value 
that is sufficient for clinical Dap resistance.  In E. faecium, mutations in yycFG operon have been 
found in Dap-resistant strains155.  
Baltz has pointed out that, in addition to the genetic studies mentioned above, other lines of 
evidence suggest a relationship between yycG and Dap’s MOA11.  Both Dap and YycG are found 
near the cell division septum of bacteria. Dap has also been shown to induce minor morphological 
changes on both S. aureus and B. subtilis, leading to unnatural division septa. When YycG is 
depleted, these septa are also changed. The depletion of YycG has been shown to cause cell death 
without lysis, similar to Dap. YycFG also positively regulates biofilm formation while Dap treats S. 
aureus biofilms effectively. Baltz therefore suggested a dual mechanism of action for Dap: 
interruption of YycG and membrane depolarization11.  
 
1.8.4 LiaRS Activation 
Dap has also been found to activate a membrane associated transcriptional regulator, 
LiaRS134,170. This two-component regulator is thought to be involved in the cell membrane adaptive 
responsive to antibacterials. Both Hachmann, et al. and Wecke, et al. have observed that when B. 
subtilis was treated with Dap, the expression of LiaRS increased >400 fold134,170. Friulimicin, another 
calcium-dependent antibiotic that is similar to Dap, was found not to up-regulate the production of 
LiaRS170. This suggests that Dap’s activation of this protein regulator is specific. Arias, et al. 
characterized several LiaRS mutations found in clinical isolates of both E. faecalis and E. faecium 
that induce resistance to Dap171. When LiaRS was activated, the expression of both LiaI and LiaH 
were greatly increased172. These proteins are known to segregate to separate domains of the plasma 
membrane but their role in Dap resistance is, to date, unknown.  
 
1.8.5 Cardiolipin 
Cardiolipin (CL) is a phospholipid found in most Gram-positive bacterial membranes. 
Hachmann, et al. observed that the lipid composition of strains of S. aureus, which were Dap-
resistant, had a decrease in the PG percentages within the membrane157. The lysyl-PG percentages 
were increased, but the CL percentages remained relatively unchanged. This suggests that Dap 
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resistant strains are not overproducing CL synthase. The role of CL in Dap’s resistance is, therefore, 
still not well understood.  
Recently, Zhang, et al. explored the role of CL in Dap resistance utilizing model membranes 
that contained varying percentages of CL111. Through use of both ITC and fluorescence studies 
(explained in Section 1.7) the authors showed that Dap inserted into liposomes containing CL. 
Although Dap was able to interact with these membranes, the translocation of the oligomer to the 
inner leaflet was prevented. This therefore prevented a pore from forming, suggesting that CL is 
directly inhibiting oligomer interaction within the membrane. However, the fact that the production of 
CL is not increased in Dap-resistant strains suggests that CL may not be overly important for Dap 
resistance in vivo.  
 
1.8.6 Other Possible Mechanisms of Resistance 
Tran, et al. outlined that some non-pathogenic bacteria have developed enzymes that 
hydrolyze the ester bond in Dap, thus destroying the antibiotic48. This has not yet been observed to 
occur in clinical isolates. 
Enhanced expression of the dlt operon has been found to occur in Dap-resistant S. aureus 
strains49,89,164,173.   Genes of the dlt operon are involved in the introduction of D-alanine to cell wall 
teichoic acids of the Gram-positive bacteria. The modification of LTA with a positively charged 
residue (the terminal amino group of alanine) could repel Dap from the membrane, reducing Dap’s 
activity. 
 
1.9 Research Goals and Objectives and Thesis Overview 
From Section 1.7, it is clear that although the mechanism of action for Dap is still not known 
with certainty, the mechanism that is best supported by the experimental evidence involves Dap 
oligomerization in the cell membrane which leads to the formation of cation-selective pores, which 
results in membrane depolarization and, finally, cell death.  The goal of this thesis is to further 
investigate this proposed mechanism of action. 
In Chapter 2, the objective was to determine the stoichiometry of calcium to Dap in the 
presence of liposomes and how calcium concentration affects Dap oligomerization and membrane 
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insertion.  These results of these studies suggest that the binding of the first calcium ion to Dap causes 
oligomer formation of Dap in the membrane. The binding of a second calcium ion to Dap causes a 
deeper insertion of this oligomer. 
In Chapter 3, the objective was to determine how pre-oligomerization of Dap affects 
antibacterial activity. This was investigated though the synthesis and characterization of a Dap dimer. 
These studies revealed that the bacterial cell wall plays an important role in Dap resistance.  
In Chapters 4 and 5, the objective was to determine the effect of liposome acyl chain 
composition on Dap’s ability to interact with, oligomerize, and form pores in liposomes.  Overall, 
these results demonstrated that the lipid acyl chain composition has drastic effects on the activity of 
Dap, which may explain the difference in Dap susceptibility among Gram-positive bacteria. 
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Chapter 2 
 
Two successive calcium-dependent transitions mediate 
membrane interaction and oligomerization of Daptomycin 
and the related antibiotic A541451 
 
 
 
 
2.1 Introduction 
The mechanism of action for Daptomycin (Dap) is subject to continued debate among 
researchers. It has been shown in the literature that a required step in Dap’s mechanism involves its 
insertion within the cytoplasmic membrane of Gram-positive bacteria, specifically to 
phosphatidylglycerol (PG)40,45,111,126. Dap is also known to require calcium for activity and many have 
theorized that Dap inserts into the membrane in multiple calcium binding events40,45,111,125,126. Previous 
studies have suggested that Dap forms distinct oligomeric structures within the membrane, with 6-8 
subunits per oligomer115. 
In the literature, model membrane systems have been used widely to study the mode of action 
of Dap45,109,118,120, mainly due to the ability to freely adjust the membrane composition. A one-to-one 
mixture of phosphatidylcholine (PC) and PG has been used previously to study Dap109,118,125,126. While 
this model doesn’t closely mimic the membranes of Gram-positive bacteria, it nevertheless has been 
shown to be sufficient to determine that Dap’s interaction with the membrane is calcium-
                                                      
1 The results displayed in this chapter have been published: “Two successive calcium-dependent 
transitions mediate membrane interaction and oligomerization of daptomycin and the related antibiotic 
A54145,” by Robert Taylor, Khalida Butt, Bradley Scott, TianHua Zhang, Jawad K. Muraih, Evan Mintzer, 
Scott Taylor and Michael Palmer, 2016, Biochim. Biophys. Acta., 1858, 1999-2005116. 
  
Authors contributions: Dr. Scott Taylor synthesized and purified acrylodan-Dap. Robert Taylor and 
Khalida Butt ran the ITC experiments. Robert Taylor completed all other results.  Manuscript was written and 
devised by Dr. Michael Palmer. 
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dependent76,82. Although PC is not found in Gram-positive bacteria106, its incorporation allows for a 
more direct determination on the role of Dap to PG interaction. This is due to the fact that PC is a 
neutral lipid, and therefore would not be involved in Dap-Ca2+-PG interactions. Dap has also been 
found to only interact with PC only membranes at un-physiologically high calcium concentrations 
and that oligomerization was not observed126. With this model, Dap was shown to form oligomers of 
definitive size, spanning both membrane leaflets126, forming an ion selective pore45. The exact details 
remain to be elucidated, with particular interest on calcium stoichiometry. Circular dichroism (CD) 
experiments suggest that Dap has two structural transitions when calcium is present, both in solution 
and with membranes82. Recently Lee, et al. have suggested, through CD experiments, that calcium 
interacts with Dap, in the membrane, in a 3:2 Ca2+:Dap ratio174.  
Isothermal titration calorimetry (ITC) experiments determined that Dap likely has two 
calcium-binding interactions within model membranes, but which amino acids were involved was 
unclear. Fluorescence was explored to answer this question, utilizing a fluorophore sensitive to 
polarity changes (acrylodan). Acrylodan is advantageous due to its prominent blue shift and 
fluorescence increase when surrounded by a hydrophobic medium175. This property was utilized to 
study the oligomer formation of Dap when bound to calcium. A similar antibiotic to Dap, in terms of 
structure, was also investigated. A54145-Factor D (A5) contains a tryptophan in the first position, 
with an acrylodan on the lysine8 residue. This allowed for a further study of four different amino acid 
positions, 1, 6, 8 and 13 (Figure 2.3). A5 has not been studied in as much detail as Dap but (as 
discussed in Chapter 1) their mechanism of action should be similar, as both require calcium and PG 
for proper activity and have very similar antibacterial activities72. Zhang, et al. also showed that 
mixtures of Dap with a semi-synthetic analog of A5, CB-182,462, form partially functional hybrid 
oligomers, thus suggesting that A5 likely has a very similar mode of action to Dap110. 
The experiments shown here outline that Dap (and likely A5) interact with the membrane in 
two successive calcium-binding events. With the first binding of calcium, Dap inserts into the 
membrane and forms oligomeric structures that are retained in the outer leaflet. The second calcium 
ion causes deeper insertion and, potentially, translocation of the oligomers into the inner leaflet. The 
oligomers on each leaflet are then united, thus forming a trans-membrane ion selective pore45.  
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2.2 Materials and Methods 
 
2.2.1 Synthesis of Acrylodan-Labeled Daptomycin 
Briefly, acrylodan (Setareh Biotech, Eugene, OR, USA) was attached to the unique free side 
chain amino group of ornithine6 of Dap (generously provided by Jared Silverman, Cubist Inc.©) in 
potassium phosphate buffer at pH 8.0 for 24 hours. The product was then purified by HPLC and 
purity was confirmed by HPLC and mass spectrometry. For details and procedures on the synthesis 
and purification of the acrylodan-Dap, see Appendix A. 
 
2.2.2 Synthesis of Acrylodan-Labeled A54145-Factor D 
Briefly, acrylodan (Setareh Biotech, Eugene, OR, USA) was attached to the unique free side 
chain amino group of lysine8 of A54145-Factor D (generously provided by Jared Silverman, Cubist 
Inc.©) in sodium phosphate buffer for 5 days. The product was then purified by HPLC and purity was 
confirmed by HPLC and mass spectrometry. For details and procedures on the synthesis and 
purification of the acrylodan-A5, see Appendix A.  
 
2.2.3 Antibacterial Activity 
Antimicrobial susceptibility tests were performed according to Wiegand, et al.176 with minor 
revisions. Serial dilutions of Dap, A5, acrylodan-Dap and acrylodan-A5 were prepared using 96-well 
microtitre plates in Luria-Bertani (LB) broth (for Bacillus subtilis ATCC 1046) that was 
supplemented with 5 mM calcium chloride. Inoculation was performed by first diluting overnight 
cultures to a turbidity of a 0.5 McFarland standard. This diluted culture was then added to the plate in 
a 1:1 mixture, with the appropriate antibiotic volume.  
Growth was assessed visually after incubation at 30oC (for Bacillus subtilis ATCC 1046) 
overnight. The transition from translucency (inhibition) to high turbidity (growth) occurred abruptly. 
Intermediate turbidity occurred only rarely, but when this was observed this concentration was not 
considered inhibitory. Control experiments included testing a positive (growth) and a negative 
(sterility) control. Each antibiotic concentration was tested three times and in triplicate.  
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2.2.4 Preparation of Liposomes 
Lipids used included 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-
sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt; DMPG), 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), and 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt; 
DOPG). All lipids were obtained from Avanti Polar Lipids, Alabaster, AL, USA.  
Equal proportions of phosphatidylcholine (PC) and phosphatidylglycerol (PG) were added to 
a round bottom flask and dissolved in a 3:1 mixture of chloroform:methanol. The dissolved lipids 
were dried under purified nitrogen and kept under high vacuum overnight. The dried lipid film was 
then suspended in HEPES-buffered saline (20 mM HEPES, 150 mM NaCl, pH 7.4) and vortexted 
until all lipids were detached from flask and suspended in buffer. These multilamellar vesicles were 
extruded under pressurized nitrogen through polycarbonate membranes (0.1 nm in diameter), fifteen 
times, to produce LUVs177. During the preparation of the LUVs the temperature of flasks/extruder 
that contained lipids was kept at 30oC, above the transition temperature of the lipid species. In 
fluorescence experiments, dimyristoyl lipids (DMPC/DMPG) were used, whereas dioleoyl lipids 
(DOPC/DOPG) were used for ITC experiments.  
 
2.2.5 Fluorescence Spectroscopy 
Steady state experiments were acquired by using a PTI QuantaMaster 4 instrument, with a 
Xenon lamp (Ushio Inc.) as the source. The samples contained HEPES-buffered saline with native 
and acrylodan-labeled Dap and A5, alone or in combination at final total concentrations of 3 µM. 
Calcium was added or titrated in as described throughout Section 2.3. Excitation wavelengths were 
280 nm for tryptophan in the case of A5, 365 nm for native Dap, acrylodan-Dap and acrylodan-A5. 
All fluorescence measurements were run in triplicates and were carried out at 37°C. 
 
2.2.6 Isothermal Titration Calorimetry (ITC) 
ITC titrations were carried out on a MicroCal ITC 200 instrument (GE Healthcare), with 
similar conditions to previous work by Dr. Evan Mintzer111. DOPC/DOPG (1/1 molar ratio) were 
loaded into the ITC cell at final concentrations of 3.55 to 4.55 mM total lipid. This was premixed 
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with Dap at final concentrations ranging from 150 to 510 µM. The Dap stock concentrations were 
determined by spectrophotometry, measuring the kynurenine13 residue178. Calcium chloride was 
loaded into the injection syringe (Malvern Instruments Ltd.) at 5 or 10 mM and injected in increments 
of 1 or 2 µL. External software (created by Dr. Michael Palmer) was used to integrate and baseline-
correct the heat peaks observed. The integrated heats were fitted using models that assumed a single 
type of binding sites, or the sequential binding to two types of sites, with either fixed or variable 
calcium/Dap stoichiometry. All ITC measurements were carried out at 25oC, as this temperature was 
previously shown to be adequate for measuring Ca2+-Dap interactions in model membranes111.  
 
2.3 Results 
 
2.3.1 Calcium Stoichiometry  
As discussed in Chapter 1, calcium was determined early on in Dap studies to be required for 
proper activity and membrane interaction. In 2014, Zhang, et al. supported these observations, 
through the use of ITC (performed by Dr. Evan Mintzer)111. Unfortunately, little emphasis was given 
to the stoichiometry of calcium to Dap. Determining this stoichiometry should provide additional 
detail on the mode of action. To accomplish this, calcium (5 or 10 mM) was titrated into a sample that 
contained 150 to 510 µM Dap with an excess of liposomes (3.55 to 4.55 mM). An excess of 
liposomes was used to more directly study the stoichiometric interaction of calcium to Dap. The 
membranes used were a 1/1 molar ratio of dioleoylphosphatidylcholine (DOPC)/ 
dioleoylphosphatidylglycerol (DOPG). The most reproducible isotherm with the largest heats 
observed was found with the following conditions: 510 µM of Dap, 3.55 mM DOPC/DOPG and 10 
mM calcium titrated into the 200 µL cell, at 1 µL increments. The raw ITC trace for one such 
experiment is shown in Figure 2.1A. Controls were run with calcium titrated into Dap and LUV 
separately. Calcium alone caused very minimal signal in either case, as shown by the titration of 
calcium into LUV alone (Figure 2.1A, blue line). The peaks, integrated relative to the baseline shown 
in red, resulted in an isotherm shown in Figure 2.1B. There is an initial downward slope in the 
isotherm but the raw trace shows similar heats generated for these data points. As the titration 
proceeds, the remaining free Dap decreases after each injection of calcium. This decrease in free Dap 
leads to peaks that appear shorter but are only wider, indicating a slower rate of reaction.  
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Figure 2.1 Isothermal titration calorimetry (ITC) for calcium titrated into a mixture of Dap and LUV. A: 
A raw trace for a representative isotherm showing calcium binding to Dap. In this case, calcium (10 
mM) was titrated into a 200 µL cell, at 1 µL increments, that contained Dap (510 µM) and LUV (3.55 
mM). The adjusted baseline is shown in red. When calcium was titrated into LUV alone, minimal 
signal was observed (blue line). B: The integrated peaks (ΔH) from the raw trace are plotted against 
the molar ratio of calcium.  
 
 
The data was then modeled using software developed by Dr. Michael Palmer, as shown in 
Figure 2.2. Using a model that dictates that a single class of calcium binding sites exists, all with the 
same affinity to Dap, a stoichiometry of 2 fits the data better than assuming a stoichiometry of 1 or 3 
(Figure 2.2A). When the stoichiometry was not confined to a defined integer and allowed to vary 
freely, a stoichiometry of 2.40 calcium ions to Dap was calculated. Although this model is a better fit 
to the isotherm, it is still relatively inaccurate (Figure 2.2B, blue line). When a model that allows for 
multiple binding sites was used a better fit was observed. The model that proved to be most 
successful, giving a more plausible stoichiometry of 2.06, assumed two sequential binding sites for 
calcium, of distinct affinity (Figure 2.2B, red line).  
A B 
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Figure 2.2 Modeled isotherms for the determination of calcium stoichiometry to Dap. A: External 
software was used to model the data assuming binding was occurring. The stoichiometry was varied 
freely. B: When the stoichiometry from the previous model was not restricted to an integer, a calcium 
stoichiometry of 2.40 was calculated (blue line). This model was more accurate than Figure 2.2A but 
still did not fit line perfectly. When the model assumed distinct, sequential binding of calcium, the 
model fit more accurately (red line). This modeled isotherm gave a calcium to Dap stoichiometry of 
2.06.  
 
 
From six independent experiments, the averaged stoichiometry was found to be 1.81±0.29. If 
it is assumed that calcium binds solely Dap and PG within the membrane, the results suggest that a 
stoichiometry of 2 calcium ions to Dap (not 1.81). A stoichiometry of 2:1 suggests that two distinct 
calcium-binding events occur with Dap. The potential for an uneven number, including a 3:2 
Ca2+:Dap  ratio, recently reported by Lee, et al.174, is possible, and remains to be explored in more 
detail. The important finding with the results presented here is that greater than one calcium ion is 
necessary for oligomer formation of Dap and therefore it is expected that separate calcium-binding 
events could be observed with fluorescence. The reaction heats and dissociation constants were 
calculated, shown in Table 2.1. Both the dissociation constant and enthalpy was found to be lower 
with the second addition of calcium, suggesting a more favourable interaction with the oligomers. 
This favourable interaction could be what drives the oligomer to translocate into the inner leaflet.  
 
 
 
 
 
 
 
 
A B 
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Parameter  Average Standard Deviation 
Stoichiometry (Ca2+/Dap) 1.81 0.29 
First Step ΔH -4.36 kJ/mol 0.48 kJ/mol 
K 5.65 x 104 M-1 3.65 x 104 M-1 
 
Second Step ΔH -6.57 kJ/mol 1.14 kJ/mol 
K 2.98 x 104 M-1 1.61 x 104 M-1 
 
Table 2.1 Parameters for the binding of calcium to Dap within 1/1 DOPC/DOPG membranes. 
Stoichiometries, reaction heats (ΔH), and dissociation constants (K) are shown, with their standard 
deviations. Only the parameters for the model that assumes two sequential binding sites with distinct 
affinities are shown. Averages and standard deviations were calculated form six different 
experiments.  
 
 
2.3.2 Calcium-Dependent Changes in Fluorescence Emission Scans 
Fluorescence has been used extensively to study the interaction of Dap to model membranes. 
Dap requires the presence of calcium and phosphatidylglycerol for membrane insertion. Muraih, et al. 
proposed that multiple calcium ions are involved in an oligomeric pore formation115,126. In this work, 
Dap was labeled with a nitrobenzoxadiazole (NBD) moiety on the ornithine6 residue. NBD is a 
fluorophore that shows an increase in signal when bound to a hydrophobic membrane. Based on their 
results, Muraih, et al. suggested that multiple calcium ions are required for Dap membrane 
interaction. This finding was supported by the ITC results presented previously, arguing that two 
calcium ions are involved in Dap to membrane interaction.  To distinguish the suspected two-calcium 
binding events, a more sensitive fluorophore was used. The NBD group was replaced with acrylodan, 
still at the ornithine6 residue (Figure 2.3). Acrylodan is a fluorophore that is highly sensitive to its 
environment127,175. Therefore replacing NBD with acrylodan gives a more sensitive measurement of 
the binding properties of ornithine. Acrylodan also has a higher quantum yield than NBD, allowing 
for a better fluorescent signal.  
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Figure 2.3 Structures of acrylodan, Dap and A5. Top: The structure of Dap. The terminal amino 
group of ornithine6 is highlighted in red. Thiol-linked acrylodan is shown and highlighted in red to 
display where the acrylodan is found on Dap. Bottom: The structure of A5. The terminal amino group 
of lysine8 is highlighted in red. Acrylodan is shown and highlighted in red to show where the 
acrylodan is found on A5. The excitation wavelengths of each fluorophore are also stated. 
 
 
When in a hydrophobic environment, acrylodan experiences a distinct blue shift and 
fluorescence increase175,179. This can be seen when acrylodan-Dap is added to LUV (1/1 
DMPC/DMPG) and calcium is titrated in, Figure 2.4. 
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Figure 2.4 Acrylodan’s sensitivity to a non-polar environment. Acrylodan-Dap (3 µM) was added to 
LUV (250 µM) and calcium was titrated in from 10 µM to 10 mM. Acrylodan’s signal is greatly 
dependent on the environment. When 0.1 mM Ca2+ is added, acrylodan has a prominent blue shift 
and fluorescence increase. Upon addition of higher concentrations of calcium, the acrylodan signal 
decreases and experiences no red shift. There is a very slight blue shift, indicating kynurenine is 
more deeply inserted into a hydrophobic medium. 
 
 
Acrylodan-Dap was used to study the interaction of ornithine6, to the membrane, in order to 
observe oligomer formation. The addition of calcium causes the acrylodan signal to increase (Figure 
2.4). This signal intensity shows two distinct stages, suggesting the presence of separate calcium 
binding effects on acrylodan. The calcium binding phases observed through fluorescence can then be 
correlated to the ITC results. It is important to note that native Dap contains a kynurenine (an 
intrinsically fluorescent amino acid), which overlaps with acrylodan in its emission spectrum. 
However, acrylodan has a much higher quantum yield than kynurenine and approximately four times 
the absorbance76. Therefore at all calcium concentrations the acrylodan signal dominates the 
spectrum.  
Both native Dap and acrylodan-Dap were incubated with 1/1 DMPC/DMPG LUV for 3 
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minutes, in HEPES-buffered saline. Calcium was then added to the sample stepwise from 10 µM to 
100 mM to observe the calcium concentrations required for membrane insertion. As seen in Figure 
2.5, the kynurenine within native Dap shows minimal signal increase until 0.1 mM calcium with a 
maximal signal at >0.1 mM calcium. In contrast, acrylodan Dap has a distinct blue shift and 
fluorescence increase with the addition of just 10 µM calcium, with maximal signal occurring at ~ 0.1 
mM calcium. The addition of any more calcium causes a decrease in fluorescence intensity (Figure 
2.5). At these calcium concentrations, acrylodan experiences a slight blue shift (green to purple line 
of Figure 2.4) which could be attributed to either acrylodan inserting more deeply within the 
membrane or the kynurenine residue of Dap starting to insert. The decrease in acrylodan signal 
suggests that mutual acrylodan interactions might be occurring within the membrane. From Figure 
2.5, it is clear that there are two calcium transitions occurring, one at ~ 0.1 mM calcium, the second at 
higher concentrations, >0.1 mM.  
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Figure 2.5 Comparison of kynurenine fluorescence between Dap and acrylodan-Dap. Dap or 
acrylodan-Dap (3 µM) was added to LUV (250 µM) and titrated with calcium. In the case of Dap, there 
is minimal signal until >0.1 mM calcium, where the signal intensity of kynurenine greatly increases. 
Acrylodan-Dap’s signal increases sharply from 10 µM to 0.1 mM calcium. The addition of higher 
concentrations of calcium causes a fluorescence decrease. This data suggests two calcium-binding 
interactions are occurring. Both samples were excited at 365 nm and emitted from 400-600 nm. Error 
bars represent the standard deviation of three different experiments, ran at 37oC. 
 
 
The experiments were repeated, where Dap and acrylodan-Dap were replaced with A5 and 
acrylodan-A5. Acrylodan was attached to the lysine8 residue of A5, shown in Figure 2.3. In regards 
to calcium saturation, Acrylodan-A5 showed similar trends in fluorescence compared to acrylodan-
Dap, shown in Figure 2.6. Acrylodan-A5 had maximal signal at 0.1 mM calcium; the addition of 
higher concentrations (>0.1 mM) caused a decrease in signal intensity, identical to that seen for 
acrylodan-Dap. Once acrylodan-A5 reaches its maximal signal at 0.1 mM Ca2+, higher calcium 
concentrations do not induce any blue or red shift. This suggests that the slight blue shift seen in 
Figure 2.4 (green to purple line of acrylodan-Dap’s emission spectrum) is due to the intrinsic 
kynurenine of Dap starting to insert into the membrane. A5 does not contain kynurenine, and 
therefore measuring the tryptophan found natively in A5 was feasible. This inherent structural 
difference also allowed the study of another residue, position 1, on its interaction with calcium and 
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the membrane. Tryptophan experiences a distinct blue shift upon entering a hydrophobic 
environment, but the signal intensity is relatively unchanged. The interaction of native A5 with the 
liposome was therefore observed by measuring the mean tryptophan wavelength at each calcium 
concentration. When comparing the interaction of kynurenine and tryptophan of Dap and A5, 
respectively, in regards to calcium saturation, they behave identically, in that, higher calcium 
concentrations are required to cause membrane insertion. The difference in calcium concentrations 
necessary for membrane interaction, between both labeled to un-labeled analogs, suggests two 
separate calcium-binding events.  
 
Figure 2.6 Comparison of fluorescence between A5 and acrylodan-A5. A5 or acrylodan-A5 (3 µM) 
was added to LUV (250 µM) and titrated with calcium. In the case of A5, the tryptophan experiences a 
blue shift at >0.1 mM calcium. A5 was excited at 280 nm and emitted from 300-400 nm. Acrylodan-
A5’s signal increases sharply from 10 µM to 0.1 mM calcium. The addition of higher concentrations of 
calcium causes a fluorescence decrease. This data suggests two calcium-binding interactions are 
occurring. Acrylodan-A5 was excited at 365 nm and emitted from 400-600 nm. Error bars represent 
the standard deviation of three different experiments, ran at 37oC. 
 
 
  71 
2.3.3 Concentration-Dependent Self-Quenching of Acrylodan 
From Figure 2.5, it is clear that acrylodan-Dap inserts into the membrane at low calcium 
concentrations. At higher concentrations of calcium the kynurenine of native Dap inserts, and the 
acrylodan-Dap signal decreases. Since this decrease is not accompanied by a red shift, the effect most 
likely occurs in the membrane. It was speculated that this decrease is due to concentration-dependent 
self-quenching of acrylodan. This result is also seen when NBD-Dap is used126. When bound to the 
membrane at lower calcium concentrations, the acrylodan moieties are far enough apart to prevent 
self-quenching. When more calcium is added the acrylodan residues become closely aligned causing 
a quenching effect. To study this further, acrylodan-Dap was mixed in a fivefold excess of native 
Dap. If the quenching is due to the acrylodan interacting closely, separating them by native Dap 
should form hybrid oligomers that prevent a signal decrease (Figure 2.7).  
Figure 2.7 Kynurenine overtaking the acrylodan-Dap spectrum. A 5:1 Dap:acrylodan-Dap ratio (3 µM 
total) was added to LUV (250 µM) and titrated with calcium. When kynurenine is in excess over 
acrylodan, the spectrum mimics that of native Dap. This ratio does not give any information of the 
self-quenching of acrylodan, since acrylodan’s signal is minor. 
 
 
Although this does reduce self-quenching (Figure 2.7), the signal from kynurenine appears to 
over-shadow this spectrum. Due to the kynurenine being in a five-fold excess over acrylodan, the 
self-quenching experiment mirrored a standard emission spectrum of native Dap (Figure 2.5). To 
remove this error a Dap analog was used that has the kynurenine replaced with a tryptophan, but 
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retains antibacterial activity. This analog, Dap-E12W1368 is a double mutant, replacing the 
kynurenine residue for tryptophan and the 3-methylglutamate residue for glutamate. The activity of 
Dap and Dap-E12W13 has been determined previously on Bacillus subtilis, with values of 0.75 and 
1.5 µg/mL (at 5 mM Ca2+), respectively68. The emission spectrum (Figure 2.8, blue line) suggests that 
tryptophan inserts into the membrane at the same concentration of calcium, compared to kynurenine. 
When a 5:1 Dap-E12W13:acrylodan-Dap ratio was tested, the self-quenching was greatly diminished 
(Figure 2.8, green line). As mentioned above, acrylodan-Dap experiences a slight blue shifting when 
the second calcium ion is bound (green to purple line of Figure 2.4). In contrast, when the second 
calcium-binding event occurs, acrylodan-A5 does not experience a second blue shift, suggesting that 
the kynurenine residue intrinsic to Dap is inserting into the membrane. This highlights that the 
acrylodan-Dap emission spectrum is observing, to a lesser extent, both calcium binding phases. 
 
Figure 2.8 Concentration-dependent self-quenching of acrylodan-Dap. Dap-E12W13, acrylodan-Dap 
and a 5:1 Dap-E12W13:acrylodan-Dap ratio (3 µM) was added to LUV (250 µM) and titrated with 
calcium. When DapE12W13 is utilized, instead of Dap, the self-quenching of acrylodan-Dap is mostly 
prevented at higher calcium concentrations. Although Dap-E12W13 does not contain a kynurenine 
the tryptophan experienced similar fluorescent increases compared to kynurenine, and therefore was 
plotted through maximum fluorescent signal not mean tryptophan wavelength (shown before for A5). 
Error bars represent the standard deviation of three different experiments, ran at 37oC. 
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The same experiments were also carried out with A5 and acrylodan-A5. These results, shown 
in Figure 2.9, had identical trends to those seen for Dap. A5 does not contain kynurenine, and 
therefore a separate analog was not necessary. The 5:1 A5:acrylodan-A5 ratio shows that the 
quenching seen for acrylodan-A5 is suppressed in the hybrid oligomers. Although the 5:1 ratio 
experiments were run in triplicates, the error bars were relatively large. This may explain the slightly 
lowered fluorescence seen for the 5:1 ratio at 0.1 mM Ca2+.  
 
 
Figure 2.9 Concentration-dependent self-quenching of acrylodan-A5. A5, acrylodan-A5 and a 5:1 
A5:acrylodan-A5 ratio (3 µM) was added to LUV (250 µM) and titrated with calcium. The self-
quenching of acrylodan-A5 is greatly diminished when the acrylodan moieties are separated by native 
A5. Error bars represent the standard deviation of three different experiments, ran at 37oC. 
 
 
When comparing these results to the ITC experiments, the data suggests that the first calcium 
ion, shown at 0.1 mM calcium, facilitates membrane insertion of ornithine6 of Dap or lysine8 of A5. 
The second calcium binding event, >0.1 mM, causes kynurenine of Dap or tryptophan of A5 to insert 
more deeply and the acrylodan residues to interact closely, both within and across leaflets, decreasing 
the signal.  
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2.3.4 Calcium-Dependent Changes in Fluorescence Anisotropy  
Fluorescence anisotropy was utilized to further study the observed two calcium-binding 
events. Both Dap and A5 were incubated with 1/1 DMPC/DMPG liposomes for 3 minutes, in 
HEPES-buffered saline. Calcium was then titrated stepwise from 10 µM to 100 mM, with 3 min 
incubations, to observe the effect of membrane interaction with anisotropy. Anisotropy reflects a 
fluorophore’s diffusional rotation when excited with polarized light180. A sample containing a specific 
fluorophore is excited with vertically polarized light, exciting a sub-population of these fluorophores 
that are orientated parallel to the plane of polarization of this light beam. These molecules then freely 
rotate within the limited lifetimes of their excited states. The molecule’s final orientation is compared 
to the initial vertically polarized light180. Dap and A5 are relatively small molecules and therefore the 
whole molecule is able to freely rotate. When in buffer they will rotate more quickly, having a lower 
anisotropy value. The individual side chains will experience different degrees of rotation depending 
on their bound state. If certain amino acids of Dap or A5 insert into a rigid membrane, their rotation 
should diminish, increasing the anisotropy (close to one). For each sample shown in Figure 2.11, a 
blank consisting of liposomes and buffer was used.  
 
Figure 2.10 Anisotropy results for Dap and A5. Dap or A5 (3 µM) were added to 1/1 DMPC/DMPG 
(250 µM) and titrated with calcium. The data for both Dap (red line) and A5 (blue line) are overlaid in 
the plot. Error bars represent the standard deviations of three separate experiments, ran at 37oC.  
 
 
As seen in Figure 2.10, the anisotropy of A5 mirrors the tryptophan emission blue shift 
(Figure 2.6). At higher concentrations of calcium (>0.1 mM), the anisotropy of A5 increases. This 
suggests the tryptophan is not membrane associated until the second calcium-binding event.  In the 
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case of Dap, the anisotropy increases rapidly, with a maximal signal at 0.1 mM calcium. From Figure 
2.5, it is clear that the ornithine6 residue likely inserts into the membrane first. This anisotropy data is 
directly measuring the kynurenine residue of Dap. The fact that it’s anisotropy increases at 0.1 mM, 
divergent from the emission scans shown previously (Figure 2.5), suggests that when Dap is initially 
bound by ornithine6, kynurenine is being restricted to rotate comparative to the Dap backbone. This 
could be due to its position on the macrolactone ring, resulting in a configuration that restricts its 
movement without proper insertion. At higher calcium concentrations, kynurenine sees a decrease in 
anisotropy. This suggests that kynurenine becomes less rotationally restricted, when the Dap oligomer 
is more deeply membrane inserted. The decrease in anisotropy could therefore be attributed to an 
increase in homo-FRET of kynurenine. The kynurenine residues will be in closer proximity when in 
an oligomeric state within the membrane, therefore able to exhibit FRET between two identical 
fluorophores181. Homo-FRET would likely increase kynurenine’s angular distribution, therefore 
decreasing the anisotropy seen in Figure 2.10, as the residue’s ability to rotate will be increased 
slightly.   
Overall, ITC shows calcium is binding to Dap in a 2:1 ratio, within the membrane. The 
fluorescence results for the native and acrylodan-labeled Dap and A5 show a similar sequential 
binding of calcium. Acrylodan-Dap/A5 interacts with the membrane first, at low calcium 
concentrations. This suggests that residues six and eight are inserting into the membrane initially, but 
restricting the movement of the other amino acids, mainly in the thirteenth position. The whole 
peptide therefore likely binds the first calcium ion, causing the peptide to force into a specific 
configuration. The second calcium ion causes a self-quenching of the acrylodan residues, suggesting a 
slightly altered configuration that brings the acrylodan residues into close proximity. This added 
calcium then causes a deeper insertion of this oligomer, which is seen through the fluorescence 
increase of kynurenine and tryptophan. 
 
2.4 Discussion 
The results from ITC and fluorescence agree that two distinct calcium-binding events occur. 
A schematic model was made to better visualize the two calcium binding events, shown in Figure 
2.11.  
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Figure 2.11 Overall schematic for the ITC and fluorescence experiments. Left: The initial oligomeric 
structure is shown bound to the membrane. The first calcium (green) binding event is evident by the 
insertion of acrylodan, from labeled Dap at ornithine6 (blue 6) and A5 at lysine8 (blue 8). The purple 
dotted polygon represents the semi-synthetically labeled A5 analog. The pyrene is in replacement of 
the fatty acyl tail of A5. The kynurenine13 (grey 13) of Dap and tryptophan1 (grey1) of A5 do not 
sense the hydrophobic membrane at this concentration of calcium. Right: The oligomer inserts more 
deeply and translocates with the second calcium-binding event. At this concentration the acrylodan 
moieties exhibit concentration-dependent self-quenching. The kynurenine13 (blue 13) and 
tryptophan1 (purple 1) of Dap and A5 insert into the membrane. This image depicts that only four 
monomers of Dap form a pore, but the more plausible subunit stoichiometry is 6-8 monomers115. 
 
As shown in this figure, the first binding of calcium occurs at ~0.1 mM. At this concentration 
the acrylodan groups on ornithine6 (Dap) and lysine8 (A5) insert into the hydrophobic membrane. 
This was seen with a pronounced blue shift and fluorescence increase when measuring acrylodan-
labeled Dap/A5. At this concentration the kynurenine13 of Dap and tryptophan1 of A5 are not bound 
to the membrane. Once the calcium concentration is increased to >0.1 mM, the oligomeric structure 
inserts more deeply. At this concentration the acrylodan moieties experience concentration-dependent 
self-quenching. Although it is unclear within Figure 2.11, this self-quenching will likely occur both 
across the membrane and within each leaflet. This suggests that when a second calcium ion is bound, 
the oligomers within leach leaflet interact more closely, bringing the acrylodan residues closer 
together. The kynurenine13 and tryptophan1 of Dap and A5 also insert into the membrane with the 
second calcium. This suggests that the first calcium-binding event causes the macrolactone ring to 
interact with the membrane. The second calcium causes the rest of the Dap/A5 structure, particularly 
close to the fatty acid tail to insert.  
In a 2016 article125, a similar calcium effect on Dap interaction was theorized. In this work a 
pyrene moiety was semi-synthetically added to A5, replacing the fatty acyl tail. This work also found 
that Dap bound to calcium in two steps, shown through pyrene excimer fluorescence125. Interestingly, 
at 0.1 mM calcium, the Py-A54145 exhibited mutual association, shown through excimer formation. 
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This indicated that the pyrene moieties were in a very close orientation. At higher calcium 
concentrations, >0.1 mM, the Py-A54145 showed an increase in the monomeric pyrene concentration 
that formed excimers. This suggests many pyrene monomers are forming in close proximity, possibly 
due to an association of tetramers across membrane leaflets. Zhang, et al. showed, through a 
dithionite-quenching assay (Section 1.7.2), that Dap oligomers translocate evenly between the leaflets 
of myristoyl chained lipid membranes111. The subunit stoichiometry of these oligomers was found to 
be 6-8, suggesting that tetramers are interacting across leaflets. The authors noted that the inclusion of 
cardiolipin (a suspected resistance mechanism of Dap) was found to prevent this translocation, 
showing a reduced oligomer subunit stoichiometry, suggesting that Dap tetramers link together across 
leaflets to form a functional pore. This work, along with the results presented above, suggests that the 
first calcium-binding event to Dap causes membrane insertion of an oligomeric structure. This 
oligomer is bound only enough to allow the acrylodan to insert but does cause the thirteenth residue 
to be strained, which is suggested by the increase in kynurenine’s anisotropy. The second calcium-
binding event then causes a deeper insertion of this oligomer and, likely, a translocation of the 
oligomer to the inner leaflet.  
The experiments from ITC and fluorescence, and also pyrene excimer fluorescence correlate 
well together. The most successful model for the ITC isotherm gave a value of two distinct binding 
sites with different affinity. In a later chapter (Chapter 4-5), the effect of the lipid acyl chain is 
investigated. Preliminary work shows that ITC produces a stoichiometry of two calcium ions to Dap 
on DOPC/DOPG membranes and a slightly lower value on DMPC/DMPG membranes. The reason 
for this discrepancy is still unknown. Recently, Lee, et al. proposed that the stoichiometry of calcium 
to Dap, within DOPC/DOPG LUVs, is instead 1.5:1174, not 2:1 in this case. This discrepancy may be 
due to the techniques used, ITC in this work versus circular dichroism. The model used for the data 
shown in Figure 2.2, also assumed that calcium bound strictly to Dap and PG within the membrane, 
supported by the fluorescence data discussed above, whereas Lee, et al.’s binding did not use a 
model. Further, Lee, et al. utilized a calcium concentration from 0-1 mM, which may not have caused 
calcium saturation with Dap. Future ITC work is needed to better elucidate these diverging findings. 
The work presented in this chapter highlights that, within the membrane, Dap is interacting 
with two separate calcium ions, but which amino acids are involved is still unclear. Dap and A5 
contain several conserved anionic residues, particularly aspartate7 and aspartate973,99. These amino 
acids are also conserved across other calcium binding antibiotics, including the 
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amphomycin/friulimicin family53,182. The four amino acids surrounding these aspartate residues also 
make up the EF-motif consisting of residues DXDG, found in calmodulin binding proteins40,73,77,82. 
When these aspartates are replaced with asparagine, a cationic amino acid, the activity of Dap is 
reduced68,73. This indicates that these amino acids are most likely binding to calcium, as their anionic 
properties are required. This still leaves another, unknown, calcium binding region. Interestingly, 
Lohani, et al. synthesized an analog of Dap that replaces the 3-methylglutamate12 with glutamate and 
the kynurenine13 with tyrosine, Dap-E12Y1368. This antibiotic’s antibacterial activity was found to 
be highly dependent on the concentration of calcium present. This suggests that the twelfth and/or 
thirteenth amino acids could be involved in a calcium-binding event. Recently, Barnawi, et al. 
showed that when the kynurenine at position 13 is replaced with alanine the activity is greatly 
diminished, compared to the replacement of 3-methylglutamate12 for alanine98. This suggests that 
position 13 may have a larger role in calcium interaction than expected. Replacing aspartate3 for 
asparagine, in Dap, diminished the activity ~80 fold73,99. Although the data presented here suggests 
that is residue is bound internally in the membrane when the Dap oligomers translocate, the reduced 
activity seen when the anionic properties are lost suggests it could have some role in calcium 
interaction. Future experiments are still required in order to fully elucidate which residues, apart from 
those found in the DXDG motif, are absolutely necessary for calcium binding.  
A possible issue in this work could be the diminished antibacterial activity of the acrylodan-
labeled Dap and A5. The acrylodan-labeled A5 retained 50% activity compared to A5. The 
acrylodan-labeled Dap retained only 25% compared to Dap. One could argue that this decrease in 
activity could mean their interaction with calcium and the membrane is diminished, comparative to 
the native antibiotics. While this possibility cannot be excluded, it was found that the labeled analogs 
detected the first calcium-binding event, where the native compounds detected the second. If the 
labeled compounds had reduced calcium affinity, they would not have bound to the membrane before 
the native compounds. It is also worth noting that two successive transitions were also evident in a 
related study that used only a single labeled analog125. The anisotropy results, which did not use a 
label on Dap or A5, also outline that two calcium-dependent transitions are occurring.  
Collectively, the ITC and fluorescence studies, utilizing acrylodan-labeled Dap and A5, show 
that two calcium-dependent binding events are occurring. The lipopeptide binds to the first calcium 
ion causing insertion of the ornithine6 residue of Dap or lysine8 residue of A5. The inserted 
monomers then form an oligomer within the outer leaflet, observed through excimer formation with a 
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pyrene labeled A5 analog. The anisotropy studies suggest that the macrolactone ring of Dap is in 
close proximity to the membrane, restricting movement of the thirteenth amino acid. The second 
calcium-binding event causes a deeper insertion and translocation of this oligomer into the inner 
leaflet, supported by results from Zhang, et al111. This is observed through an increase in kynurenine 
and tryptophan’s emission. The acrylodan residues are quenched at this concentration suggesting that 
the Dap subunits within each leaflet and across the membrane are in a very close proximity. Py-
A54145 experiments also show an increase in the excimer signal intensity, due to a higher number of 
pyrene monomers forming excimers, at this concentration, suggesting an interaction between 
tetramers across leaflets. This interaction of tetramers likely forms a pore, leading to permeabilization 
of the cell membrane40,45,126. This mechanism is reminiscent of many structurally diverse oligomer-
forming, membrane-permeabilizing protein toxins that also form oligomeric “pre-pores” prior to the 
functional, membrane-inserted pores183–185 
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Chapter 3 
 
An Acyl-Linked Dimer of Daptomycin is Strongly Inhibited 
by the Bacterial Cell Wall2 
 
 
 
 
3.1 Introduction 
Resistance to Daptomycin (Dap) is a growing concern, with some clinical trials already 
showing lower Dap activity49,89,186. To overcome this issue, many analogs of Dap have been 
synthesized, through various methods (Section 1.5), to better understand the mode of action of this 
antibiotic, and to potentially increase activity.  
In this work, a dimer of Dap (Figure 3.1) was synthesized in an attempt to improve oligomer 
formation, therefore improving antimicrobial activity. An octadecanedioate linker, replacing the fatty 
acyl tails, connected two Dap monomers. Oligomer formation would likely have a high entropic cost, 
due to the creation of an ordered system (of monomeric Dap) within the membrane. This dimer Dap 
could slightly decrease the oligomer formation’s entropic cost, which would shift the equilibrium of 
oligomerization to lower monomer concentrations, thus improving activity. The fatty acyl chains are 
in close proximity within the oligomer105,125 and therefore joining them together should not impose 
any unfavourable constraints.  
Previous studies have shown Dap’s ability to oligomerize115 and permeabilize45 equimolar 
PC/PG model membranes.  In this work, it was found that the dimer was also able to interact, 
                                                      
2 The results displayed in this chapter have been published: “An Acyl Linked Dimer of Daptomycin is 
Strongly Inhibited by the Bacterial Cell Wall,” by Robert Taylor, Bradley Scott, Scott Taylor and Michael 
Palmer, 2017, ACS – Infect. Dis., 3, 462-466117. 
 
Authors contributions: Dr. Scott Taylor synthesized and purified the Dap dimer. L-form’s were 
cultured from B. subtilis PDC 134 by Bradley Scott. Robert Taylor did all other experiments. Manuscript was 
written and devised by Dr. Michael Palmer. Level II MIC results were completed in Dr. Gary Dmitrenko’s 
laboratory, with training of the flow hood from Valerie Goodfellow and Carol Tanner.   
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oligomerize and permeabilize model membranes. However, this dimeric Dap was found to be inactive 
against Gram-positive bacteria. It was speculated that since the dimer is much larger than native Dap, 
it might be too large to pass the peptidoglycan layer of the cell. To investigate this theory, L-form 
bacteria (cells lacking a cell wall but remain viable187) were utilized. The dimer proved to be highly 
active on these cells.  
 
Figure 3.1 Structure of the dimeric Dap analog. The monomers of Dap are connected, at the N-
terminal regions, by a bivalent octadecanedioate linker. 
 
The work herein suggests that the dimer of Dap is unable to pass the outer cell wall of Gram-
positive bacteria. Once the cell wall is removed (L-forms and liposomes) the dimer is able to interact 
with the membrane having an activity comparable to native Dap. The dimer also proved to transport 
sodium ions more rapidly than native Dap on model membranes, potentially suggesting improved 
oligomer formation. Overall, this data suggests that Dap must be in a monomeric state to traverse the 
peptidoglycan layer and insert into the membrane.  
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3.2 Methods and Materials 
 
3.2.1 Synthesis of Dimeric Daptomycin 
Briefly, the side-chain amino group of Dap’s ornithine residue was protected with a tert-
butyloxycarbonyl (BOC) protecting group. The decanoyl residue of Dap was enzymatically removed. 
Two Dap monomers (with their decanoyl groups removed) were then linked through acylation with 
an activated octadecanedioate. For details and procedures on the synthesis and purification of the 
dimeric Dap, see Appendix A. 
 
3.2.2 Antibacterial Activity 
Antimicrobial susceptibility tests were performed as outlined in Section 2.2.3, with minor 
additions. Serial dilutions of monomeric and dimeric Dap were prepared in Luria-Bertani (LB) broth 
(for Bacillus subtilis) or Mueller-Hinton broth (for Staphylococcus aureus) that was supplemented 
with the concentrations of calcium indicated in Table 3.1-3.3 (Section 3.3). Growth was assessed 
visually after incubation at 30oC (for Bacillus subtilis) or 37oC (for Staphylococcus aureus) overnight.  
 
3.2.3 Preparation of Liposomes 
LUVs consisting of DMPC/DMPG were prepared as described in Section 2.2.4. 
 
3.2.4 Fluorescence Spectroscopy 
Steady state experiments were performed as described in Section 2.2.5 for monomeric and 
dimeric Dap. 
 
3.2.5 Permeabilization Assay Utilizing Pyranine 
The permeabilization assay was followed similar to Zhang, 201445, with some revisions. 
DMPC/DMPG lipids, at an equimolar concentration, were prepared as described in Section 2.2.4. 
Pyranine (Sigma Aldrich, 1 mM) was entrapped within the liposomes through vortexing with a low 
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pH buffer (5 mM MES, 5 mM Tricine, 5 mM NaCl, 250 mM sucrose, pH 6.0) until all lipids were 
suspended. LUVs were prepared through extrusion, through 100 nm polycarbonate filters, with 
pressurized nitrogen. The resulting pyranine entrapped LUVs were passed through a size exclusion 
column (Bio-Rad P-6DG, Bio-Rad, Richmond, CA, USA), to remove the excess non-entrapped 
pyranine.  
Dap (2 µM) and the proton ionophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 5 
nM), were added alone or in combination, as indicated. The buffer used during measurements was a 
higher pH than what was used for pyranine encapsulation (5 mM MES, 5 mM Tricine, 100 mM NaCl, 
250 mM sucrose, pH 8.0). Calcium chloride, at the reported concentrations, was pre-mixed with 
buffer before addition of LUVs. At time 0, LUVs and/or analogs were added to the cuvette. 
Fluorescence (excitation wavelength, 460 nm; emission wavelength, 510 nm) was monitored for 300 
seconds. Triton X-100 (0.1%) was then added to solubilize the LUVs. The fluorescence intensity after 
Triton X-100 was added was used to normalize the entire curve. All permeabilization assays were run 
at 30oC. A schematic for the permeabilization assay is shown in Figure 3.2.  
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Figure 3.2 A schematic for the permeabilization assay, utilizing LUVs entrapped with pyranine. The 
internal LUV buffer had a low pH and salt concentration. Outside the LUV the buffer pH was more 
alkaline, with an excess of salt (NaCl). This created an opposing ion concentration gradient across 
the membrane. When Dap or CCCP are added separately, proper in/efflux is unable to occur. It is not 
until both are present in unison that allows for the pH inside the LUVs to increase, deprotonating the 
pyranine, resulting in a fluorescence intensity increase. CCCP is necessary to allow efflux of protons, 
balancing the charge gradient across the leaflets.  
 
3.2.6 Generation and Antibacterial Testing of L-form Bacteria 
The Bacillus subtilis strain PDC 134 has been engineered to make expression of several 
enzymes in peptidoglycan synthesis dependent on xylose187. This allows L-forms to be obtained 
simply by withdrawing xylose. Xylose-free LB medium, supplemented with MSM (20 mM 
magnesium chloride, 500 mM sucrose and 20 mM maleic acid) at pH 7.0 was inoculated with a liquid 
culture of PDC 134 grown beforehand in the presence of xylose (0.5% w/v) and chloramphenicol (20 
mg/mL). The culture was incubated at 30oC overnight. To suppress growth of residual vegetative 
forms, ampicillin was added to this culture at 75 µg/mL. Conversion of the rod-shaped vegetative 
cells to spherical L-forms was confirmed by microscopy (Figure 3.3). Ampicillin was not present in 
the Dap MIC tests. Antimicrobial activity tests were described as in Section 3.2.2, except that LB-
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MSM medium was used and incubation at 30oC was performed until the growth controls were 
unequivocally positive, which took 3-4 days.  
Figure 3.3 The microscopy results for the B. subtilis PDC 134 strain. A: One colony of PDC 134 N-
forms (vegetative cells) grown in LB broth, supplemented with 0.5% xylose and 20 µg/mL 
chloramphenicol. B: PDC 134 N-forms subcultured in MSM LB broth. C: PDC 134 N- and L-forms 
subcultured into MSM LB broth, supplemented with 75 µg/mL ampicillin, giving a pure L-form culture. 
Figure was taken from Bradley Scott’s M.Sc. Thesis188 with permission.  
 
3.3 Results 
 
3.3.1 Antibacterial Assays for the Dimeric Daptomycin 
The most supported model for Dap action is through oligomer formation on the membrane. 
These oligomers then translocate and form a functional pore, causing the permeabilization of small 
cations. It was speculated that oligomer formation would have an entropic cost, as a more ordered 
system of monomeric Dap was created within the membrane. Since the dimeric Dap has the lipid tails 
connected, it could slightly lower this entropic cost. In theory, this dimeric Dap would allow for 
oligomer formation and permeabilization to occur at a lower antibiotic concentration and potentially 
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require lower calcium concentrations. To test whether this analog was similar in activity to Dap, both 
the monomer and dimer were tested for antibacterial activity on Bacillus subtilis ATCC 1046 (Table 
3.1).   
 
 Bacillus subtilis ATCC 1046 
CaCl2 (mM) 1.8 5.0 100 
Dap 1.0 0.75 0.5 
Dap Dimer >100 >100 7.5 
Table 3.1 Minimum Inhibitory Concentrations (MICs, µg/mL) of Dap and dimeric Dap on B. subtilis 
ATCC 1046. The MICs were done on Bacillus subtilis ATCC 1046 at varying calcium concentrations, 
in LB broth. Assays were preformed five times, with each assay run in triplicate.  
 
As can be seen in Table 3.1, the dimer had extremely low activity on B. subtilis, having an 
MIC value greater than 100 µg/mL. Interestingly, the dimers activity increased greatly when the 
calcium concentration was increased to un-physiologically high levels. An explanation is proposed in 
Section 3.4. The dimer was also tested against several strains of Staphylococcus aureus, both 
susceptible and resistant to methicillin. These findings are shown in Table 3.2.  
 
 MSSA MRSA 
 ATCC 6538 ATCC 25293 Isolate 1-3 Isolates 4, 5 
Dap 0.25 0.5 0.5 0.5 
Dap Dimer 5 75 30 75 
Table 3.2 MICs (µg/mL) of Dap and dimeric Dap on strains of S. aureus. The MICs were done on 
various strains of S. aureus, either susceptible (MSSA) or resistant (MRSA) to methicillin. Calcium 
(1.25 mM) was used for all assays, in Mueller Hinton broth. The MRSA strains were distinct clinical 
isolates, not contained in type culture collections. Assays were preformed three times, with each 
assay run in triplicate.  
 
The dimeric Dap again showed low activity against both MSSA and MRSA strains of S. 
aureus. As seen in Table 3.2, the MIC values of monomeric and dimeric Dap were much lower than 
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expected with the MSSA ATCC 6538 strain. This strain appears to be more susceptible than any other 
strain tested but the trend between the monomer and dimer is the same.  
 
3.3.2 Membrane Insertion of the Dimer to LUVs 
One possible explanation for why there is such a marked reduction in the dimeric Dap’s 
activity shown in Tables 3.1-3.2 could be a lack of membrane pore formation. To better understand 
the dimer’s ability to interact with the membrane, fluorescence spectroscopy was utilized. Kynurenine 
is an intrinsic fluorophore of Dap and can be used to determine if Dap is inserting into the membrane 
or not (Section 1.6.2)76,116. The insertion of the monomeric and dimeric Dap was tested using an 
equimolar ratio of PC/PG (Figure 3.4). 
 
Figure 3.4 Dap (3 µM) and dimeric Dap (1.5 µM) membrane interaction with DMPC/DMPG LUVs 
(250 µM, total lipid). The kynurenine residue experiences a fluorescence increase as a function of 
calcium concentration. The monomer and dimer of Dap show identical trends, showing that >0.1 mM 
calcium is necessary for insertion. Error bars represent standard deviations from two experiments, 
ran at 37oC. 
 
The dimer interacts with the PC/PG membrane, comparable to the monomer, at half the molar 
concentration. Although a lower concentration of the dimer is necessary to observe membrane 
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interactions, the same concentrations of calcium are necessary, compared to the monomer. This could 
suggest that pre-oligomerization is not decreasing the entropic cost of oligomer formation by a 
measurable amount. Both antibiotics require >0.1 mM calcium to cause signal intensity increase in 
kynurenine. This signal increase indicates a membrane insertion event.  
 
3.3.3 Permeabilization of Daptomycin and Dimeric Daptomycin 
Previously, Zhang, et al. has shown the permeabilization ability of Dap, in a coupled 
fluorescence assay45. This assay was further developed and used in this work to determine if dimeric 
Dap causes ion transport on DMPC/DMPG liposomes. Unexpectedly, the dimer permeabilized the 
membranes more rapidly than Dap (Figure 3.5), without the need for the proton ionophore CCCP. 
The reason for the unexpected decrease seen when the dimer and CCCP are added in unison is not 
clear but could suggest that the dimer is forming pores large enough to allow sodium ions and buffer 
bound protons to pass across the membrane freely. Additionally, the dimers signal plateaus at ~ 100 s, 
suggesting that immediate lysis of the membrane is not occurring, compared to the addition of the 
membrane solubilizing detergent, Triton X-100. The reason for this plateau in signal is currently 
unknown, but might suggest that a larger pore formed by the dimer rapidly creates an equilibrium of 
charged ions across the bilayer.  
 
 
 
 
 
 
 
 
 
 
  89 
 
Figure 3.5 Permeabilization assay on PC/PG membranes, utilizing pyranine. The fluorescence of 
pyranine entrapped in the liposomes rises with the internal pH as protons are exchanged across the 
membrane for sodium ions that permeate across pores formed by Dap. The experimental is 
described in Section 3.2.5. Only when Dap and CCCP are present in unison does the pyranine signal 
increase. The dimeric Dap does not require CCCP to form a pore. Experiments were run in triplicate 
at 30oC. 
 
The fluorescence work described previously highlights that the dimeric Dap is interacting 
with model membranes (Figure 3.4) and forming a functional pore (Figure 3.5) on liposomes. Still, 
the activity of the dimer is greatly diminished. This suggests that another factor is preventing the 
antibacterial activity of the dimer against both B. subtilis and S. aureus. Although the dimeric Dap 
might decrease the entropic cost of oligomer formation the overall size is greatly increased, compared 
to native Dap. It was speculated that this increase in size could be preventing dimeric Dap from 
passing across the cell wall of Gram-positive bacteria.  
 
3.3.4 Antibacterial Assays on L-form Bacteria 
To test this hypothesis, L-form bacteria were utilized. L-forms are Gram-positive cells that 
lack an outer cell wall but are still viable. These L-forms have been used in the literature to study the 
activity of several antibiotics187. Wolf, et al. originally constructed several L-form strains, one in 
particular, PDC 134, is described in their 2012 paper187. The PDC 134 L-form strain of B. subtilis was 
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used in this thesis, because it has several enzymes in the murein synthesis, mainly the murE operon 
expression system, under the control of xylose. If xylose is present, vegetative rod cells form. In the 
absence of xylose, the rod cells are converted to cell wall lacking L-forms189. These L-forms are 
highly sensitive to osmotic lysis and therefore require osmolarity protection, in this case, with 
sucrose. This PDC 134 strain was used to produce both vegetative and L-form bacteria. The L-forms 
were confirmed by microscopy (Figure 3.3) and a lysis check in water. The activities of the dimeric 
and monomeric Dap antibiotics were tested against these cells (Table 3.3).  
 Bacillus subtilis strain 
 1046 PDC 134 
CaCl2 (mM) 1.8 5.0 100 5 5 
L-forms (Y/N) N N N N Y 
Dap 1.0 0.75 0.5 0.5 0.075 
Dap Dimer >100 >100 7.5 25 0.2 
Table 3.3 MICs (µg/mL) of Dap and dimeric Dap on B. subtilis PDC 134. The MICs done on B. 
subtilis ATCC 1046 were completed at varying calcium concentrations, in LB broth. The B. subtilis 
PDC 134 strain produced vegetative (N-forms) or L-form bacteria and was tested at 5 mM calcium 
chloride. Assays were preformed five times, with each assay run in triplicate.  
 
As is shown in Table 3.3, the dimer’s activity is drastically improved with the L-form 
bacteria. The monomer also shows a 10-fold increase in activity. These data suggest that the dimer, 
and even the monomer to a certain extent, is prevented from reaching the bacterial membrane by the 
murein layer. Once they are membrane inserted, pore formation occurs, as observed previously on 
model membranes.  
 
3.4 Discussion 
In the literature, the most supported mode of action of Dap involves oligomer formation on 
membranes containing PG. This oligomer formation is likely to have an entropic cost, due to the 
increase in order when comparing an oligomer to individual monomeric molecules. In this work, it 
was thought that by reducing the entropic cost of oligomer formation, activity would be increased. To 
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investigate this, a dimeric Dap analog was synthesized that connected the N-terminal tryptophan 
residues of two monomers, by an octadecanedioate linker. Unexpectedly, the activity of the dimer 
against vegetative B. subtilis (Table 3.1) and S. aureus (Table 3.2) strains was much lower, in 
comparison to the monomer. Initially it was suspected that the dimer might be forming unfavourable 
steric constraints within the membrane, preventing permeabilization to occur. From the experiments 
with liposomes, it is clear that not only does the dimer insert into the membrane (Figure 3.4) at the 
same calcium concentration compared to Dap but permeabilization of sodium ions occurs more 
rapidly (Figure 3.5). The presence of carbonyl cyanide m-chlorophenyl hydrazone (CCCP) is required 
for Dap permeabilization, to allow for a proton efflux with simultaneous influx of sodium. In the case 
of the dimer, CCCP is not required, and actually decreases the fluorescence. This suggests the dimer 
is forming a larger pore than native Dap, allowing for a more rapid influx of sodium ions, and also a 
transport of buffer bound protons. Future work involving the determination of the subunit 
stoichiometry of the oligomers formed by dimeric Dap, in a similar study shown by Muraih, et al.115 
would allow for a better determination of the dimer’s pore size, within model membranes.  
Although the dimer was interacting with model membranes and forming a functional pore on 
liposomes, the question still remained as to why the activity was so low on vegetative cells. One 
possibility for this reduced activity is the fact that the dimer is much larger than native Dap. Due to 
this increased size, the dimer might be unable to cross the cell wall of Gram-positive bacteria. The 
cell wall is known for its antibiotic selectivity, acting as a barrier to the cell membrane. Increases in 
cell wall thickness186 and the extent of D-alanine modification on cell wall lipotechoic acids49,89 have 
previously been associated with Dap resistance, in clinical isolates. To determine if the cell wall was 
involved in this dimer resistance, a strain of B. subtilis was cultured (constructed by Wolf, et al.187) 
that had control of the murein synthesis (with the presence or absence of xylose). In the absence of 
xylose, B. subtilis PDC 134 cells lack a cell wall but still remain viable, when the osmolarity is 
retained. The monomer and dimer of Dap were tested against these cell wall lacking bacteria (L-
forms). As shown in Table 3.3, the dimer’s activity was dramatically increased on these L-forms, 
from 25 to 0.2 µg/mL (for PDC 134). The monomer of Dap surprisingly also saw an increase in 
activity. The vegetative form of this PDC 134 strain showed similar results to the other B. subtilis and 
S. aureus strains tested. This highlights that the mutations in the PDC 134 strain189 are not having an 
effect on the susceptibility of these vegetative cells. The results presented in Table 3.3 suggest that 
the dimer, and to a certain extent the monomer, are unable to pass the outer cell wall of the bacteria 
tested.  
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In a recent study, it has been speculated that the mechanism of action for Dap is through 
inhibition of cell wall synthesis enzymes119. In this proposed mechanism, Dap inserts into the 
membrane and oligomerizes and then, by redistributing the lipids within the outer membrane, flips 
Dap oligomers to the inner leaflet. This dislodges cell wall synthesis enzymes, mainly PlsX and 
MurG, from the cell membrane, resulting in cell death. However, the observation made here and 
earlier187 that Dap kills L-forms, reaffirms that Dap’s mechanism of action does not hinge on 
disruption of cell wall synthesis. This is at least true with B. subtilis. Permeabilization of the bacterial 
cell membrane has been observed repeatedly before for Dap, suggesting that pore formation is the 
primary mode of action46,137,190. Dap has also been shown to readily kill bacterial cells, which are 
prevented from dividing by a bacteriostatic antibiotic, rifampicin191. If they are prevented from 
dividing, they are likely to be protected from death by inhibition of cell wall synthesis alone. Even 
though the data suggests that permeabilization through pore formation is the mechanism of action for 
Dap, more empirical evidence is required, therefore, the possibility still remains that Dap both 
permeabilizes membranes and inhibits cell wall biosynthesis, similar to the lantibiotic nisin42.   
In Table 3.1, it was shown that when the calcium concentration was increased to un-
physiologically high concentrations (100 mM), that the MIC of the dimer was greatly increased (>100 
to 7.5 µg/mL). This suggests that the added calcium could be ‘shielding’ the dimer while passing 
through the murein layer. If the inability of the dimer to pass through the cell wall is due to not only 
size but also charge, the added calcium could be making the dimer more electrostatically neutral. This 
would then allow a more efficient passage across the cell wall, leading to permeabilization. Although 
it was expected that the activity of the dimer should be identical to Dap (0.075 µg/mL) on L-forms, 
the dimer was shown to have lower activity (0.2 µg/mL). This is unexpected since the dimer caused 
such a rapid transport of sodium ions seen in the coupled pyranine assay (Figure 3.5). This could be 
explained by a dual mechanism of action, where Dap is both permeabilizing the membrane and 
inhibiting a part of some biosynthetic pathway119,135,138,190,192, whereby the dimer is unable to promote 
this later mechanism. However, the antibacterial activity of Dap varies with the length of the fatty 
acyl residue60, and accordingly the replacement of Dap’s native decanoyl residue by octadecanedioate 
to effect dimerization might also account for the observed difference in activity. To better distinguish 
these two mechanisms of action for Dap, studies involving the permeabilization assays with pyranine 
on L-form bacteria would be useful. Since L-form bacteria lack a cell wall, Dap should not cause ion 
transport temporally with model membranes, if cell synthesis inhibition was a primary mechanism of 
action.  
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Overall, this work shows that the cell wall is an important obstacle in the action of Dap, and 
future work that looks into developing Dap analogs needs to take into account the size constraints for 
Dap activity. In a study of Dap aggregation utilizing NMR55, it was suggested that Dap, at relatively 
high concentrations, might form oligomeric aggregates of 14 subunits that approach the membrane. 
Since a dimer of Dap is unable to pass the cell wall it seems unlikely that a 14 subunit non-covalent 
aggregate is possible. The work shown in this chapter suggests that Dap must approach and interact 
with the membrane as a monomer. 
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Chapter 4 
 
Daptomycin Pore Formation is Restricted by Lipid Acyl 
Chain Composition3  
 
 
 
 
4.1 Introduction 
Dap has been found to depolarize Staphylococcus aureus cells through membrane 
permeabilization46,191. In contrast, a recent paper stated that Dap, at bactericidal concentrations, does 
not induce potassium leakage from Bacillus subtilis cells, suggesting instead that Dap is inserting into 
the membrane and causing the dislodgment of cell wall synthesis enzymes119. Dap’s mechanism of 
action on model membranes is debated amongst researchers even more. Two studies, from the 
Hancock group, that used Dap concentrations far higher than bactericidal concentrations suggested 
that the membranes undergo rapid lipid flip-flop when Dap is bound82. Their work also stated that 
Dap, at high concentrations, permeabilized membranes allowing the probe calcein to leave82. In their 
more recent studies they argued that the membranes undergo fusion when Dap is bound, suggesting a 
non-selective Dap interaction with the membrane and a permeabilization event that is non-specific109. 
Another study noticed that Dap shrank the surface of giant unilameller vesicles, stating that this effect 
was due to Dap removing specific lipids from the membrane, causing a membrane lesion120. In this 
work, they utilized a large dye called Texas Red within the liposomes, which did not leak out. From 
this the authors suggested the membrane lesion was unable to allow ions to pass, and only extract 
                                                      
3 The results displayed in this chapter have been published: “Daptomycin Pore Formation is Restricted 
by Lipid Acyl Chain Composition,” by Robert Taylor, David Beriashvili, Scott Taylor and Michael Palmer, 
2017, ACS Infect. Dis., 3, 11, 797-801209.  
 
Authors contributions: David Beriashvili ran the translocation and oligomer formation assays with 
NBD-Dap. Dr. Scott Taylor synthesized the PBFI probe. The ratiometric analysis was done by Dr. Michael 
Palmer, with experiments ran by David Beriashvili and Robert Taylor. Robert Taylor ran all other synthesis and 
experiments. Manuscript was written and devised by Dr. Michael Palmer. 
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specific lipids. In a separate study, a coupled fluorescence assay utilizing a fluorescent probe pyranine 
found that Dap permeabilized large unilamellar vesicles45. The pores that formed in these vesicles 
were selective for small cations, mainly sodium and potassium. 
Due to the varying results with bacteria and model membranes, especially in regards to 
different experimental conditions, the true mechanism of action for Dap still remains unclear. That 
being said, all scientists agree that Dap first requires insertion into the cell membrane, which may 
give insight into why Dap’s mechanism of action is continually elusive. The lipid composition of the 
cell membrane varies between bacterial strains. In the literature, model membranes that have been 
used to study Dap’s mechanism of action have also between greatly varied in terms of lipid 
composition. This inherent property of membranes could be the reason for Dap’s varying mechanistic 
models.  
Dap is dependent on the membrane for activity but most scientific research into Dap’s 
mechanism have ignored the importance of the complexity of membrane lipid composition. While 
most model studies used mixtures of phosphatidylcholine (PC) and PG, these phospholipids differed 
widely in their acyl chain composition. The Hancock group speculated that Dap non-selectively 
permeabilizes membranes, leading to lipid flip-flop82 and membrane fusion109. This work utilized 
palmitoyl-oleoyl lipids. Membrane shrinkage leading to lipid extraction, reported by Chen, et al.120 
used dioleoyl lipids. Cation-selective pore formation of Dap by Zhang, et al.45 was demonstrated 
using dimyristoyl lipids.  
The work herein was done to better understand these model membrane systems and their 
effect on Dap activity. The researchers above paid attention to the lipid head groups but neglected the 
importance of the acyl chain. In this study, the permeabilization of Dap was compared on each lipid 
type mentioned, with Dap concentrations that are similar to those required for antibacterial activity. 
Under these conditions it was observed that only dimyristoyl lipids permitted transport of ions. The 
lack of permeabilization in the other models corresponded to a reduced membrane translocation of 
Dap within the membrane and an overall decrease in oligomer subunit stoichiometry. The results 
presented demonstrate that the acyl chain moieties of lipids are vital to Dap’s permeabilization and 
activity. This may shed light onto why permeabilization of Dap was observed in Staphylococcus 
aureus but not Bacillus subtilis, as these bacteria vary in their lipid composition.   
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4.2 Methods and Materials 
 
4.2.1 Synthesis of NBD-Daptomycin 
Briefly, the side-chain amino group of Dap’s ornithine residue mixed with 7-chloro-4- 
nitrobenzoxadiazole (NBD-Cl) for 1 hour at 55oC, under reflux. Sodium bicarbonate was added to 
buffer the reaction. After 1 hour was reached, concentrated hydrochloric acid was added to quench 
the reaction. For details and procedures on the synthesis and purification of NBD-Dap, see Appendix 
A. 
 
4.2.2 Antibacterial Activity 
Antimicrobial susceptibility tests were performed as outlined in Section 2.2.3, with minor 
additions. Serial dilutions of Dap and NBD-Dap were prepared in Luria-Bertani (LB) broth (for 
Bacillus subtilis ATCC 1046) that was supplemented with 5 mM calcium chloride.  
 
4.2.3 Preparation of Liposomes 
Lipids used included those described in Section 2.2.4, with the addition of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-
glycerol) (sodium salt; POPG). All lipids were obtained from Avanti Polar Lipids, Alabaster, AL, 
USA.  
The methodology for liposome preparation of equimolar mixtures of LUV’s has been 
described in a preceding chapter (Section 2.2.4). 
 
4.2.4 Fluorescence Spectroscopy 
Steady state experiments were performed as described in Section 2.2.5. 
 
  97 
4.2.5 Permeabilization Assays Utilizing Pyranine 
The methodology for the permeabilization assay with pyranine has been described in a 
preceding chapter (Section 3.2.5). 
 
4.2.6 Ion-Leakage Assays with PBFI 
Ion-Leakage assays were preformed exactly like Zhang, et al.118 with several added controls. 
POPC/POPG liposomes were prepared as described above at an equimolar concentration (8.2 mM 
total lipid). 4,4′-[1,4,10,13-Tetraoxa-7,16-diazacyclooctadecane-7,16-diylbis(5-methoxy-6,2-
benzofurandiyl)]bis-1,3-benzenedicarboxylic acid (PBFI) was dissolved in HEPES-buffer (20 mM 
HEPES, pH 7.4). PBFI (0.85 mM, 1 mL) was added to the POPC/POPG lipids and sonicated for 45 
minutes in a bath sonicator. After sonication the liposomes were filtered through a 0.22 µm filter. The 
liposomes were then run on a size-exclusion column (Sephadex G-50) to remove non-encapsulated 
PBFI, using a potassium buffer (20 mM HEPES, 200 mM KCl, pH 7.4) as the eluent.   
Fluorescence (excitation wavelength, 338 nm; emission wavelength, 507 nm) was acquired 
on a PTI Quanta Master 4 instrument. At time 0, PBFI entrapped liposomes (0.55 mM total lipid) 
were added to potassium buffer. Dap (4.8 µM), valinomycin (0.5 µM) or Dap-E12W13 (4.8 µM) was 
added, separately, each with calcium chloride (0.6 mM) after 60 s. At 300 s, the assay was terminated 
using Triton X-100 (0.1%) to solubilize the liposomes. The fluorescence intensity after Triton X-100 
was added was used to normalize the entire curve. All assays were run at room temperature. 
 
4.2.7 Oligomer Subunit Stoichiometry Experiments 
Oligomer subunit stoichiometry of Dap was performed identical to Muraih, et al.115 LUV’s 
were prepared as described above, in HEPES-buffered saline (20 mM HEPES, 150 mM NaCl, pH 
7.4). Pre-mixed ratios (4:1, 6:1, 8:1 and 10:1) of Dap and NBD-Dap, respectively, at a final 
concentration of 10 µM, were added to each LUV suspension in HEPES-buffered saline with calcium 
(5 mM). Fluorescence resonance energy transfer (FRET) (excitation wavelength, 365 nm; emission 
wavelengths, 400-600 nm) was acquired on a PTI Quanta Master 4 instrument after a 3-minute 
incubation. Unlabeled Dap (4 µM) was then added, with a 3-minute incubation time, to correct for 
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FRET between (as opposed to within) oligomers. The relative kynurenine fluorescence was calculated 
with the following equation (equations and assumptions made were followed by Muraih, et al.115): 
 𝐹! =  !!!! ( !!!!!!!!!!!!!!) 
Fr – Relative kynurenine fluorescence 
D1/D2 – Molar amounts of native Dap added at first and second step 
I0, I1, I2 – Emission intensities at 445 nm of a liposome blank and the reaction mixture before and  
   after Dap is added 
V1/V2 – Volumes before and after Dap addition, respectively. Used to account for the 4% dilution due  
   to adding Dap.  
 
In this experiment, kynurenine of Dap is the donor and NBD of NBD-Dap is the acceptor. In 
order to calculate the subunit stoichiometry, several assumptions were made: 
1. All Dap oligomers have the same number of subunits 
2. Conversion of monomeric Dap to oligomers is quantitative on the time scale of the 
experiment 
3. When native Dap and NBD-Dap are mixed before application to membranes, they will form 
oligomers randomly, without any positive or negative mutual discrimination 
4. In hybrid oligomers, the kynurenine fluorescence of all unlabeled Dap molecules is 
completely quenched by FRET. Therefore, any remaining kynurenine fluorescence originates 
from oligomers that consist of unlabeled Dap only 
5. Oligomers are stable on the time scale of the experiment 
According to assumption 3, Dap and NBD-Dap will form oligomers randomly. To account 
for all native Dap monomers that formed donor only oligomers, from the pre-mixture, the following 
equation was used.  𝐷 = 𝑑!𝑑 = 𝑑!!! 
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D – fraction of all Dap, from pre-mixture, before oligomerization, that formed Dap only oligomers 
d – The fraction of Dap, after oligomerization has occurred, that was incorporated into oligomers of 
both Dap and NBD-Dap 
dn – The fraction of Dap, after oligomerization has occurred, that formed Dap only oligomers 
Assumption 4 states that any native Dap that forms mixed oligomers will be quenched by 
FRET. In other words, when excited, these Dap subunits will transfer the photons from kynurenine to 
NBD, thus eliminating kynurenine signal. Therefore, in the pre-mixture, only oligomers that formed 
with Dap only (represented by fraction D, above) will have signal from kynurenine. The fraction D 
then simplifies to equal the relative kynurenine fluorescence seen in pre-mixed oligomers, i.e. Fr 
(from the first equation). Substituting Fr for D in the second equation yields: 𝑛 = 1 + 𝑙𝑜𝑔! 𝐹! = 1 + ln (𝐹!)ln (𝑑)  
The subunit stoichiometry (n) of the oligomer can be determined by comparing the 
kynurenine fluorescence of the mixed oligomers to that of pure Dap oligomers.  
 
4.2.8 Membrane Translocation Assays with Dithionite  
Membrane translocation assays were conducted similar to Zhang, et al.111 but with some 
deviations. The buffer used for all samples was HEPES-buffered saline, supplemented with 25 mM 
calcium chloride. The assay was affected by the concentration of calcium present. At 25 mM the 
experimental variation was minimal compared to lower concentrations. A mixture of 
Dap:nitrobenzodiaxole (NBD)-Dap, at a molar ratio of 2:1, respectively, was added to the varying 
liposomes at a final concentration of 1 µM. A mixture of native Dap was necessary to prevent NBD-
Dap self-quenching. The sample was allowed to incubate for 5 minutes before collecting the 
spectrum. Fluorescence (excitation wavelength, 465 nm; emission wavelength, 530 nm) was acquired 
on a PTI Quanta Master 4 instrument. Dithionite (1 mM) was added at 60 seconds to quench the 
NBD-Dap. A lower dithionite concentration was used, compared to Zhang, et al. to improve batch-to-
batch reproducibility. When the dithionite concentration was increased to greater than 3-4 mM, there 
was extensive NBD quenching. It is suspected that this may be related to the introduction of sulfuric 
acid that forms through spontaneous chemical decay193, but this has not systematically been examined 
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yet. At 300 seconds, Triton X-100 (0.1%, total) was added to solubilize the membranes, exposing all 
NBD groups.  
 
4.3 Results 
 
4.3.1 Membrane Insertion of Daptomycin into Dimyristoyl, Dioleoyl and Palmitoyl-
oleoyl Liposomes 
 The interaction of Dap has been shown previously to occur on 
dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) 
membranes45,115,116. The kynurenine residue intrinsic to Dap has a prominent blue shift and 
fluorescence increase as the residue becomes inserted into the hydrophobic membrane76. Equimolar 
mixtures of PC to PG containing liposomes, with three different acyl chain compositions, were 
measured for kynurenine’s ability to insert (Figure 4.1). The lipid mixtures used were a one-to-one 
molar ratio of: DMPC/DMPG, dioleoylphosphatidylcholine (DOPC)/dioleoylphosphatidylglycerol 
(DOPG) and palmitoleoylphosphatidylcholine (POPC)/palmitoleoylphosphatidylcholine (POPG).  
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Figure 4.1 Daptomycin membrane interaction on three different types of large unilamellar vesicles 
(LUVs). LUVs consisting of DMPC/DMPG, DOPC/DOPG and POPC/POPG (molar ratio of 1/1 for PC 
to PG, 250 µM) were incubated with Dap (3 µM) at varying calcium concentrations, for 3 minutes. An 
increase in the intrinsic kynurenine residue (excitation, 365 nm; emission, 445 nm) indicates 
membrane insertion. Error bars represent the standard deviation of three different experiments, ran at 
37oC 
 
 
The interaction of Dap to these membranes is calcium-dependent. The increase in 
kynurenine’s fluorescence, indicative of membrane insertion, occurs as the concentration of calcium 
is increased. Dap inserts into both DOPC/DOPG and POPC/POPG more avidly than the 
DMPC/DMPG but all show that the saturation point for kynurenine’s signal occurs at a calcium 
concentration of >0.1 mM.  
 
4.3.2 Biologically Relevant Concentrations of Daptomycin Permeabilize Dimyristoyl 
but not Dioleoyl or Palmitoyl-oleoyl Membranes 
Previously, Zhang, et al.45 reported that Dap causes the permeabilization for small cations in 
LUVs. This was done utilizing a coupled fluorescence assay, with pyranine, as discussed in Section 
1.7.2143. Briefly, pyranine is loaded into liposomes and a pH/salt gradient is created across the bilayer. 
When ions are able to transport across the membrane, protons leave the liposome increasing the pH, 
causing an increase in pyranine’s fluorescence intensity. Equimolar mixtures of PC to PG containing 
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membranes, consisting of DMPC/DMPG, DOPC/DOPG and POPC/POPG were tested, as shown in 
Figure 4.2.  
 
 
 
Figure 4.2 Permeabilization of Dap on three different LUVs. DMPC/DMPG, DOPC/DOPG, 
POPC/POPG (molar ratio of 1/1 for PC to PG, 250 µM) were entrapped with pyranine (1 mM) with a 
low pH and low sodium buffer. Time-based fluorescence was measured (excitation, 470 nm; 
emission, 510 nm) for 360 seconds. The loaded LUVs were incubated with a calcium (5 mM) pre-
mixed buffer, which contained a high pH and increased sodium ions, thus creating a proton/sodium 
gradient across the bilayer. A proton ionophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 
5 nM) and Dap (2 µM) were added both separately or not at all (dotted lines) and together (solid lines) 
and measured from 0-300 seconds. At 300 seconds, Triton X-100 was added (0.1%) to solubilize the 
membranes. The experiments were run in triplicates at 30oC. 
 
 
Controls were run with each separate lipid type with liposomes either alone or adding: CCCP 
(5 nM), Dap (2 µM) and Dap/CCCP. Other controls with valinomycin (0.5 µM) and gramicidin (10 
nM) were also preformed, exactly as described by Zhang, et al.111 In the case of valinomycin, a 
potassium selective carrier, no increase in signal was seen for DMPC/DMPG or POPC/POPG 
liposomes, due to the absence of potassium. For DOPC/DOPG valinomycin did cause a fluorescence 
increase. The reason for this is unknown.  In the case of gramicidin, a rapid increase in fluorescence 
was observed. Gramicidin is a cation-selective channel194; having a very rapid rate of ion transport 
(106 ions per second194). Zhang, et al. observed that Dap’s rate of transport was only ~0.12 ions per 
second45, indicating that although both of these antibiotics form pores on model membranes, they 
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cannot be directly compared, in the context of ion transport rates. In Figure 4.2, it was observed that 
both DOPC/DOPG and POPC/POPG prevented Dap cation permeabilization. The DMPC/DMPG 
liposomes allowed for proper permeabilization at bactericidal concentrations of Dap. All three of 
these lipid types contain the same head group moieties, but differ in their acyl chain composition. 
Therefore, the difference in Dap permeabilization must be attributed to their fatty acyl tail groups.  
 
A relatively recent study also utilized pyranine to examine membrane permeabilization of 
Dap (Figure 4.3). Zhang, et al.118 were unable to mimic an equimolar PC to PG ratio, using a 3 to 1 
ratio instead, but stated that the DMPC/DMPG membranes are susceptible to CCCP alone, at 10 nM. 
This could be due to the low calcium concentrations used, as it was found by Taylor, et al.117 that 
calcium concentrations of > 1 mM was necessary for liposome stability. The inclusion of sucrose was 
found to also greatly improve stability. Zhang, et al.’s results, although interesting, suggest that their 
liposomes, without any analog added, are quite unstable and therefore the results are inconclusive. 
The experimental conditions and results used throughout this thesis and by Zhang, et al. are compared 
in Figure 4.3 below.  
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Figure 4.3 Compared results of Zhang, et al.118 and Taylor, et al.117 in the permeabilization assay with 
pyranine. Top: The conditions and results for Zhang, et al. are shown. The slashed bars represent 5 
min incubation and the black bars represent 30 min incubation, with the compounds shown. The bar 
graph was reprinted with permission from Zhang, J.; Scoten, K.; Straus, S. K. Am. Chem. Soc. – 
Infect. Dis. 2016, 2, 682-687. Copyright 2016, American Chemical Society. Bottom: The conditions 
and results for Taylor, et al. are shown. The bars represent 5 min incubations. As seen, the conditions 
used were widely different which may explain Zhang, et al. observing highly unstable liposomes 
 
Zhang, et al. also used POPC/POPG, at an equimolar ratio, with this pyranine coupled assay 
and showed no Dap permeabilization118. However, using another assay that employed potassium and 
sodium probes, PBFI and SBFI (Figure 4.4), the same authors concluded that POPC/POPG 
membranes were in fact permeabilized by Dap, for both ions.  
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Figure 4.4 Permeabilization assay using the conditions by Zhang, et al. utilizing PBFI118. 1/1 
POPC/POPG (0.55 mM) LUV’s were encapsulated with PBFI (as described in Section 4.2.6). CaCl2 
(0.6 mM) was added to LUV’s and ran for ~200 seconds. Dap (4.8 µM) was then added. Zhang, et al. 
attributed this instantaneous increase in fluorescence to Dap forming an ion selective pore for 
potassium (or sodium, utilizing SBFI). Triton X-100 was added at ~1500 seconds to solubilize the 
membranes. The figure was used with permission. 
 
Since Zhang, et al. used the same concentrations for Dap in both assays the results appear 
quite contradictory. To resolve this question, the PBFI-based assay as described by Zhang, et al.118 
was repeated, but with some added controls that were absent from the original publication.  
One large flaw with this PBFI assay is the strong spectral overlap that PBFI and Dap share, in 
both their absorption and fluorescence. The kynurenine residue of Dap has a maximal excitation at 
365 nm, and emits at 445 nm. PBFI was excited at 338 nm and emitted at 507 nm118. It was 
speculated that the difference in these excitation/emission wavelengths was too small and that overlap 
would be present. To determine if this was the case, Dap’s membrane interaction (similar to Figure 
4.1) was tested on POPC/POPG (one-to-one molar ratio of PC to PG) at the concentrations used for 
Zhang, et al.’s PBFI work. Dap (4.8 µM) was added to POPC/POPG (0.55 mM) LUVs and mixed 
with calcium (0.6 mM). The excitation and emission spectra were determined, shown in Figure 4.5.  
 
namely, 31 ± 3% (average ± one standard deviation, from ﬁve
repeats) for Na+ versus 64 ± 2% (average ± one standard
deviation, from ﬁve repeats) for K+. This selectivity for
potassium is in sharp contrast to the ﬁndings reported in ref
19, where similar ﬂuorescence curves were obtained for K+,
Na+, Cs+, and Mg2+. Unfortunately, one li itation of using
cation-sensitive dyes is that we could not determine the
transport eﬃciencies for Cs+ and Mg2+. Fluorescence indicators
for cesium are not commercially available, and those for
magnesium also bind Ca2+, which, in the case of daptomycin, is
required for membrane interaction. Nevertheless, the ﬁndings
obtained here suggest that daptomycin has an aﬃnity for K+, in
keeping with previous results obtained in bacterial cells.14,16−18
The results shown herein suggest that a careful choice of lipid
composition is needed to accurately model the more complex
biological system and that the use of ionophores such as CCCP
can have an impact on the permeability observed. In
conclusion, the ﬁndings presented suggest that the mode of
action of daptomycin involves a preferential interaction with
potassium, but whether leakage or the interaction of
daptomycin with other targets (e.g., proteins or other cell
wall components) is the cause of bacterial killing remains to be
determined.
■ MATERIALS AND METHODS
Materials. Daptomycin was a generous gift from Cubist
Pharmaceuticals (Lexington, MA, USA). 1-Palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-(1′-rac-glycerol) (POPG), 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glyc-
ero-3-phospho-(1′-rac-glycerol) (DMPG), and cardiolipin (CL;
heart, bovine, disodium salt) were purchased from Avanti Polar
Lipids, Inc. (Alabaster, AL, USA). Pyranine and carbonyl
cyanide m-chlorophenyl hydrazine (CCCP) were purchased
from Acros Organics (Morris Plains, NJ, USA). PBFI and SBFI
were purchased from ThermoFisher Scientiﬁc (Waltham, MA,
USA). 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
(HEPES) and acetonitrile were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Sodium phosphate dibasic, sodium
chloride, and potassium chloride were purchased from Fisher
Scientiﬁc (Fair Lawn, NJ, USA).
In Vitro Ion Translocation Experiments Using Pyr-
anine. The translocation experiments were performed using
the method reported in Otis et al.,21 but using a 3:1 DMPC/
PG, 1:1 POPC/PG, or 1:1 POPG/CL (mol/mol) mixture
instead of the phosphatidylcholine (PC) lipid reported in that
paper. Brieﬂy, vesicles were prepared by drying DMPC/
DMPG, POPC/POPG, or POPG/CL under vacuum overnight.
Lipids were suspended in 2 mL of internal buﬀer containing a
pH-sensitive dye (15 mM Na2HPO4, 4 mM pyranine, pH 6.2)
to reach a concentration of 8.2 mM and sonicated for 45 min.
The suspension was ﬁltered through a 0.22 μm ﬁlter. Pyranine
not trapped in vesicles was removed by purifying vesicles
through a Sephadex G-50 column (1.8 × 15 cm) with external
buﬀer composed of 15 mM Na2HPO4 and 200 mM MCl at pH
7.2 as eluent. The MCl solution was either NaCl or KCl.
For the experiments run at room temperature, ﬂuorescence
was measured on a PerkinElmer LS50B luminescence
spectrometer. For the experiments run at 15 and 35 °C,
measurements were conducted using a Varian Eclipse
ﬂuorometer, equipped with a multicell holder and temperature
control unit. The excitation wavelength was set to 460 nm, and
the emission wavelength was 520 nm. For each assay, sensitivity
was adjusted to obtain a signal near 900 arbitrary units (au)
after the lysis of vesicles by Triton X-100. Stock solutions of
daptomycin or aurein 2.3 were prepared in triﬂuoroethanol
(TFE) or water. A stock solution of Ca2+ was also prepared.
One hundred microliters of pyranine loaded vesicle solution
was added to 3 mL of external buﬀer (pH 7.2) in a 1 cm path
length cuvette equipped with a stir bar. For daptomycin, 14 μL
of concentrated Ca2+ was also added to reach the
corresponding concentration for diﬀerent concentrations of
daptomycin. After stabilization of the signal for ca. 100 s, 20 μL
of the peptide solution was added to reach the ﬁnal
concentration speciﬁed in the ﬁgure captions. For the
experiments used to investigate the eﬀect of CCCP, CCCP
was added after the signal had stabilized. Final concentrations
of daptomycin, Ca2+, and CCCP are speciﬁed in the ﬁgure
captions. Fluorescence intensity was measured until the signal
reached a plateau, after which 10 μL of a 10% aqueous solution
of Triton X-100 was added to completely lyse vesicles for the
determination of maximum ﬂuorescence signal. The ion
transport eﬃciency was calculated employing the formula
= −−
F F
F F
% transport efficiency 0
max 0 (1)
where F0 is the ﬂuorescence intensity of the liposomes before
the addition of peptide, F is the measured ﬂuorescence
intensity, and Fmax is the ﬂuorescence intensity when the
Triton was added.
In Vitro Ion Translocation Experiments Using PBFI
and SBFI. The translocation experiments were performed
using 1:1 POPC/PG and the potassium ﬂuorescent indicator,
PBFI, or the sodium ﬂuorescence indicator, SBFI. Brieﬂy,
vesicles were prepared by drying POPC and POPG ﬁrst under
a stream of N2 and then under vacuum overnight. Lipids were
suspended in 1 mL of internal buﬀer containing PBFI or SBFI
(20 mM HEPES, 0.85 mM PBFI, pH 7.4) to reach a total lipid
concentration of 8.2 mM and sonicated for 45 min. The
suspension was ﬁltered through a 0.22 μm ﬁlter. PBFI (or
SBFI) not trapped in vesicles was removed by purifying vesicles
through a Sephadex G-50 column (1.8 × 15 cm) with external
Figure 4. Typical trace obtained for transport eﬃciency for potassium
using PBFI and 1:1 POPC/PG liposomes. Daptomycin (4.8 μM) and
Ca2+ (600 μM) were added at time t = 241 s. Triton X-100 s added
to lyse the vesicle near the end point (t = 1512 s). The ﬂuorescence
intensity after vesicle lysis was set to 100%.
ACS Infectious Diseases Letter
DOI: 10.1021/acsinfecdis.6b00152
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Figure 4.5 Excitation and emission spectra of Dap added to POPC/POPG (1/1 molar ratio, 550 µM). 
Dap (4.8 µM) was added to LUVs in HEPES-buffered saline with 0.6 mM calcium and incubated for 3 
minutes. The excitation and emission wavelengths for PBFI are shown, overlapping with the 
excitation (red) and emission (blue) of Dap on these membranes. 
 
The red and blue arrows (Figure 4.5) show the excitation and emission wavelengths used for 
PBFI, respectively. These results show that when PBFI is excited, Dap will also get excited. The 
emission of Dap when excited at 338 nm is ~half the signal intensity than when excited at 365 nm, 
but a strong signal is still observed.  Zhang, et al.’s work was repeated, where PBFI was entrapped 
within POPC/POPG liposomes through sonication. The excess PBFI was removed by gel filtration 
with a high salt buffer (20 mM HEPES, 200 mM KCl, pH 7.4) as the elutant. Loaded liposomes were 
then measured through fluorescence (excitation, 338 nm; emission, 507 nm) with Dap added with or 
without calcium (Figure 4.6). 
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Figure 4.6 Time-based fluorescence scan of PBFI loaded POPC/POPG LUVs (1/1 molar ratio, PC to 
PG, 550 µM). A potassium ion sensitive probe, PBFI (0.85 mM) was loaded into POPC/POPG LUVs 
in buffer (20 mM HEPES, pH 7.4). Fluorescence was measured (excitation, 338 nm; emission, 507 
nm) for 360 seconds. At 0 seconds, buffer (20 mM HEPES, 200 mM KCl, pH 7.4) was mixed with 
PBFI loaded LUVs. At 60 seconds, either valinomycin (0.5 µM) or Dap (4.8 µM)/Dap-E12W13 (4.8 
µM) were added with 0.6 mM calcium. At 300 seconds, Triton X-100 (0.1%) was added to solubilize 
the membranes. Of all tested compounds, only Dap produced a step change in fluorescence 
emission. The potassium ionophore valinomycin as well as Dap-E12W13, which contains tryptophan 
instead of kynurenine in position 1368, are indistinguishable from control and only exhibit increased 
fluorescence when the entrapped PBFI is released into the buffer by Triton X-100. The experiments 
were run in triplicates at room temperature. 
 
 
If a pore formed, one would expect a gradual increase in Dap’s signal, over time, similar to 
the pyranine results seen in Figure 4.2. Interestingly, when Dap and calcium were added to PBFI 
loaded liposomes the fluorescence instantaneously increased and then remained constant until Triton 
X-100 was added. The Triton X-100 causes the membranes to solubilize, causing any PBFI within the 
membranes to be exposed to the high potassium buffer and fluoresce. When taking into account that 
there is an extensive overlap between Dap and PBFI’s excitation and emission spectra, this result can 
be explained. The instantaneous increase in signal when Dap and calcium are added must be 
attributed to the kynurenine insertion into the POPC/POPG membranes. In Figure 4.1, it was shown 
that at >0.1 mM calcium, maximal signal occurred for Dap. The calcium concentrations used in this 
work was 0.6 mM, suggesting that the intensity increase was solely due to kynurenine.  
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To prove that this was the cause of this rapid increase in signal a separate analog of Dap was 
used. This analog, Dap-E12W1368, has the 3-methylglutamate of position twelve changed to 
glutamate and the kynurenine residue of position thirteen changed to tryptophan. Lohani, et al. 
synthesized this analog through solid phase peptide synthesis68. The antibacterial activity (MIC) of 
this analog was compared to Dap. Dap-E12W13 was found to have an MIC of 1.5 µg/mL; Dap’s MIC 
was found to be 0.75 µg/mL (on B. subtilis ATCC 1046 at 5 mM calcium). The interaction of this 
analog was tested against DMPC/DMPG LUVs and found to insert (Figure 4.7A) and permeabilize 
(Figure 4.7B) the model membranes at the same concentrations necessary for Dap. 
 
 
 
Figure 4.7 The interaction and permeabilization of the Dap analog Dap-E12W13 on model 
membranes. A: DMPC/DMPG LUVs (1/1 molar ratio, 250 µM) were incubated with Dap (3 µM) and 
Dap-E12W13 (3 µM) at varying calcium concentrations, for 3 minutes. Insertion of Dap was monitored 
using kynurenine (E445), whereas insertion of Dap-E12W13 was monitored by the blue shift of 
tryptophan (E339/E365). Error bars represent the standard deviation of triplicate experiments, ran at 
37oC. B: Permeabilization of Dap and Dap-E12W13 were monitored on DMPC/DMPG membranes, 
utilizing pyranine (1 mM).  DMPC/DMPG LUVs (1/1 molar ratio, 250 µM) were entrapped with 
pyranine (1 mM) with a low pH and sodium buffer. Time-based fluorescence was measured 
(excitation, 470 nm; emission, 510 nm) for 360 seconds. The loaded LUVs were incubated with a 
calcium (5 mM) pre-mixed buffer, which contained a high pH and increased sodium ions, thus 
creating a proton/sodium gradient across the bilayer. A proton ionophore carbonyl cyanide m-
chlorophenyl hydrazone (CCCP, 5 nM), Dap (2 µM) and Dap-E12W13 (2 µM) were added both 
separately or not at all (dotted lines) and together (solid lines) and measured from 0-300 seconds. At 
300 seconds, Triton X-100 was added (0.1%) to solubilize the membranes. The experiments were run 
in triplicates at 30oC. 
 
 
This data suggests that the Dap-E12W13 analog interacts with the membrane by the same 
mechanism as Dap, and therefore is useful in validating the PBFI assay. When this analog was used, 
in Figure 4.6 (green line), the instantaneous increase in fluorescence was not observed, due to the lack 
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of kynurenine present. This indicates that the signal seen for Dap and calcium permeabilization, with 
the PBFI assay, is entirely due to kynurenine.  
A “mock” PBFI assay was also performed, where the same experiment shown in Figure 4.6 
was repeated, expected with a lack of PBFI present (Figure 4.8). These POPC/POPG membranes 
were tested with Dap and Dap-E12W13 at the same concentrations presented above. This plot shows 
that Dap will be excited even in the absence of PBFI, further demonstrating that the signal seen by 
Zhang, et al.118, was erroneous.  
 
Figure 4.8 Mock PBFI assay to demonstrate Dap’s signal overlap. The time-based fluorescence 
spectrum of POPC/POPG LUVs (1/1 molar ratio, PC to PG, 550 µM) without PBFI added. 
Fluorescence was measured (excitation, 338 nm; emission, 507 nm) for 360 seconds. At 0 seconds, 
buffer (20 mM HEPES, 200 mM KCl, pH 7.4) was mixed with LUVs. At 60 seconds, either Dap (4.8 
µM) or Dap-E12W13 (4.8 µM) was added with 0.6 mM calcium. At 300 seconds, Triton X-100 (0.1%) 
was added to solubilize the membranes. Since no dye was present, Triton X-100 had minimal signal. 
Dap produced a step change in fluorescence emission. Dap-E12W13, which contains tryptophan 
instead of kynurenine in position 1368, are indistinguishable from control. The experiments were run in 
duplicate at room temperature. 
 
Zhang, et al.’s PBFI work118 also utilized a sodium probe, SBFI. The analogous experiments 
with the sodium indicator SBFI were not carried out in this study, since the fluorophore in SBFI is the 
same as PBFI. The excitation wavelength used for SBFI is 333 nm, and therefore it would be 
suspected that the results shown here would be the same for this probe. The data obtained and shown 
by Zhang, et al.118 with PBFI and SBFI do not support the conclusion that POPC/POPG membranes 
are permeabilized toward potassium or sodium by Dap. 
Figure S3
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4.3.3 Translocation and Oligomer Formation of Daptomycin on Dioleoyl Membranes 
In Chapter 2, it was suggested that the mechanism of action of Dap occurs through two 
calcium-binding events. The first calcium ion causes Dap to oligomerize in the outer cytoplasmic 
membrane. The second calcium ion causes a deeper insertion and translocation of this oligomer. 
DOPC/DOPG and POPC/POPG, as seen previously, prevent permeabilization of Dap but which 
phase of calcium-binding they inhibit was unclear. To attempt to solve this question, the ability of 
Dap to translocate across leaflets and even further, the oligomer stoichiometry of Dap within the 
membrane, was investigated. To determine if translocation was occurring, a dithionite quenching 
experiment was done utilizing NBD-Dap (Figure 4.9). 
 
 
 
Figure 4.9 Structures of Dap and the NBD moiety. The NBD moiety is attached to the ornithine6 
residue of native Dap.  
 
 
In this assay (Figure 4.10), NBD-Dap was pre-mixed with native Dap (to prevent NBD self-
quenching) and allowed to insert into the membranes. After a baseline was reached, dithionite was 
added to quench the NBD-Dap195 that would be found on the outer leaflet. The NBD-Dap that had 
translocated before addition of dithionite would be found on the inner leaflet of the membrane and 
therefore be protected, initially, from dithionite. Over time the NBD groups gradually become 
reduced by dithionite in the external buffer, since NBD-Dap is able to transiently move back and forth 
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across the membrane leaflets45. The addition of Triton X-100 was used to solubilize the membranes, 
allowing for any remaining NBD groups to be quenched, showing minimal signal.  
 
Figure 4.10 Translocation of NBD-Dap across DMPC/DMPG and DOPC/DOPG LUVs. The LUVs 
were each incubated with a 2:1 mixture of Dap to NBD-Dap (1 µM total), respectively, at 25 mM 
calcium. At 60 seconds, dithionite (1 mM) was added to quench the NBD-Dap exposed to the external 
buffer. At 400 seconds, Triton X-100 (0.1%) was added to solubilize the membrane, exposing any 
NBD-Dap contained in inner leaflet that has not yet been quenched. NBD fluorescence was 
measured over time (excitation wavelength, 478 nm; emission wavelength, 520 nm; each curve is the 
average of three separate experiments). Curves are offset by 5 seconds to avoid overlap, to better 
visualize the difference in translocation. 
 
 
Zhang, et al.111 reported that close to 50% of the NBD-Dap inserted into DMPC/DMPG 
membranes are immediately quenched and therefore approximately 50% of NBD-Dap is on the outer 
leaflet. This correlates with the results displayed in Figure 4.10, which show 48%±6% quenching of 
NBD immediately. In a control experiment to confirm that Dap does not lead to the transport of 
dithionite, Zhang, et al. added NBD labeled phosphatidylethanolamine (PE) into these DMPC/DMPG 
membranes. They observed 50% quenching of NBD with and without Dap added, confirming that 
Dap does not cause the transport of dithionite across the membrane. On DOPC/DOPG or 
POPC/POPG membranes, ~70% are immediately reduced, with remaining NBD signals of 31%±3% 
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and 35%±1%, respectively (Figure 4.10). This suggests that the translocation of NBD-Dap across 
these membranes is partially prevented. When the incubation time before adding dithionite to these 
membranes was increased, the difference in NBD quenching was minimal, suggesting there is a shift 
in the distribution of NBD-Dap across DOPC/DOPG and POPC/POPG membranes.   
Although DOPC/DOPG and POPC/POPG membranes prevent some translocation of 
oligomers into the inner leaflet, ~30% is still translocated. This suggests another factor is, in part, 
preventing permeabilization. A potential reason for the lack of ion transport could be an inability for 
Dap oligomers in opposing leaflets to be proper aligned. To investigate this, the number of monomers 
of Dap per oligomer in the membrane was determined. This subunit stoichiometry result utilized a 
FRET based assay that determined the ratio of florescence within and between Dap/NBD-Dap 
oligomers115. From this ratio, the average number of subunits was calculated (Section 4.2.7 details the 
methodology). Zhang, et al.45 reported that DMPC/DMPG membranes had a Dap subunit 
stoichiometry of  >6, whereas values of 4.7±0.7 subunits and 3.6±0.9 subunits were observed on 
DOPC/DOPG and POPC/POPG membranes, respectively. The data between DOPC/DOPG and 
POPC/POPG membranes are compatible, with a subunit stoichiometry of ~4. This suggests that 
tetramers found in each leaflet of the membrane are unable to align across the bilayer, preventing 
FRET to occur, and ultimately accounting for the absence of pore formation.  
 
4.4 Discussion 
Many proposed mechanisms of action for Dap are found in the literature, with many groups 
utilizing model membranes. The effect of the lipid head group in these membranes has been 
examined in detail, proving that Dap requires PG for activity40, and also suggesting the presence of 
lysyl-PG134 and cardiolipin (CL)107 to be resistance mechanisms. Although extensive work has been 
done into the varying head groups of lipids, little emphasis has been given to the composition of the 
acyl tails.  
The important finding to this chapter is the extreme difference between DMPC/DMPG 
membranes and DOPC/DOPG or POPC/POPG containing membranes. Dap permeabilizes 
DMPC/DMPG membranes rapidly, while the other lipids are permeabilization resistant (Figure 4.2). 
Interestingly, Dap not only inserts to but also oligomerizes on these permeabilization resistant 
liposomes. This highlights that the study of Dap, using model membranes, must be done carefully. 
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The chain composition of these membranes must be taken into consideration when examining the 
activity and mechanism of Dap, and cannot be chosen strictly based on technical simplicity.  
Zhang, et al.118 utilized a potassium-sensitive fluorophore, PBFI, to detect Dap 
permeabilization. They suggested from their work that permeabilization is ion selective. 
Unfortunately, Dap’s intrinsic kynurenine residue overlaps strongly with the excitation of this PBFI 
(Figure 4.5). This gave rise to an instantaneous increase in fluorescence after Dap was added, that was 
previously attributed to indicate ion leakage. Several experiments were performed to show that the 
kynurenine residue of Dap was the main cause for this increase. To further confirm this fluorescent 
jump, dual wavelength ratio metric experiments were preformed (Figure 4.11). Dap was added to 
POPC/POPG liposomes containing PBFI as outlined in Section 4.2.6. Again, an instantaneous 
increase was observed when Dap and calcium were added. The increase seen was significantly larger 
when the sample was emitted at 445 nm (the maximal emission of kynurenine). This further 
highlights that the increase seen is due to kynurenine insertion, as the intensity is comparable to the 
emission scan of Dap itself. The addition of Triton X-100 to the PBFI loaded POPC/POPG showed 
similar intensity increases with either wavelength, which is also comparable to the PBFI emission 
spectrum. From the data here and in Section 4.3.2, it is clear that the observed increase in 
fluorescence seen by Zhang, et al. is entirely due to a fluorescence artifact. The POPC/POPG 
membranes do not allow for Dap permeabilization, as shown in Figure 4.2.  
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Figure 4.11 Dual wavelength monitoring of the PBFI assay of permeabilization using Dap. A: 
Emission spectrum of Dap on POPC/POPG LUVs (1/1 molar ratio, 0.55 mM) at varying calcium 
concentrations. Solid and dashed arrows indicate changes in emission at 507 and 445 nm, 
respectively. These differences were used to calculate the characteristic emission ratio shown in D. 
B: Emission spectrum of PBFI, in the presence of 0.1% Triton X-100. There was a blue shift upon 
Triton X-100 addition with the addition of potassium. Triton X-100 was added to mimic the conditions 
used in C. Solid and dashed arrows indicate changes in emission at 507 and 445 nm, respectively. C: 
Dual wavelength time-based emission scan of Dap added to PBFI loaded POPC/POPG LUVs. Solid 
and dashed arrows indicate changes in emission after adding Dap (60 seconds) and Triton X-100 
(300 seconds) at 507 and 445 nm. These ratios were also used in the calculations for part D. D: 
Ratios of emission changes at 507 and 445 nm calculated A-C. Adding Dap to PBFI loaded 
liposomes causes a change that resembles an increased kynurenine emission, whereas adding 
Triton X-100 causes a change resembling an increase in PBFI emission. 
 
 
In order to compare our experimental observations with bacterial membranes a look into the 
lipid composition of these bacteria is required. The numbers given below are complied from different 
references, which used different quantitative methods and growth conditions that may have affected 
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experimental results. The experimental growth conditions, primarily pH and temperature, have shown 
to have large implications on the final lipid composition of bacterial strains100,86,101,106. 
Among all B. subtilis species, the most common bacterial lipids consist of terminally 
methylated, either iso or anteiso, branched acyl chains196,100. These chains range from 14-17 carbons 
in length196,100. The percentage of mono-unsaturated tails is minor and poly-unsaturation is virtually 
non-existent196. In the case of S. aureus, the acyl composition is similar to B. subtilis100,197, but fifteen 
carbon branched chains are the most prevalent197, with minor percentages of unsaturation100. Dap is 
also used clinically against Enterococcus faecalis198. This bacterium has a fairly different acyl chain 
composition from those previously discussed. This bacterium is composed of mainly 16 and 18 
carbon lengths, with 10-15% longer mono-unsaturated chains48,104. These varying percentages are 
shown in Figure 4.12, below. 
 
Figure 4.12 Lipid acyl chain composition of varying bacteria mentioned above. The acyl chain 
structures are colour coded according to their acyl chain moieties. The iso and anteiso chains were 
group together as “methylated.” From this figure it is clear that E. faecalis contains, on average, 
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Bacillus subtilis
 0
 10
 20
 30
 40
 50
 60
 70
 80
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Bacillus megaterium
 0
 10
 20
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
En erococcus faecalis
 0
 10
 20
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Enterococcus faecium
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Acyl chain structures
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Staphylococcus aureus
straight, saturated
straight, unsaturated
methylated (iso/anteiso)
cyclopropyl
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl hain le gth (n)
Bacillus subtilis
 0
 10
 20
 30
 40
 50
 60
 70
 80
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Bacillus megaterium
 0
 10
 20
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Enterococcus faecalis
 0
 10
 20
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Enterococcus faecium
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Acyl chain structures
Ab
un
da
nc
e 
(%
)
Acyl hain le gth (n)
Staphylococcus aur us
straight, saturated
straight, unsaturated
methylated (iso/anteiso)
cyclopropyl
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Bacillus subtilis
 0
 10
 20
 30
 40
 50
 60
 70
 80
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Bacillus megaterium
 0
 10
 
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Enterococcus faecalis
 0
 10
 20
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Enterococcus faecium
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Acyl chain structures
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Staphylococcus aureus
straight, saturated
straight, unsaturated
methylated (iso/anteiso)
cyclopropyl
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Bacillu  subtilis
 0
 10
 20
 30
 40
 50
 60
 70
 80
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Bacillus megaterium
 0
 10
 20
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Enterococcus faecalis
 0
 10
 20
 30
 40
 50
 60
13 14 15 16 17 18 19
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Enterococcu  faecium
 0
 10
 20
 30
 40
 50
13 14 15 16 17 18 19
Acyl chain structures
Ab
un
da
nc
e 
(%
)
Acyl chain length (n)
Staphylococcus aureus
straight, saturated
straight, unsaturated
methylated (iso/anteiso)
cyclopropyl
  116 
longer acyl chains than the other strains discussed. Several references were used for this figure, 
outlined in the paragraph above.  
 
The bacterial species also vary greatly in lipid head group composition, and this will certainly 
affect susceptibility or resistance to Dap. Several studies have shown the membranes of B. subtilis to 
contain PG, CL, phosphatidylethanolamine (PE) and lysyl-PG percentages of approximately 35, 13, 
35 and 18, respectively106,199. In the case of S. aureus, the lipid composition has been observed to 
contain a large percentage of PG (~80%), with lower percentages of lysyl-PG and CL, at ~15% and 
10%100,101–103,104. E. faecalis contains PG, CL and lysyl-PG at percentages of approximately 13%, 30% 
and 10%48,104.  
All the bacteria mentioned above are highly susceptible to Dap, yet they all have variable 
phospholipid content. This lipid variation, in conjunction with our data, suggests that consideration of 
only lipid head moieties is erroneous and that acyl tails are an important, overlooked, factor impacting 
Dap’s bactericidal activity.  
Recently, Müller, et al. proposed that Dap does not permeabilize B. subtilis 168 through pore 
formation119. Interestingly, Bishop, et al. showed that B. subtilis 168 has a dramatically increased CL 
percentage, and a low PG content, only 13%200, compared to other Bacillus spp., may also explain the 
decreased Dap permeabilization observed by Müller, et al.119 This may also account for the slightly 
diminished activity of Dap against E. faecalis strains observed by Barry, et al.130 since this bacterium 
contains only ~13% PG. Although it is likely that the diminished percentages of the PG lipid are the 
major reason for decreased activity, the possible effects of acyl tails should not be overlooked. E. 
faecalis contains longer acyl tails than S. aureus or B. subtilis. The results from this chapter suggest 
that the decreased activity of Dap within E. faecalis could be due to both head group and acyl chain 
differences. This hypothesis is investigated further in Chapter 5 with the synthesis of a longer tailed 
Dap analog. Recently, Hines, et al. characterized the lipid composition of Dap resistant S. aureus 
strains and observed an increase in the acyl chain length of the bilayer201, which correlates with the 
date observed in this chapter. Overall, the findings in this work and in the literature show that bacteria 
choice must be taken into consideration when studying Dap. The lipid composition of bacteria varies, 
and therefore to better understand Dap’s mechanism, clinically susceptible strains of bacteria, mainly 
S. aureus and E. faecalis, should be used. If other strains are used, researchers must take care to note 
differences in membrane composition.  
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In previous work, it has been suggested that Dap forms oligomers within the membrane that 
then translocate across leaflets. This leads to tetrameric oligomers that come together to form a 
functional octameric pore111. Through dithionite quenching experiments it has been shown that Dap is 
found 50% in the outer and inner leaflets of DMPC/DMPG membranes. POPC/POPG and 
DOPC/DOPG membranes were shown to interact with Dap more avidly (Figure 4.1) and allow for at 
least partial translocation (Figure 4.9, ~70% immediate dithionite quenching). Although partial 
translocation occurs, the Dap oligomers are still restricted to four subunits. One reasoning for this 
could be a spatial gap, where the Dap tetramers are translocating but the lipid acyl chain composition 
is preventing the oligomers from interacting. This theory is investigated more deeply in Chapter 5, 
with synthesis of a longer acyl chain on Dap. Nevertheless, this data highlights that the oligomer 
formation and translocation of Dap into the inner leaflet is necessary but not sufficient for proper pore 
formation.  
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Chapter 5 
 
Investigating the Role of Lipid Chains in Preventing 
Daptomycin Pore Formation4 
 
 
 
 
5.1 Introduction  
In the previous chapter, it was shown that the pore formation of Dap was highly dependent on 
the acyl chain composition of the membrane, and that the lipid composition varies greatly between 
several bacterial species.102,103,106,200 Researchers utilize these bacteria to study Dap, as well as varying 
model membrane systems, with little emphasis on retaining similar acyl tail compositions. Lipid flip 
flop and membrane fusion was shown with palmitoyl-oleoyl chained lipids82,109, lipid extraction from 
bilayers consisting of dioleoyl chained lipids120 and cation-selective pore formation with myristoyl 
chained lipids45. The use of POPC/POPG and DOPC/DOPG lipids was shown, in the previous 
Chapter, to prevent permeabilization by Dap. These membranes still allowed for Dap interaction and 
oligomerization, but the oligomer subunit stoichiometry and translocation into the inner leaflet were 
found to be lower, compared to DMPC/DMPG. This highlighted that translocation of the oligomer 
was necessary but not sufficient for pore formation. This divergence between lipid acyl chains may be 
relevant to the observation of different antibacterial action models of Dap on different bacterial 
species.  
 The work herein was done to better understand the reason for this diminished 
permeabilization. In the previous Chapter, it was suggested that the tetramers that form in each leaflet 
are being prevented from interacting across leaflets, preventing permeabilization (Figure 5.1). 
                                                      
4 The results shown in this chapter are unpublished work. Authors contributions: The preliminary dithionite-
quenching assay on TMCL membranes (shown in Appendix A) was run by David Beriashvili. Robert Taylor 
completed all other synthesis and results. David Beriashvili ran replicate trials for Figures 5.4 and 5.10.  
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Figure 5.1 Hypothetical model for reduced pore formation seen with membranes containing longer 
acyl tails. Experimental findings in Chapter 4 show reduced pore formation and translocation of Dap 
within longer acyl tailed membranes. This suggests that there is a spatial gap occurring. The oleoyl 
lipids interact with Dap more avidly, than myristoyl containing lipids, but prevent the tetramers in each 
leaflet to link together, thus preventing permeabilization.  
 
 Recently, Zhang, et al.111 observed that cardiolipin (CL) also prevented translocation and 
pore formation of Dap. Unfortunately, Zhang, et al. used a tetraoleoyl-CL (TOCL) and therefore it is 
unclear whether the effect observed by Zhang, et al. was due to the oleoyl chain or the CL head 
group. The role of CL in the membrane was therefore revisited, with use of a myristoyl chained-CL 
(TMCL). TMCL and TOCL both prevented Dap permeabilization, suggesting that Zhang, et al. 
conclusions were accurate. 
In the previous chapter the use of homogenous acyl tail compositions prevented Dap 
permeabilization, but it was unclear if this effect was due to the acyl chain itself or the head group. It 
was speculated that since the only variation between the three lipid species analyzed was the acyl 
chain, therefore this was the reason for diminished permeabilization. This theory was investigated 
further, by using hybrid mixtures of both myristoyl and oleoyl chained PC/PG membranes. It was 
observed that the head group was not involved in the inhibition of this pore. Since these hybrid 
mixtures contained only 50% DOPC or DOPG, the question then arose as to how much of a DOPC 
lipid was required to disrupt pore formation. To study this, membranes were utilized that were 
composed of decreasing percentages of DOPC, with DMPG kept constant at 50%, and DMPC used to 
balance the final percentage. Unexpectedly, only 1-5% incorporation of DOPC was necessary to 
For Table of Contents Use Only
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reduce Dap permeabilization. When Dap was added in a molar excess of DOPC, permeabilization 
resumed. This suggests that the added DOPC is, in some way, acting near-stoichiometrically with 
Dap, preventing pore formation.  
Chapter 4 speculated that DOPC/DOPG was creating a spatial gap across the membrane, 
preventing tetramers in opposing leaflets to properly align (Figure 5.1). To elucidate the inhibitory 
effects of these lipids, two different approaches were undertaken. Firstly, it was determined that the 
unsaturation point of oleoyl chained lipids was not involved in this inhibitory effect, by utilizing a PC 
lipid with an unsaturated fourteen-carbon acyl chain. This added acyl chain did not alter the ion 
transport of Dap. To probe the theory of a spatial gap between leaflets, an analog of Dap was 
synthesized that replaced the decanoyl tail with a longer, fourteen carbon, acyl chain (14C-Dap). This 
analog is similar to the natural fermentation of Dap derivatives from S. roseosporus, which Debono, 
et al. has shown contain fatty acyl tails ≥12 carbons74. It was suspected that increasing the acyl chain 
length of Dap might improve its ability to permeabilize these DOPC/DOPG membranes, by allowing 
the oligomers in opposing leaflets to properly link together. However, DOPC/DOPG membranes also 
inhibited the permeabilization of 14C-Dap. This finding further supports the previously mentioned 
conclusion; that acyl chain composition of membranes has drastic effects on the ability of Dap to 
form a pore. 
 
5.2 Methods and Materials 
 
5.2.1 Synthesis of 14Carbon-Daptomycin (14C-Dap) 
Firstly, a myristic acid succiminidyl ester was synthesized. The steps for this synthesis were 
done using the method by Gantner, et al.202 Briefly, Myristic acid and N, N’-dicyclohexylcarbodimide 
were added to a round bottom flask in THF and stirred at room temperature for 10 minutes. N-
hydroxysuccinimide was added and the reaction was stirred for 22.5 hours at room temperature. The 
solvent was removed under reduced pressure, and dry-loaded onto a silica gel column. The column 
was eluted with 50:1 chloroform:methanol. The product was separated with an Rf = 0.76. The product 
was concentrated under reduced pressure and lyophilized to produce a white powder. For further 
details regarding the synthesis and purification of the myristic acid succiminidyl ester, see Appendix 
A. 
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 For the semi-synthesis of 14C-Dap, a solution of Boc-deacyldaptomycin in dry DMF was 
added to myristic acid succiminidyl ester. Triethylamine was added and the mixture stirred for three 
days, at room temperature. After this, TFA/0.2% thioanisole was added and stirred at 0oC for 20 
minutes, under argon. The sample was then purified by HPLC. For details regarding the synthesis and 
purification of 14C-Dap, see Appendix A. 
 
5.2.2 Antibacterial Activity 
Antimicrobial susceptibility tests were performed as outlined in Section 2.2.3, with minor 
additions. Serial dilutions of Dap and 14C-Dap were prepared in Luria-Bertani (LB) broth (for 
Bacillus subtilis ATCC 1046) that was supplemented with 5 mM calcium chloride. Growth was 
assessed visually after incubation at 30oC (for Bacillus subtilis).   
 
5.2.3 Preparation of Liposomes 
Lipids used included those described in Section 2.2.4, with the addition of 1,2-
dimyristoleoyl-sn-glycero-3-phosphocholine (14:1 PC), 1',3'-bis[1,2-dioleoyl-sn-glycero-3-phospho]-
sn-glycerol (sodium salt; TOCL) and 1',3'-bis[1,2-dimyristoyl-sn-glycero-3-phospho]-sn-glycerol 
(sodium salt; TMCL). All lipids were obtained from Avanti Polar Lipids, Alabaster, AL, USA.  
The methodology for liposome preparation of mixtures of LUV’s has been described in a 
preceding chapter (Section 2.2.4). 
 
5.2.4 Fluorescence Spectroscopy 
Steady state experiments were performed as described in Section 2.2.5. 
 
5.2.5 Permeabilization Assays Utilizing Pyranine 
The methodology for the permeabilization assay with pyranine was described in Section 
3.2.5. 
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5.3 Results 
 
5.3.1 DOPC and POPC Inhibit Membrane Permeabilization by Dap 
In Chapter 4 it was speculated that the lack of permeabilization observed with oleoyl chain 
containing membranes was due to the acyl chain composition, since the only variance between the 
three lipids tested (DMPC/DMPG, DOPC/DOPG and POPC/POPG) was the fatty acyl chains. Since 
Dap requires PG to insert into the membrane it was unclear whether PG was a required constituent to 
cause this inhibition in Dap permeabilization. To elucidate this, permeabilization experiments were 
run with Dap on hybrid mixtures of oleoyl and myristoyl chained lipids (Figure 5.2). Oleoyl chained 
PC was mixed with myristoyl chained PG and vice versa, both at equimolar mixtures of PC to PG.  
 
Figure 5.2 Permeabilization assay of Dap on hybrid mixtures of DOPC/DMPG (solid lines) and 
DMPC/DOPG (dashed lines) with molar ratios of 1/1, PC to PG, 250 µM. LUVs were entrapped with 
pyranine (1 mM) with a low pH and sodium buffer. Time-based fluorescence was measured 
(excitation, 470 nm; emission, 510 nm) for 360 seconds. The loaded LUVs were added to calcium (5 
mM) buffer, which contained a high pH and increased sodium ions, thus creating a proton/sodium 
gradient across the bilayer. A proton ionophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 
5 nM) and Dap (2 µM) were added separately or together. At 300 seconds, Triton X-100 was added 
(0.1%) to solubilize the membranes. Assays were run in duplicates, at 30oC. 
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Both hybrid mixtures showed no permeabilization by Dap at typical antibacterial 
concentrations. This indicates that the presence of only 50% of an oleoyl chained lipid is required to 
prevent permeabilization, and that this acyl chain can be connected to either PG or a neutral, non-
involved head group, PC. This result confirms that the acyl chains inhibit pore formation, even 
though the PG is likely required to oligomerize the Dap monomers within the membrane.   
The analogous experiments with hybrids of palmitoyl-oleoyl chained lipids and myristoyl 
chained lipids were not performed. This is due to the structural similarities between both oleoyl-
containing lipids, shown in Figure 5.3. 
 
 
Figure 5.3 Structures of all three lipid types examined. Top: Lipid structure of a myrisotyl PC lipid 
(DMPC), with a saturated 14-carbon chain. Middle: Lipid structure of a palmitoyl-oleoyl PC lipid 
(POPC), with one chain being a 16 carbon saturated chain and the other being a oleoyl 18 carbon 
chain with one unsaturation point. Bottom: Lipid structure of a dioleoyl PC lipid (DOPC), with both 
chains being 18 carbon chains, with unsaturation points at the ninth carbon of each fatty acid chain. 
 
Since DOPC and POPC both contain an oleoyl chain within their lipid tails, and it was shown 
in Figure 5.2 that only 50% of an oleoyl chain is necessary to prevent permeabilization, it was 
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assumption requires further analysis since POPC, although containing an oleoyl chain also contains a 
palmitoyl (16:0) chain, which might induce effects not seen with DOPC.  
 
5.3.2 Revisiting the Inhibitory Effect of Cardiolipin 
In a recent study, Zhang, et al.111 investigated the effects of cardiolipin (CL) on Dap. CL, also 
known as di-phosphatidylglycerol, consists of two PG lipids connected through a glycerol head 
group. The literature suggests that increased conversion of PG to CL can mediate bacterial resistance 
to Dap. Zhang, et al. elucidated that CL caused Dap to be restricted to the outer leaflet, therefore 
preventing oligomer translocation. The oligomer subunit stoichiometry was also diminished, 
compared to homogenous DMPC/DMPG, which was ascribed to the inability of oligomers to link 
together across leaflets.  
At the time of those experiments, the role of the lipid acyl chain on Dap activity was not 
known or considered, and TOCL was used. Since the previous section outlined that oleoyl chained 
lipids prevent Dap permeabilization, even when they are not part of a required PG lipid, the question 
arose as to whether the previously described inhibitory effect was in fact due to the CL head group or 
to the acyl chain. To answer this question, the effect of Dap on liposomes composed of DMPC, 
DMPG and TMCL was utilized. Zhang, et al. stated that the incorporation of only 10% CL was 
enough to prevent permeabilization, therefore tests were run with 10% TOCL (to confirm these 
results) and with 10% TMCL. Firstly, the kynurenine fluorescence of Dap was tested against these 
varying lipid ratios, shown in Figure 5.4.   
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Figure 5.4 Kynurenine fluorescence of Dap was compared against different LUVs, containing 
cardiolipin. Dap (3 µM) was added to LUVs (250 µM) consisting of: DMPC/DMPG, DOPC/DOPG, 
TOCL/DMPC/DMPG and TMCL/DMPC/DMPG. Calcium was then titrated into the reaction mixture 
stepwise, with 3 minute incubations. An increase in kynurenine’s signal indicates membrane insertion. 
Error bars represent the standard deviation of assays were run in triplicates for DMPC/DMPG and 
DOPC/DOPG and in duplicates for the TOCL and TMCL containing membranes, at 37oC. 
 
 
The interaction of Dap to the TOCL and TMCL containing membranes resembles that of 
DMPC/DMPG. This suggests that oligomerization and at least partial translocation is occurring on 
each of these membranes, further suggested from preliminary work by David Beriashvili 
demonstrating that TMCL also prevents most (but not all) translocation of Dap oligomers (Appendix 
A, Figure A17). The permeabilization of Dap on membranes containing TOCL was examined, to 
confirm the results reported by Zhang, et al.111 (Figure 5.5). 
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Figure 5.5 Permeabilization assay of Dap on TOCL/DMPC/DMPG (molar ratio 1/4/5, 250 µM). The 
assay was performed as described in Figure 5.2.  Assays were run in duplicates, at 30oC. 
 
 
The presence of 10% TOCL in a membrane consisting of TOCL, DMPC and DMPG was 
shown to prevent pore formation of Dap. This supports and confirms the results obtained by Zhang, et 
al. that TOCL is preventing permeabilization. The analogous experiments were then performed with 
TMCL containing membranes (Figure 5.6).  
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Figure 5.6 Permeabilization assay of Dap on TMCL/DMPC/DMPG (molar ratio 1/4/5, 250 µM). The 
assay was performed as described in Figure 5.2. Assays were run in duplicates, at 30oC. 
 
 
As seen in Figure 5.6, pore formation by Dap was significantly reduced with the addition of 
10% TMCL. This indicates that CL alone is preventing the pore formation of Dap on liposomes, 
confirming the results by Zhang, et al. TMCL does appear to inhibit permeabilization to a lesser 
extent that TOCL or DOPC, suggesting that the effect of the acyl tails is more pronounced than the 
head group.  
 
 
5.3.3 Percentage of Oleoyl Lipid Required to Prevent Daptomycin Pore Formation  
The incorporation of an oleoyl chained lipid (at 50% total lipid) was shown to abolish the 
ability of Dap to form a pore (Figure 5.2). In the last section it was shown that only 10% CL was 
necessary to prevent this pore formation (Figure 5.5-5.6). These results prompted the question, how 
much of a DOPC lipid is necessary to decrease the pore formation of Dap. To answer this, liposomes 
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were prepared with decreasing percentages of DOPC, while DMPG was kept constant at 50%, and 
DMPC made up the balance. The use of 50% PG was also done to keep the equimolar ratio of PC to 
PG constant. The permeabilization assay with pyranine was utilized, with the percentages of DOPC 
shown in Figure 5.7. The percentage of normalized pyranine fluorescence, relative to the Triton X-
100 control, was reported.  
 
 
Figure 5.7 The percentage of pore formation for mixtures of LUVs containing: DOPC, DOPG, DMPC 
and DMPG. The assay was performed as described in Figure 5.2. The percentages were taken from 
the value at 295 seconds (before Triton X-100 addition). All lipid ratios were done in duplicate trials, 
except for DMPC/DMPG and DOPC/DOPG, which were in triplicates, standard deviations were within 
5-7% for all trials. This table outlines that Dap’s pore formation is halted by very low percentages of 
DOPC (1-5%). The raw spectra for these mixtures are shown in Appendix A. All assays were run at 
30oC, as described in Section 5.2.5. The addition of 10 µM Dap was only performed for percentages, 
50%, 10%, 5% and 1%. 
 
 
As observed in Figure 5.7, the controls remained stable and reproducible across all mixtures, 
all having final percentages < 15%. In the case of homogenous DMPC/DMPG (0%, Figure 5.7), 
~60% pore formation is observed, which is similar to what has been seen in previous chapters. In the 
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case of DOPC/DOPG (50%, Figure 5.7) pore formation is greatly diminished (<10% signal with Dap 
and CCCP).  
Interestingly, Figure 5.7 shows that only 1-5% of DOPC is necessary to reduce Dap pore 
formation. This pore formation is then improved, upon the addition of higher concentrations of Dap 
(10 µM).  When 1-5% DOPC is added, there will be ~0.5-2.5% in each leaflet, corresponding to 
~1.25-6.25 µM DOPC. Since Dap is added at 2 or 10 µM, this data suggests that DOPC is acting 
stoichiometrically with Dap, which is non-logical, as Dap is known not to interact with PC at 
physiological calcium concentrations126. Another possible theory could potentially be a formation of 
separate lipid micro-domains that contain DOPC. Dap selectively interacts with DOPC/DOPG 
(Figure 4.1). This more avid insertion into these oleoyl chained lipids could be causing Dap to 
interact initially with PG, but then localize to a small patch of DOPC lipids within the membrane. 
Since it has been suggested that DOPC/DOPG membranes prevent the alignment of Dap oligomers 
across membrane leaflets, the decrease in permeabilization seen with 1-5% DOPC could be due to a 
spatial gap. The addition of higher concentrations of Dap would force insertion and pore formation of 
the lipopeptide into regions of the membrane containing only DMPC/DMPG. Future work is 
necessary to better elucidate this potential DOPC to Dap dose-response interaction. 
 
5.3.4 Understanding the Reason for the Oleoyl Lipid’s Ability to Prevent Daptomycin 
Permeabilization 
As described previously, the inhibitory effects observed on DOPC/DOPG membranes are 
thought to be due to a reduced translocation of oligomers into the inner leaflet of the membrane, 
concomitantly with an inability of oligomers to align across leaflets. This theory was examined 
further by analyzing the structural differences between DOPC/DOPG and DMPC/DMPG, since 
DMPC/DMPG membranes have been observed to allow for Dap permeabilization. As seen in Figure 
5.3, DOPC and DMPC have two main structural differences. The first is the presence of an 
unsaturation point at the ninth carbon. To determine if this was the reason for decreased pore 
formation, a 14:1 PC lipid was utilized. This lipid chain contains a 14-carbon chain, like 
DMPC/DMPG, but with an unsaturation point at the ninth carbon. The permeabilization experiment 
with this lipid is shown in Figure 5.8.  
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Figure 5.8 Permeabilization of Dap on 14:1PC/DMPC/DMPG (molar ratio 1/4/5, 250 µM). The assay 
was performed as described in Figure 5.2.  Assays were run in duplicates, at 30oC. 
 
 
This lipid mixture contained 10% of the 14:1 PC lipid, within DMPC/DMPG LUVs. This 
percentage was used since it was observed in the previous section that 10% DOPC was the lowest 
percentage necessary to prevent any measurable pore formation (Figure 5.7). This 14:1 PC lipid does 
not inhibit the pore formation of Dap, suggesting that the presence of the unsaturation alone is not 
important to permeabilization. As can be seen in Figure 5.8, the controls for this experiment were 
much larger than with a homogenous membrane consisting of DMPC/DMPG. This indicates that the 
14:1 PC lipid is affecting liposome stability, although the controls are still considerably lower than 
the sample that has both added in unison.   
It was speculated that if a Dap analog was synthesized that could bridge the spatial gap 
between leaflets of DOPC/DOPG membranes, permeabilization might occur. In Chapter 2, it was 
suggested that the acyl tails of Dap oligomers interacted across leaflets. Therefore, if a longer tailed 
Dap analog was used, the oligomers of Dap might be able to interact across leaflets properly, forming 
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a pore. It was thought that since DOPC is four carbons longer than DMPC, that the incorporation of a 
14-carbon acyl tail to Dap (14C-Dap), instead of its standard decanoyl tail, might induce 
permeabilization. Additionally, Debono, et al. showed that when the fermentation of S. roseosporus is 
not altered, i.e. external addition of fatty acyl tails is not performed, that naturally produced Dap 
contains fatty acyls tails ≥12 carbons. It was thought that an increase to 14 carbons would be 
sufficient to bridge this gap. This 14C-Dap was produced semi-synthetically (Figure 5.9). 
 
 
 
Figure 5.9 Structure of 14C-Dap. The myristoyl moiety was attached to the terminal tryptophan 
residue, increasing native Dap’s fatty acid tail by four carbons (bolded). The minimum inhibitory 
concentration (MIC) of 14C-Dap was found to be lower than native Dap with a value of 0.5 µg/mL, 
over 0.75 µg/mL for Dap (tested on Bacillus subtilis ATCC 1046, 5 mM calcium).  
 
 
This 14C-Dap was found to have comparable activity to native Dap on Bacillus subtilis 
(Figure 5.9), suggesting that the increased carbon tail should not impose any constraints on oligomer 
and pore formation. To confirm this, the kynurenine fluorescence was measured with both 
DMPC/DMPG and DOPC/DOPG containing membranes, shown in Figure 5.10.  
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Figure 5.10 Kynurenine fluorescence of Dap and 14C-Dap were compared against different LUVs. 
The assay was performed as described in Figure 5.4.  Error bars represent the standard deviations of 
each assay, run in triplicates, at 37oC. 
 
 
The 14C-Dap analog was found to interact more avidly than Dap on both membrane 
compositions. In both cases, 14C-Dap and Dap have similar calcium concentrations required for 
saturation (>0.1 mM). This highlights that the 14C-Dap is interacting with both membranes equally. 
The ability of permeabilization for 14C-Dap was then tested on DMPC/DMPG membranes that 
contained pyranine, shown in Figure 5.11.  
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Figure 5.11 Permeabilization of Dap and 14C-Dap on DMPC/DMPG (molar ratio 1/1, PC to PG, 250 
µM). The assay was performed as described in Figure 5.2. Assays were run in triplicates, at 30oC. 
 
 
As expected, 14C-Dap permeabilizes DMPC/DMPG. This indicates that the 14C-Dap is also 
able to form oligomers that translocated across the membrane leaflets, forming a functional pore. The 
14C-Dap was then tested against oleoyl lipids, DOPC/DOPG, shown in Figure 5.12.  
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Figure 5.12 Permeabilization of Dap and 14C-Dap on DOPC/DOPG (molar ratio 1/1, PC to PG, 250 
µM). The assay was performed as described in Figure 5.2.  Assays were run in triplicates, at 30oC. 
 
 
Unexpectedly, pore formation of 14C-Dap was prevented on DOPC/DOPG at low and high 
concentrations. However, there is a slight increase in signal observed at higher concentrations of 14C-
Dap, when no CCCP is added. This mirrors data observed in Chapter 3 that suggested that a Dap 
dimer created larger pores within the membrane, negating the requirement of CCCP. Testing the 
permeabilization of 14C-Dap at even higher concentrations on these liposomes may show a similar 
non-dependence of CCCP.  
 
5.4 Discussion  
In Chapter 4 it was shown that the presence on longer, unsaturated lipid acyl chains 
detrimentally affected the permeabilization of Dap. Three lipid compositions, DOPC/DOPG, 
POPC/POPG and DMPC/DMPG were utilized, with Dap permeabilization only observed on the latter 
(Figure 4.2). Since the variation of these membranes is their acyl chain moieties, it was speculated 
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that this was the sole reason for decreased permeabilization. Since Dap requires PG to insert into the 
membrane9,11,40 it was unclear whether PG was a required constituent to cause this inhibition in Dap 
permeabilization. To elucidate this, permeabilization experiments were run with Dap on hybrid 
mixtures of oleoyl and myristoyl chained lipids (Figure 5.2). Oddly, the presence of PG is not 
required to prevent permeabilization, confirming the results in Chapter 4, that the acyl chain is the 
sole reason for a lack of pore formation, regardless of head group.  
In 2014, Zhang, et al. showed that the presence of cardiolipin (CL) into model membranes 
prevented the translocation of Dap oligomers and an inability for any oligomer to link together across 
leaflets111. At the time of this article, the role of lipid acyl chain composition was unknown and 
therefore a TOCL lipid was utilized. Since oleoyl chained lipids attached to a neutral PC head group 
were found to prevent permeabilization, it was unclear if the results obtained by Zhang, et al. were 
measuring the interaction of CL in the membrane or the oleoyl chain. This was therefore revisited, 
and a myristoyl chained CL (TMCL) was utilized. It was observed that both TOCL and TMCL, at 
10% total lipid, prevented Dap permeabilization in DMPC/DMPG membranes. This suggests that the 
conclusions drawn by Zhang, et al. were accurate, and that the inhibition of permeabilization with 
acyl chains could be through a similar mechanism of resistance. 
Since only 10% TMCL was necessary to induce inhibition of Dap permeabilization the 
question arose as to how much of a longer chained DOPC lipid was necessary to prevent this 
permeabilization. From Figure 5.7, it was shown that only 1-5% DOPC incorporation is required to 
prevent Dap permeabilization. This is a strikingly low concentration, corresponding to ~0.5-2.5% 
DOPC in each membrane leaflet. When taking into account that the total liposome concentration used 
is 250 µM, the molar concentration of DOPC found within the membrane is ~1.25-6.5 µM. Dap, at 2 
µM is prevented from forming a pore, but when Dap is increased to 10 µM, pore formation resumes. 
This suggests a dose response activity of Dap within these membranes. One theory is that the added 
DOPC lipid could be forming micro-domains within the membrane, supported by the literature that 
with eukaryotic cells, bacterial membrane lipids have been shown to create separate domains203, and 
Dap appears to interact preferentially to some of them134,135,157. Although Dap has been found to bind 
more avidly with DOPC/DOPG containing membrane, it is unlikely that Dap is binding directly to 
DOPC. Dap is likely binding to DMPG, but then potentially localizing to areas of the membrane that 
contain higher percentages of DOPC. These patches might then inhibit Dap pore formation similar to 
that seen with a homogenous DOPC/DOPG membrane, by preventing both translocation and 
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alignment of oligomers across leaflets. Another theory, based on the extremely low concentration of 
DOPC necessary to prevent Dap permeabilization could be that DOPC is acting somewhat 
stoichiometrtically to Dap. This is counterintuitive, as Dap does not bind DOPC only containing 
membranes.126 The acyl chains of lipids might have a more direct interaction with Dap oligomers, 
interrupting the interaction of Dap fatty acyl tails across leaflets. Future work is necessary to better 
elucidate the role of DOPC in preventing Dap pore formation, specifically focusing on the interaction 
of stoichiometric concentrations of DOPC on the membrane insertion of Dap.  
DOPC/DOPG membranes are clearly affecting the ability of Dap to form a pore, but the exact 
reason for this remains unclear. Oleoyl chained lipids differ from the Dap permeabilizing myristoyl 
chain lipids in regards to unsaturation and an increase carbon length (Figure 5.3). The role of 
unsaturation was studied using a 14:1 PC lipid, incorporated into DMPC/DMPG membranes. It was 
observed that this lipid does not affect Dap pore formation, suggesting that unsaturation alone is not 
involved in the inhibition. In Chapter 2 it was speculated that Dap oligomers interact across leaflets, 
potentially through their acyl chains. This is supported by Zhang, et al.’s findings that Dap oligomers 
translocate evenly across DMPC/DMPG membranes111, concomitantly with the finding that a pyrene 
labeled A5 analog showed two stages of excimer formation, with one stage potentially occurring 
across leaflets125 (See Chapter 2 for details). It was theorized that a longer chained Dap analog, 
similar to the structure of naturally produced Dap60, could potentially bridge the spatial gap that was 
speculated to occur between leaflets of DOPC/DOPG membranes. Since these membranes are four 
carbons longer than DMPC/DMPG, the addition of a fourteen carbon tail was added to Dap (14C-
Dap). It was speculated that this increased length, would allow for oligomers to link together across 
leaflets. This 14C-Dap was shown to interact identically with both DMPC/DMPG and DOPC/DOPG, 
suggesting that oligomer formation was occurring on each lipid type. Unexpectedly, DOPC/DOPG 
membranes also inhibited 14C-Dap. This suggests that the inhibition observed by DOPC/DOPG 
membranes is not limited to their increased carbon length. This could indicate that a more complex 
mechanism of inhibition due to DOPC/DOPG membranes might be occurring. The increase in Dap’s 
acyl tail could be causing constraint or improper associations within the membrane, leading to a lack 
of permeabilization observed. This could explain the slightly reduced pore formation observed on 
DMPC/DMPG membranes, compared to Dap (Figure 5.11). Future work involves the use of lipids 
that contain longer acyl chains (16:0 or 18:0), performing a similar study as that shown in Figure 5.8. 
An addition of a 16:0 or 18:0 acyl chained PC into DMPC/DMPG membranes might better explain 
the lack of a pore formation observed with both Dap and 14C-Dap on DOPC/DOPG membranes. In 
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summary, although questions remain to be answered about the interaction of Dap oligomers with 
oleoyl chained lipids, the data in this chapter supports the previous contention that the lipid 
composition has drastic effects of the ability of Dap to form a pore. 
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Chapter 6 
 
Summary and Future Work 
 
 
 
 
6.1 Summary  
As discussed throughout this thesis the mechanism of action for the important lipopeptide 
antibiotic, Daptomycin (Dap), still remains under debate. This thesis attempted to further elucidate 
the most experimentally supported mode of action, which is the permeabilization of small cations 
through formation of a pore.  
Fluorescence and ITC were utilized to study the interaction of calcium, Dap and a model 
membrane. Through use of native and acrylodan-labeled Dap and A5 (a similar antibiotic in both 
structure and activity), four separate amino acids were probed, corresponding to residues 1, 6, 8 and 
13 of the lipopeptides. From this work it was determined that calcium interacts with Dap in two 
sequential steps. The first calcium ion causes the macrolactone ring of Dap, particularly residues 6 
and 8 to insert into the membrane. At this concentration, Zhang, et al. observed excimer formation 
through use of a pyrene labeled A5 analog. Taken together, the results suggest that the first calcium 
ion causes oligomer formation in the outer membrane leaflet, with the tails interacting within the 
membrane. The second calcium ion forces this oligomer to be inserted more deeply into the 
membrane. This was observed through the emission increase of residues 1 and 13 of Dap and A5. At 
this concentration the acrylodan residues also experience concentration dependent self-quenching, 
suggesting a more tightly bound oligomer. The local concentration of pyrene monomers that could 
form excimers, observed by Zhang, et al. was also increased, suggesting that the second calcium was 
not only causing a deeper oligomer insertion but also a translocation of oligomers in the inner leaflet 
(or proper alignment of already translocated oligomers across leaflets). Zhang, et al. supported this 
using an NBD-Dap analog, showing that Dap oligomers translocate evenly between the leaflets of 
myristoyl chained lipid membranes, upon addition of higher calcium concentrations. 
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Oligomer formation is necessary for Dap activity. This oligomer formation would likely have 
an entropic cost. To lower this cost a dimer of Dap was synthesized that connected the N-terminal 
tryptophan’s of two monomers by an octadecanedioate linker. It was thought that this dimer might 
improve oligomer formation, thus improving overall activity. Unexpectedly, the dimer was relatively 
inactive on both Bacillus subtilis and Staphylococcus aureus strains. Interestingly, the dimer inserted 
into model membranes and formed a functional pore. It was speculated that the dimer might be too 
large to pass the peptidoglycan layer of Gram-positive bacteria. Call wall lacking bacteria, L-forms, 
were cultured, and the dimer was shown to be active on these cells. Additionally, the activity of the 
dimer was greatly improved when the concentration of calcium was increased to un-physiologically 
high concentrations, when tested against vegetative cells. This suggests an inability of the dimer to 
pass the cell wall, which could be due, primarily, to electrostatics. Overall, this work highlights that 
Dap must traverse the cell wall and then insert into the cytoplasmic membrane as a monomer. 
The effect of membrane lipid composition on Dap activity was then investigated. In the 
literature, many studies on the mode of action, and on the role of specific lipids, have been performed. 
Unfortunately, these studies did not take into account the possible effects of lipid acyl chain 
composition. This work highlighted that Dap, even though it interacts similarly to varying model 
membranes, composed of oleoyl, palmitoyl-oleoyl or myristoyl chained lipids, only permeabilizes the 
latter. The palmitoyl-oleoyl and oleoyl chained lipids also showed reduced membrane translocation 
and smaller subunit stoichiometry. This suggests that translocation of the Dap oligomer is necessary 
but not sufficient for Dap pore formation.  
The reason for the diminished permeabilization observed with oleoyl chain containing 
membranes was then explored. Only 1-5% of an oleoyl lipid was required to reduce Dap’s pore 
formation on model membranes. Permeabilization was restored when the molar percentage of Dap 
surpassed the molar percentage of the DOPC lipid within the DMPC/DMPG membrane. This 
suggests a specific dose response interaction is occurring with DOPC and Dap, within the membrane.  
DOPC/DOPG membranes differ from DMPC/DMPG membranes by a unsaturation point at 
the ninth carbon and longer acyl tail. Studies with an unsaturated myristoyl chained PC lipid showed 
that unsaturation has minimal effects on pore formation.  The effect of the oleoyl chained lipids 
increased carbon length was investigated through the synthesis of a longer tailed Dap analog, as it 
was expected that this increase in length would bridge the spatial gap between DOPC/DOPG 
membrane leaflets. This longer tailed Dap analog exhibited antibacterial activity equal to that of Dap.  
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This analog was able to form pores in DMPC/DMPG liposomes but not DOPC/DOPG liposomes, 
suggesting that the inhibition of pore formation observed by oleoyl chained lipids is more 
complicated than originally thought. Overall, these results demonstrate that the lipid acyl chain 
composition has drastic effects on the activity of Dap, which may explain the difference in Dap 
susceptibility among different bacteria. 
 
6.2 Future Work  
 
6.2.1 Studying Permeabilization of Bacteria Susceptible to Daptomycin   
As discussed in this thesis, the lipid composition of the membrane has drastic effects on the 
permeabilization of Dap. Many scientists have used varying lipids to study Dap, which could explain 
why there are varying proposed modes of action of this antibiotic. Interestingly, in the literature 
Staphylococcus aureus has been shown to be permeabilized by Dap46,114,191, whereas Bacillus subtilis 
has not119. The lipid composition could be the main reason for these differences in permeabilization. 
The use of membranes composed of phosphatidylcholine (PC) and phosphatidylglycerol (PG) is a 
simplistic model to study the interaction of Dap to PG, but these membranes do not capture the 
complexity of a pathogenic bacterial cell membrane. To better understand the in vivo mechanism of 
Dap action, the use of natural bacterial membranes is crucial. These bacterial systems, mainly 
Staphylococcus aureus, which Dap is used against, can be stripped of all components except the 
lipids, usually done through a cholorform/methanol extraction. The methodology used in this thesis 
could then be utilized, but with a membrane system that is much more similar to a bacterial 
membrane. Investigating the permeabilization of Dap with techniques explored by Silverman, et al.46 
on these model liposomes would also allow for a better understand of Dap’s membrane interaction. 
Although this approach would allow for a more accurate lipid composition, there are still 
shortcomings. The localization of lipid head groups within the membranes and the potential 
interaction of Dap with transmembrane proteins would require the use of live bacterial systems.  
The importance of PG for Dap’s activity has been shown countless times both in vitro and in 
vivo. Nevertheless, Bacillus polymyxa, which only contains ~3% PG in its membrane204, would allow 
for a viable cell system to study this inherent resistance. B. polymyxa also contains a higher PE 
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content, compared to other Bacillus spp. which would allow for an in vivo system to study the 
potential role of this lipid in Dap activity and its mode of action.  
 The inhibition of cell wall synthesis enzymes is a prominent proposed mode of action for Dap 
in the literature119,136,149. To better determine if Dap interacts with this process, to use of mycoplasma 
is useful, since mycoplasma bacteria lack a cell wall/cell wall synthesis enzymes205 and are therefore 
similar to L-forms152 (discussed in Chapter 3117). The use of these bacteria could potentially give a 
model membrane system, which is viable. It has been speculated that part of Dap’s mechanism of 
action is through inhibition of cell wall synthesis enzymes119. Since mycoplasma lack these enzymes, 
this work could determine if pore formation or cell wall enzyme inhibition, is the true mode of action. 
Also, the cell membrane of these bacteria can be varied depending on the lipid content within the 
growth medium205. This could allow for a viable cell system to that better mimics the cell membrane 
of pathogenic bacteria, susceptible to Dap.  
 
6.2.2 Developing Analogs to Study and Improve Daptomycin’s Activity 
The synthesis of new analogs of Dap is a focus point of many researchers, to better 
understand Dap’s mechanism of action and to develop analogs that improve activity. There are 
several different approaches to analog synthesis (discussed in Chapter 1), but the most recent 
advancement is that of total synthesis. This has been shown by Lohani, et al. to be a promising route 
to the development of new Dap analogs due to the ability to alter each amino acid in the structure of 
Dap specifically99. Unfortunately, with 20 standard amino acids to choose from, the creation of every 
type of analog possible for Dap is impossible. Therefore, a more rational approach is necessary, 
focusing on the role of each amino acid in Dap’s activity. This could help identify crucial interactions 
within oligomers of Dap and the lipid membrane. To determine the residues vital to Dap activity an 
alanine scan can be used. Alanine is a chemically inert amino acid that has been used for years to 
study the effect of specific amino acids in a proteins structure. Very recently, Barnawi, et al. 
investigated an alanine scan of Dap, showing that the replacement of some amino acid positions (D-
asparagine2, glycine5, ornithine6 and D-serine11) for alanine had lower reduced activity than all other 
amino acids tested98. The replacement of these positions with other standard amino acids might 
produce an analog with greater activity than native Dap. The incorporation of cysteine into these 
positions could also allow for the attachment of varying fluorophores at different positions in Dap, 
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which could be used to further elucidate these residues interactions with calcium and the bacterial 
membrane.  
Fluorine 19F-NMR is another approach to further elucidate the mechanism of action of Dap. 
The fluorine atom is sensitive to its environment and exhibits a peak-broadening effect in 
hydrophobic environments206. Targeting specific amino acids in the structure of Dap with a 
fluorinated compound, could allow for a better understanding of Dap’s oligomerization within 
membranes. Overall, Dap is a complex peptide, but through peptide synthesis, the creation of new and 
improved antibiotics to combat the ever-growing concern of antibiotic-resistant bacteria, is right 
around the corner. 
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Appendix A 
 
Unless otherwise stated, the thesis author, Robert Taylor, performed all synthesis and experiments 
shown in this appendix. 
Chapter 2 
 
The semi-synthesis and purification of the acrylodan-labeled Daptomycin (completed by Dr. Scott 
Taylor): 
Acrylodan (Setareh Biotech, Eugene, OR, USA) was attached to the unique free side chain 
amino group of ornithine6 of Dap (generously provided by Jared Silverman, Cubist Inc.©). The amino 
group of ornithine was first converted to a sulfhydryl group using Traut’s reagent207, to which 
acrylodan was then attached. To a solution of Dap (20 mg, 0.0123 mmol) in potassium phosphate 
buffer (50 mM, pH 8.0, 0.5 mL) was added Traut’s reagent (3.0 mg, 0.0281 mmol, 1.8 equiv). The 
mixture was stirred for 1 h. A solution of acrylodan (5.5 mg, 0.0246 mmol, 2 equiv) in DMF (1 mL) 
was added and the mixture was stirred for 24 h.  
The mixture was concentrated under reduced pressure and lyophilized to give a white 
powder. The product was then purified by HPLC on a reversed-phase column (Higgins Analytical, C-
18, 10 µm) utilizing a mobile phase of 0.1% trifluoroacetic acid with milli-q water and an acetonitrile 
gradient from 50% to 80%. The chromatogram has one major peak corresponding to the product (tr = 
8.4 min). This gave pure acrylodan-Dap as a pale yellow solid after lyophilization. The purity was 
confirmed by HPLC (Figure A1) and mass spectrometry (Figure A2).  
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Figure A1. The analytical RP-HPLC chromatogram (at 220 nm) of pure acrylodan-Dap is shown. 
Figure A2. The ESI+-MS of acrylodan-Dap is shown. The peaks with m/z = 1947, 974 and 1298 
correspond to the singly, doubly and triply charged dimer peaks of the product. 
 
The semi-synthesis and purification of the acrylodan-labeled A54145-Factor D: 
  164 
Acrylodan (Setareh Biotech, Eugene, OR, USA) was attached to the unique free side chain 
amino group of lysine8 of A54145-Factor D (generously provided by Jared Silverman, Cubist Inc.©). 
To a solution of A5 (5 mg) in sodium phosphate buffer (50 mM, pH 8.0, 0.25 mL) was added a 
solution of acrylodan (1.0 mg) in DMF (0.25 mL) and the mixture stirred for 5 days at room 
temperature.  
The mixture was concentrated under reduced pressure and lyophilized to give a white 
powder. The product was then purified by RP-HPLC (Higgins Analytical, C-18, 10 µm) utilizing a 
mobile phase of 0.1% trifluoroacetic acid with milli-q water and an acetonitrile gradient from 40% to 
50%. The chromatogram has three peaks corresponding to the product (tr = 39 min), native Dap (tr = 
23 min), and a disubstituted acrylodan analog (tr = 43 min). This gave pure acrylodan-A5 as a white 
solid after lyophilization (2.75 mg, 48.5% yield). The purity was confirmed by RP-HPLC (Figure A3) 
and mass spectrometry (Figure A4).  
 
 
 
Figure A3. The analytical RP-HPLC chromatogram (at 220 nm) of pure acrylodan-A5 is shown. 
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Figure A2. The ESI+-MS of the acrylodan-A5 is shown. The peaks with m/z = 1884, 942 and 1263 
correspond to the singly, doubly and triply charged dimer peaks of the product.  
 
 
Chapter 3 
 
 
The synthesis and purification of the activated octadecanedioate (completed by Dr. Scott Taylor): 
 
1,18-octadecanedioic acid (1, 48.1 mg, 0.153 mmol) was treated with a solution of N-
hydroxysuccinimide (106 mg, 0.923 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC, 177 mg, 0.923 mmol) in anhydrous DMF (2 mL) and stirred at room 
temperature under argon for 6 days. The solvent was removed under reduced pressure, diethyl ether 
(20 mL) was added, and the suspension was vacuum filtered. The filtrate was washed with milli-q 
water (1 x 20 mL) and brine (1 x 20 mL), then dried (MgSO4). The sample was then filtered, and the 
solvent was removed under reduced pressure to obtain Bis(2,5-dioxopyrrolidin-1-yl)octadecanedioate 
as white solid (60.0 mg, 74%). 1H NMR (300 MHz, CDCl3): δ 2.81 (s, 8H), 2.57 (t, J = 7.5 Hz, 4H), 
1.72 (quint, J = 7.4 Hz, 4H), 1.37-1.23 (m, 24H); 13C NMR (75.5 MHz, CDCl3): δ 24.5, 25.5, 28.7, 
29.0, 29.3, 29.5, 29.6, 29.6, 30.9, 168.7, 169.2; LRMS (ESI-MS) m/z (%): 509 (M+,100); HRMS 
(ESI+-MS) calcd. for C26H41N2O8 509.2863; found 509.2877.  
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The semi-synthesis and purification of the dimeric Dap (completed by Dr. Scott Taylor): 
 
To a solution of Boc-deacyldaptomycin (15.6 mg, 10 µmol) in dry DMF (0.5 ml) was added 
Bis(2,5-dioxopyrrolidin-1-yl)octadecanedioate (3 mg, 6 µmol, 0.6 eq.). Triethylamine (7 µL, 50 µmol, 
5 eq.) was added and the mixture stirred for two days. Analytic RP-HPLC of the mixture showed that 
all of the Boc-deacyldaptomycin was consumed and a single major peak was present (tr = 26.3 min, 
Higgins Clipeus analytical C-8 column, 5 µm) utilizing a mobile phase of 0.1% trifluoroacetic acid 
with milli-q water and an acetonitrile gradient from 5% to 100% over 45 minutes. The solvent was 
removed under reduced pressure and the residue dissolved in milli-q water and lyophilized. The 
resulting white powder was dissolved in ice-cold trifluoroacetic acid containing 2% thioanisole and 
stirred at 0 oC (ice bath) for 20 minutes, following concentration under reduced pressure. 
 
The residue was taken up in milli-q water and lyophilized to give a white powder. The 
powder was dissolved in milli-q water and purified by semi-preparative RP-HPLC (Higgins Clipeus 
C-18 semi-preparative column, 10 µm) utilizing a mobile phase of 0.1% trifluoroacetic acid with 
milli-q water and an acetonitrile gradient from 30% to 40% over 70 minutes, then remaining at 40% 
acetonitrile for 5 minutes. This gave one major peak corresponding to dimeric Dap at tr = 68.8 min. 
This product was lyophilized to give pure Dap dimer as a white solid (7 mg). The purity was 
confirmed by RP-HPLC (Figure A5) and mass spectrometry (Figure A6). 
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Figure A5. The analytical RP-HPLC chromatogram (at 220 nm) of pure Daptomycin dimer is shown. 
  
 
Figure A6. The ESI+-MS of the daptomycin dimer is shown. The peaks with m/z = 803, 1071 and 
1606 correspond to the quadruply, triply and doubly charged dimer respectively. The peak at m/z = 
1285 corresponds to a quintuply charged dimer-dimer complex. 
 
  168 
Chapter 4 
 
The semi-synthesis and purification of nitrobenzoxadiazole (NBD)-Dap: 
 
Dap (79.4 mg, 1.0 equiv.) was dissolved in milli-q water (4 mL) into a dual opening 50 mL 
round bottom flask, with a stir bar. Sodium bicarbonate (NaHCO3, 12.3 mg) was added and both were 
stirred and brought to 55oC in an oil bath. 7-chloro-4- nitrobenzoxadiazole (NBD-Cl) (10.75 mg, 1.1 
equiv.) was dissolved in methanol (HPLC grade, 4 mL). This NBD-Cl was added drop wise to the 
solution over 10 min, then allowed to stir at 55oC for 1 hour, under reflux. After the 1 hour was 
reached, 1 M HCl was added to quench the reaction to ~ 2-3 pH units. The solution was then 
rotovaped to dryness and lyophilized.  
 
Analytic RP-HPLC (Higgins Clipeus, C-18, 10 µm) of the mixture, utilizing a mobile phase 
of 0.1% trifluoroacetic acid with milli-q water and an acetonitrile gradient from 35% to 45% over 50 
minutes, showed two major products. The first peak corresponded to native Dap (tr = 26 min) and the 
second, NBD-Dap (tr = 40 min). These were separated on a semi-preparative column (Higgins 
Clipeus, C-18, 10 µm) with a linear gradient of 35% to 45% acetonitrile over 50 minutes. The peaks 
were collected and concentrated; giving pure NBD-Dap, yellow powder, after lyophilization (8.81 
mg, 10.1% yield).  
 
The analytical RP-HPLC chromatogram (Higgins Clipeus analytical C-18 column, 5 µm) 
utilizing a mobile phase of 0.1% trifluoroacetic acid with milli-q water and an acetonitrile gradient 
from 35% to 45% over 50 minutes, gave pure NBD-Dap showing one peak with a tr = 41 min (See 
Figure A7). The high-resolution mass spectrometry showed one singly charged peak at 1784.7 (M + 
H+)+ (See Figure A8). 
 
  169 
 
Figure A7. The analytical RP-HPLC chromatogram (at 220 nm) of the pure NBD-Dap is shown.  
 
 
Figure A8. The ESI+-MS of the NBD-Dap is shown. The peaks with m/z = 1784, 892 and1190 
correspond to the singly, doubly and triply charged dimer peaks of NBD-Dap.  
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Chapter 5 
 
The synthesis and purification of myristic acid succiminidyl ester, used in the synthesis of the 14 
Carbon - Daptomycin: 
 
The steps for this synthesis were done using the method by Gantner, et al.202 Myristic acid 
(1.31 mmol) and N, N’-dicyclohexylcarbodimide (1.57 mmol) were added to a round bottom flask in 
THF (2.62 mL) and stirred at room temperature for 10 minutes. N-hydroxysuccinimide (1.57 mmol in 
1.41 mL THF) was added and the reaction was stirred for 22.5 hours at room temperature.  
The solvent was removed under reduced pressure, and dry loaded onto a silica gel column. 
The column had solvent system of 50:1 chloroform:methanol. The product was separated with an Rf = 
0.76. The product was concentrated under reduced pressure and lyophilized to produce a white 
powder (221.33 mg, 51.76% yield). 1H NMR (300 MHz, CDCl3): δ 2.83 (s, 4H), 2.60 (t, J = 7.4 Hz, 
2H), 1.74 (papp, J = 6.9 Hz, 2H), 1.26 (m, 20H), 0.88 (t, J = 5.8 Hz, 3H). LRMS (ESI-MS) m/z: 326 
(M+H+)+; HRMS (ESI+-MS) calculated for C18H31N1O4 326.2461; found 326.2359.  
 
 
The semi-synthesis and purification of the 14C-Daptomycin: 
 
To a solution of Boc-deacyldaptomycin (15.6 mg, 10 µmol) in dry DMF (0.5 ml) was added 
myristic acid succiminidyl ester (3 mg, 6 µmol, 0.6 eq.). Triethylamine (7 µL, 50 µmol, 5 eq.) was 
added and the mixture stirred for three days, at room temperature. After this, trifluroacetic acid with 
0.2% thioanisole (5 mL) was added and stirred at 0oC for 20 minutes, under argon. Analytic RP-
HPLC (Higgins Clipeus, C-18 column, 10 µm) utilizing a mobile phase of 0.1% trifluoroacetic acid 
with milli-q water and an acetonitrile gradient from 10% to 90% over 60 minutes showed that all of 
the Boc-deacyldaptomycin was consumed and a single major peak was present (tr = 44 min) as well 
as a native Dap peak at tr = 19 min. The solvent was removed under reduced pressure and the residue 
dissolved in milli-q water and lyophilized, resulting in a white powder (17.0 mg, 98% yield).  
The analytical RP-HPLC chromatogram (Higgins Clipeus, C-18 column, 10 µm) utilizing a 
mobile phase of 0.1% trifluoroacetic acid with milli-q water and an acetonitrile gradient from 10% to 
90% over 60 minutes, gave pure 14C-Dap showing one major peak with a tr = 17.0 min (See Figure 
A9). The high-resolution mass spectrometry showed one singly charged peak at 1677.8 (M + H+)+ 
(See Figure A10). 
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Figure A9. The analytical RP-HPLC chromatogram (at 220 nm) of pure 14C-Dap is shown. 
  
Figure A10. The ESI+-MS of the 14C-Dap is shown. The peaks with m/z = 1677, 838 and1118 
correspond to the singly, doubly, triply charged dimer peaks of 14C-Dap.  
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The individual spectra for the permeabilization results shown in Table 5.1: 
 
Figure A11. Permeabilization results of Dap on 1/1/2 DOPC/DMPC/DMPG (molar ratio 1/1, PC to 
PG, 250 µM). LUVs were entrapped with pyranine (1 mM) with a low pH and sodium buffer. Time-
based fluorescence was measured (excitation, 470 nm; emission, 510 nm) for 360 seconds. The 
loaded LUVs were incubated with a calcium (5 mM) pre-mixed buffer, which contained a high pH and 
increased sodium ions, thus creating a proton/sodium gradient across the bilayer. A proton ionophore 
carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 5 nM) and Dap (2 and/or 10 µM) were added 
separately or together. At 300 seconds, Triton X-100 was added (0.1%) to solubilize the membranes. 
Assays were run in duplicates, at 30oC. 
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Figure A12. Permeabilization results of Dap on 1/3/4 DOPC/DMPC/DMPG (molar ratio 1/1, PC to 
PG, 250 µM). The experiment was run with conditions as described in Figure A11. Assays were run in 
duplicates, at 30oC. 
 
Figure A13. Permeabilization results of Dap on 1/4/5 DOPC/DMPC/DMPG (molar ratio 1/1, PC to 
PG, 250 µM). The experiment was run with conditions as described in Figure A11. Assays Assays 
were run in duplicates, at 30oC. 
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Figure A14. Permeabilization results of Dap on 1/9/10 DOPC/DMPC/DMPG (molar ratio 1/1, PC to 
PG, 250 µM). The experiment was run with conditions as described in Figure A11. Assays Assays 
were run in duplicates, at 30oC. 
 
Figure A15. Permeabilization results of Dap on 1/49/50 DOPC/DMPC/DMPG (molar ratio 1/1, PC to 
PG, 250 µM). The experiment was run with conditions as described in Figure A11. Assays Assays 
were run in duplicates, at 30oC. 
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Figure A16. Preliminary translocation results of NBD-Dap across 1/4/5 TMCL/DMPC/DMPG LUVs. 
The LUVs were incubated with a 2:1 mixture of Dap to NBD-Dap (1 µM total), respectively, at 25 mM 
calcium. At 50 seconds, dithionite (1 mM) was added to quench the NBD-Dap exposed to the external 
buffer. At 400 seconds, Triton X-100 (0.1%) was added to solubilize the membrane, exposing any 
NBD-Dap contained in inner leaflet that has not yet been quenched. NBD fluorescence was 
measured over time (excitation wavelength, 478 nm; emission wavelength, 520 nm; the assay is a 
singlet trial). The results presented here show that the TMCL containing membranes mimic the data 
with a 1/1 DOPC/DOPG composition.  
 
Figure A17. Anisotropy results for 1/4/5 TMCL/DMPC/DMPG LUVs. The experimental protocol was 
done similar to Thulborn, et al.208 Diphenylhexatriene (DPH, 10 µM) was added to liposomes (250 
µM) and the anisotropy monitored over varying temperatures. Each temperature was allowed to 
stabilize for 10 minutes before measuring sample. The results were repeated in triplicates, with 
standard deviations shown. From data, the Tm was determined to be ~27oC (mid point of asymptote). 
